

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 7
JULY 2013**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2013

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Cumulative Supplement 7

July 2013

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

**CUMULATIVE SUPPLEMENT 7
July 2013**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

BIONICHE PHARMA USA LLC
(BIONICHE PHARMA USA)

MYLAN INSTITUTIONAL LLC
(MYLAN LLC)

BOCA PHARMACAL INC
(BOCA PHARMA)

BOCA PHARMACAL LLC
(BOCA PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt,

ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2012</u>	<u>MAR 2013</u>	<u>JUN 2013</u>	<u>SEPT 2013</u>	<u>DEC 2013</u>
DRUG PRODUCTS LISTED	15343	15445	15408		
SINGLE SOURCE	2400 (15.9%)	2467 (16.0%)	2440 (15.8%)		
MULTISOURCE	12825 (83.6%)	12900 (83.5%)	12890 (83.7%)		
THERAPEUTICALLY EQUIVALENT	12683 (82.7%)	12758 (82.6%)	12750 (82.7%)		
NOT THERAPEUTICALLY EQUIVALENT	142 (0.9%)	142 (0.9%)	140 (0.9%)		
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)	78 (0.5%)		
NEW MOLECULAR ENTITIES APPROVED	17	9	5		
NUMBER OF APPLICANTS	835	844	841		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL							
ACAMPROSATE CALCIUM							
>A>	AB	GLENMARK GENERICS	333MG	A202229	001	Jul 16, 2013	Jul NEWA
CAMPRAL							
>D>	+	FOREST LABS	333MG	N021431	001	Jul 29, 2004	Jul CFTG
>A>	AB	+	333MG	N021431	001	Jul 29, 2004	Jul CFTG

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL							
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
>D>	AA	WEST WARD	500MG;50MG;40MG	A040261	001	Oct 28, 1998	Jul DISC
>A>		@	500MG;50MG;40MG	A040261	001	Oct 28, 1998	Jul DISC
ESGIC-PLUS							
>D>	AA	+ MIKART	500MG;50MG;40MG	A040085	001	Mar 28, 1996	Jul CTEC
>A>		+	500MG;50MG;40MG	A040085	001	Mar 28, 1996	Jul CTEC
TABLET; ORAL							
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
		@ MIRROR PHARMS LLC	500MG;50MG;40MG	A040883	001	Dec 23, 2008	Feb DISC

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL							
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE							
		@ MIKART	356.4MG;30MG;16MG	A040109	001	Aug 26, 1997	Feb DISC
		@ WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007	Jun DISC
TABLET; ORAL							
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE							
		@ BOCA PHARMA	712.8MG;60MG;32MG	A040701	001	Apr 03, 2007	Jun DISC
		@ MIKART	712.8MG;60MG;32MG	A040316	001	Apr 28, 1999	Feb DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL							
ACETAMINOPHEN AND CODEINE PHOSPHATE							
AA		AUROLIFE PHARMA LLC	300MG;15MG	A202800	001	Apr 15, 2013	Apr NEWA
AA			300MG;30MG	A202800	002	Apr 15, 2013	Apr NEWA
AA			300MG;60MG	A202800	003	Apr 15, 2013	Apr NEWA
		@ MIKART	300MG;30MG	A089238	001	Feb 25, 1986	Jun DISC
		@	650MG;30MG	A089231	001	Mar 03, 1986	Feb DISC
		@	650MG;60MG	A089363	001	Sep 09, 1991	Feb DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL							
HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
		@ MIKART	500MG;5MG	A081067	001	Nov 30, 1989	Feb DISC
		@	500MG;5MG	A089008	001	Feb 21, 1986	Jun DISC
SOLUTION; ORAL							
HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
AA		PAI	325MG/15ML;7.5MG/15ML	A040838	001	May 10, 2013	Apr NEWA
TABLET; ORAL							
HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
AA		CARACO	325MG;5MG	A090118	001	Dec 23, 2008	May CAHN
AA			325MG;7.5MG	A090118	002	Dec 23, 2008	May CAHN
AA			325MG;10MG	A090118	003	Dec 23, 2008	May CAHN
AA			500MG;5MG	A090265	001	Dec 23, 2008	May CAHN
AA			500MG;7.5MG	A090265	002	Dec 23, 2008	May CAHN
AA			500MG;10MG	A090265	003	Dec 23, 2008	May CAHN
AA			650MG;7.5MG	A090380	001	Dec 23, 2008	Jun CAHN
AA			650MG;10MG	A090380	002	Dec 23, 2008	Jun CAHN
AA			660MG;10MG	A090380	003	Dec 23, 2008	Jun CAHN
AA			750MG;7.5MG	A090380	004	Dec 23, 2008	Jun CAHN
>D>		MIKART	325MG;2.5MG	A040846	001	Jun 09, 2010	Jul CRLD
>A>	+		325MG;2.5MG	A040846	001	Jun 09, 2010	Jul CRLD
		@	500MG;2.5MG	A089698	001	Aug 25, 1989	Feb DISC
		@	650MG;5MG	A040849	001	Jun 09, 2010	Feb DISC
AA		TRIS PHARMA INC	325MG;5MG	A202214	001	Mar 27, 2013	Mar NEWA
AA			325MG;7.5MG	A202214	002	Mar 27, 2013	Mar NEWA
AA			325MG;10MG	A202214	003	Mar 27, 2013	Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ACTAVIS ELIZABETH	325MG;2.5MG	A201447	001	Apr 12, 2013	Apr	NEWA
AA		325MG;5MG	A201447	002	Apr 12, 2013	Apr	NEWA
AA		325MG;7.5MG	A201447	003	Apr 12, 2013	Apr	NEWA
AA		325MG;10MG	A201447	004	Apr 12, 2013	Apr	NEWA
>A> AA	AUROLIFE PHARMA LLC	325MG;2.5MG	A201972	001	Jul 15, 2013	Jul	NEWA
>A> AA		325MG;5MG	A201972	002	Jul 15, 2013	Jul	NEWA
>A> AA		325MG;7.5MG	A201972	003	Jul 15, 2013	Jul	NEWA
>A> AA		325MG;10MG	A201972	004	Jul 15, 2013	Jul	NEWA
>D>	+ MIKART	400MG;2.5MG	A040679	001	May 16, 2006	Jul	DISC
>A>	@	400MG;2.5MG	A040679	001	May 16, 2006	Jul	DISC
>A> AA	VINTAGE PHARMS	325MG;2.5MG	A090733	001	Jul 11, 2013	Jul	NEWA
>A> AA		325MG;7.5MG	A090734	001	Jul 11, 2013	Jul	NEWA
>A> AA		325MG;10MG	A090734	002	Jul 11, 2013	Jul	NEWA

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

@ WATSON LABS	250MG	A088882	001	Oct 22, 1985	Jan	DISC
---------------	-------	---------	-----	--------------	-----	------

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	SAGENT AGILA	EQ 500MG BASE/VIAL	A200880	001	May 09, 2012	Jan	CAHN
----	--------------	--------------------	---------	-----	--------------	-----	------

ACITRETIN

CAPSULE; ORAL

ACITRETIN

AB	BARR LABS INC	10MG	A091455	001	Apr 04, 2013	Mar	NEWA
AB		25MG	A091455	002	Apr 04, 2013	Mar	NEWA
AB	TEVA PHARMS USA	17.5MG	A202897	001	Apr 04, 2013	Mar	NEWA
AB		22.5MG	A202897	002	Apr 04, 2013	Mar	NEWA
	SORIATANE						
AB	STIEFEL LABS INC	10MG	N019821	001	Oct 28, 1996	Mar	CFTG
AB		17.5MG	N019821	003	Aug 06, 2009	Mar	CFTG
AB		22.5MG	N019821	004	Aug 06, 2009	Mar	CFTG
AB	+	25MG	N019821	002	Oct 28, 1996	Mar	CFTG

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

+	ACTIENT PHARMS	8MG;60MG	N019806	001	Mar 25, 1994	May	CAHN
---	----------------	----------	---------	-----	--------------	-----	------

ACYCLOVIR

CREAM; TOPICAL

ZOVIRAX

>A>	+	VALEANT BERMUDA	5%	N021478	001	Dec 30, 2002	Jul	CAHN
>D>	+	VALEANT INTL	5%	N021478	001	Dec 30, 2002	Jul	CAHN

OINTMENT; TOPICAL

ACYCLOVIR

AB	MYLAN PHARMS INC	5%	A202459	001	Apr 03, 2013	Mar	NEWA	
	ZOVIRAX							
AB	+	VALEANT BERMUDA	5%	N018604	001	Mar 29, 1982	May	CAHN
AB	+	VALEANT INTL	5%	N018604	001	Mar 29, 1982	Mar	CFTG
	SUSPENSION; ORAL							
	ZOVIRAX							
AB	+	DELCOR ASSET	200MG/5ML	N019909	001	Dec 22, 1989	Jun	CAHN
	TABLET; BUCCAL							
	SITAVIG							
	+	BIOALLIANCE PHARMA	50MG	N203791	001	Apr 12, 2013	Apr	NEWA

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

+	VALEANT BERMUDA	5%;1%	N022436	001	Jul 31, 2009	Apr	CAHN
---	-----------------	-------	---------	-----	--------------	-----	------

ADENOSINE

INJECTABLE; INJECTION
ADENOSINE

@ TEVA PHARMS USA	3MG/ML	A076564	001	Jun 16, 2004	Apr CAHN
@	3MG/ML	A078676	001	Jul 31, 2008	Apr CAHN

>A> AFATINIB DIMALEATE

TABLET; ORAL
GILOTRIF

>A>	BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292	001	Jul 12, 2013	Jul NEWA
>A>		EQ 30MG BASE	N201292	002	Jul 12, 2013	Jul NEWA
>A>	+	EQ 40MG BASE	N201292	003	Jul 12, 2013	Jul NEWA

ALBENDAZOLE

TABLET; ORAL
ALBENZA

+	AMEDRA PHARMS	200MG	N020666	001	Jun 11, 1996	Feb CAHN
---	---------------	-------	---------	-----	--------------	----------

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION
PROAIR HFA

BX	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Apr CAHN
		VENTOLIN HFA					

BX	+	GLAXO GRP LTD	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001	May CAHN
----	---	---------------	--------------------	---------	-----	--------------	----------

SOLUTION; INHALATION
ALBUTEROL SULFATE

	@	APOTEX INC	EQ 0.021% BASE	A078623	001	Apr 05, 2010	Apr DISC
	@		EQ 0.042% BASE	A078623	002	Apr 05, 2010	Apr DISC
	@		EQ 0.083% BASE	A075717	001	Feb 02, 2007	Apr DISC
	@		EQ 0.5% BASE	A076391	001	Apr 01, 2003	Apr DISC
AN	+	MYLAN SPECLT	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Jan CAHN
	@	WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394	001	Nov 22, 1999	Mar DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@ APOTEX INC	EQ 0.083% BASE;0.017%	A077117	001	Dec 31, 2007	Apr DISC
--------------	-----------------------	---------	-----	--------------	----------

ALENDRONATE SODIUM

SOLUTION; ORAL
ALENDRONATE SODIUM

AA		ROXANE	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013	Feb NEWA
----	--	--------	-------------------	---------	-----	--------------	----------

AA	+	MERCK	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003	Feb CFTG
----	---	-------	-------------------	---------	-----	--------------	----------

TABLET; ORAL
ALENDRONATE SODIUM

>A>	AB	CIPLA LTD	EQ 5MG BASE	A076768	001	Aug 04, 2008	Jul CAHN
>A>	AB		EQ 10MG BASE	A076768	002	Aug 04, 2008	Jul CAHN
>A>	AB		EQ 35MG BASE	A076768	003	Aug 04, 2008	Jul CAHN
>A>	AB		EQ 40MG BASE	A076768	004	Aug 04, 2008	Jul CAHN
>A>	AB		EQ 70MG BASE	A076768	005	Aug 04, 2008	Jul CAHN
>D>	AB	WATSON LABS	EQ 5MG BASE	A076768	001	Aug 04, 2008	Jul CAHN
>D>	AB		EQ 10MG BASE	A076768	002	Aug 04, 2008	Jul CAHN
>D>	AB		EQ 35MG BASE	A076768	003	Aug 04, 2008	Jul CAHN
>D>	AB		EQ 40MG BASE	A076768	004	Aug 04, 2008	Jul CAHN
>D>	AB		EQ 70MG BASE	A076768	005	Aug 04, 2008	Jul CAHN

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
UROXATRAL

AB	+	COVIS PHARMA SARL	10MG	N021287	001	Jun 12, 2003	Apr CAHN
----	---	-------------------	------	---------	-----	--------------	----------

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

AB		ACCORD HLTHCARE	100MG	A203154	001	May 06, 2013	Apr NEWA
AB			300MG	A203154	002	May 06, 2013	Apr NEWA

ALOGLIPTIN BENZOATETABLET; ORAL
NESINA

TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271	001	Jan 25, 2013	Jan NEWA
	EQ 12.5MG BASE	N022271	002	Jan 25, 2013	Jan NEWA
+	EQ 25MG BASE	N022271	003	Jan 25, 2013	Jan NEWA

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDETABLET; ORAL
KAZANO

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;1GM	N203414	002	Jan 25, 2013	Jan NEWA
		EQ 12.5MG BASE;500MG	N203414	001	Jan 25, 2013	Jan NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONETABLET; ORAL
OSEN

TAKEDA PHARMS USA	EQ 12.5MG BASE;15MG	N022426	004	Jan 25, 2013	Jan NEWA
	EQ 12.5MG BASE;30MG	N022426	005	Jan 25, 2013	Jan NEWA
	EQ 12.5MG BASE;45MG	N022426	006	Jan 25, 2013	Jan NEWA
	EQ 25MG BASE;15MG	N022426	001	Jan 25, 2013	Jan NEWA
	EQ 25MG BASE;30MG	N022426	002	Jan 25, 2013	Jan NEWA
+	EQ 25MG BASE;45MG	N022426	003	Jan 25, 2013	Jan NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDETABLET; ORAL
OSEN

TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426	004	Jan 25, 2013	Feb CAIN
	EQ 12.5MG BASE;EQ 30MG BASE	N022426	005	Jan 25, 2013	Feb CAIN
	EQ 12.5MG BASE;EQ 45MG BASE	N022426	006	Jan 25, 2013	Feb CAIN
	EQ 25MG BASE;EQ 15MG BASE	N022426	001	Jan 25, 2013	Feb CAIN
	EQ 25MG BASE;EQ 30MG BASE	N022426	002	Jan 25, 2013	Feb CAIN
+	EQ 25MG BASE;EQ 45MG BASE	N022426	003	Jan 25, 2013	Feb CAIN

ALPRAZOLAMTABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

@ TEVA PHARMS USA	0.5MG	A077979	001	Feb 28, 2007	Jun DISC
@	1MG	A077979	002	Feb 28, 2007	Jun DISC
@	2MG	A077979	003	Feb 28, 2007	Jun DISC
@	3MG	A077979	004	Feb 28, 2007	Jun DISC

ALPROSTADILINJECTABLE; INJECTION
ALPROSTADIL

AP	TEVA PHARMS USA	0.5MG/ML	A075196	001	Apr 30, 1999	Apr CAHN
----	-----------------	----------	---------	-----	--------------	----------

AMIKACIN SULFATEINJECTABLE; INJECTION
AMIKACIN SULFATE

@ HOSPIRA	EQ 250MG BASE/ML	A063264	001	Nov 30, 1994	Mar DISC
@ TEVA PHARMS USA	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993	Jun CAHN
AP	EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Jun CAHN

AMINOPHYLLINEINJECTABLE; INJECTION
AMINOPHYLLINE

@ INTL MEDICATION	25MG/ML	A087209	001	Feb 01, 1982	Jun DISC
@ PHARMA SERVE NY	25MG/ML	A087392	001	Dec 15, 1983	Jun DISC

TABLET; ORAL
AMINOPHYLLINE

>D>	+	WEST WARD	100MG	A084540	001	Jul DISC
>A>	@		100MG	A084540	001	Jul DISC
>D>	+		200MG	A085003	001	Jul DISC
>A>	@		200MG	A085003	001	Jul DISC

AMIODARONE HYDROCHLORIDEINJECTABLE; INJECTION
AMIODARONE HYDROCHLORIDE

@ APOTEX INC	50MG/ML	A076394	001	Apr 25, 2003	Apr DISC	
AP	+	MYLAN INSTITUTIONAL	50MG/ML	A076217	001	Oct 15, 2002
	@	TEVA PHARMS USA	50MG/ML	A076163	001	Sep 05, 2003

AMLEXANOX

PASTE; DENTAL
APHTHASOL
@ ULURU

5%

N020511 001 Dec 17, 1996 Jun DISC

AMLODIPINE BESYLATE

TABLET; ORAL
AMLODIPINE BESYLATE

AB	ACCORD HLTHCARE	EQ 2.5MG BASE	A202553	001	Apr 29, 2013	Apr	NEWA
AB		EQ 5MG BASE	A202553	002	Apr 29, 2013	Apr	NEWA
AB		EQ 10MG BASE	A202553	003	Apr 29, 2013	Apr	NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL
AMLODIPINE BESYLATE AND VALSARTAN

AB	PAR PHARM INC	EQ 5MG BASE;160MG	A090011	001	Mar 28, 2013	Mar	NEWA
AB		EQ 5MG BASE;320MG	A090144	001	Mar 28, 2013	Mar	NEWA
AB		EQ 10MG BASE;160MG	A090011	002	Mar 28, 2013	Mar	NEWA
AB		EQ 10MG BASE;320MG	A090011	004	Mar 28, 2013	Mar	NEWA
	EXFORGE						
AB	NOVARTIS	EQ 5MG BASE;160MG	N021990	002	Jun 20, 2007	Mar	CFTG
AB		EQ 5MG BASE;320MG	N021990	004	Jun 20, 2007	Mar	CFTG
AB	+	EQ 10MG BASE;160MG	N021990	003	Jun 20, 2007	Mar	CFTG
AB	+	EQ 10MG BASE;320MG	N021990	005	Jun 20, 2007	Mar	CFTG

AMMONIA N-13

INJECTABLE; INTRAVENOUS
AMMONIA N 13

AP	CARDINAL HEALTH 414	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203700	001	Feb 25, 2013	Feb	NEWA
AP	+	FEINSTEIN 30MCI-300MCI/8ML (3.75-37.5MCI/ML)	N022119	001	Aug 23, 2007	Feb	CFTG
AP	MCPRF	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203321	001	Feb 25, 2013	Feb	NEWA
AP	UCLA BIOMEDICAL	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203812	001	Jun 27, 2013	Jun	NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL
AMOXICILLIN

@ RANBAXY 200MG/5ML
@ 400MG/5ML

A065113 001 Nov 29, 2002 Feb DISC
A065113 002 Nov 29, 2002 Feb DISC

TABLET; ORAL
AMOXICILLIN

@ DAVA PHARMS INC 875MG

A065344 001 Jan 15, 2009 Jun DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

@ DAVA PHARMS INC 125MG
@ 250MG
@ RANBAXY 200MG
@ 400MG

A064139 001 Jan 29, 1996 Mar DISC
A064139 002 Jan 29, 1996 Mar DISC
A065060 001 Nov 29, 2000 Feb DISC
A065060 002 Nov 29, 2000 Feb DISC

AMOXIL

@ DR REDDYS LABS INC 200MG
@ 400MG

N050761 001 Apr 15, 1999 Feb DISC
N050761 002 Apr 15, 1999 Feb DISC

TABLET, FOR SUSPENSION; ORAL

AMOXICILLIN

@ AUROBINDO PHARMA LTD 200MG
@ 400MG

A065324 001 Jan 17, 2007 Jan DISC
A065324 002 Jan 17, 2007 Jan DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	@ APOTEX INC	250MG;EQ 125MG BASE	A065333	001	Feb 24, 2009	Apr	DISC
	@	500MG;EQ 125MG BASE	A065333	002	Feb 24, 2009	Apr	DISC
	@	875MG;EQ 125MG BASE	A065317	003	Oct 20, 2008	Apr	DISC
	@ RANBAXY LABS	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002	Apr	DISC
AB	TEVA PHARMS USA	875MG;EQ 125MG BASE	A065096	001	Oct 29, 2002	Apr	CRLD
	AUGMENTIN '250'						
AB	+	DR REDDYS LABS INC 250MG;EQ 125MG BASE	N050564	001	Aug 06, 1984	Apr	CRLD
	AUGMENTIN '500'						
AB	+	DR REDDYS LABS INC 500MG;EQ 125MG BASE	N050564	002	Aug 06, 1984	Apr	CRLD
	AUGMENTIN '875'						
AB	+	DR REDDYS LABS INC 875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Apr	CRLD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A 077488	001	Apr 29, 2013	Apr NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A 077488	002	Apr 29, 2013	Apr NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A 077488	003	Apr 29, 2013	Apr NEWA
AB		5MG;5MG;5MG;5MG	A 077488	004	Apr 29, 2013	Apr NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A 077488	005	Apr 29, 2013	Apr NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A 077488	006	Apr 29, 2013	Apr NEWA

DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE

AB	BARR LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A 076536	001	Feb 12, 2013	Jan NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A 076536	002	Feb 12, 2013	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A 076536	003	Feb 12, 2013	Jan NEWA
AB		5MG;5MG;5MG;5MG	A 076536	004	Feb 12, 2013	Jan NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A 076536	005	Feb 12, 2013	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A 076536	006	Feb 12, 2013	Jan NEWA

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@	TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A 040472	001	Sep 30, 2003	Jan DISC
@		2.5MG;2.5MG;2.5MG;2.5MG	A 040472	002	Sep 30, 2003	Jan DISC
@		5MG;5MG;5MG;5MG	A 040472	003	Sep 30, 2003	Jan DISC
@		7.5MG;7.5MG;7.5MG;7.5MG	A 040472	004	Sep 30, 2003	Jan DISC

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A 090884	002	Apr 03, 2013	Mar NEWA
AP		EQ 2GM BASE/VIAL	A 090884	003	Apr 03, 2013	Mar NEWA
AP		EQ 10GM BASE/VIAL	A 090889	001	Apr 03, 2013	Mar NEWA
AP		EQ 500MG BASE/VIAL	A 090884	001	Apr 03, 2013	Mar NEWA
	@ ANTIBIOTICE	EQ 1GM BASE/VIAL	A 090354	003	Dec 28, 2009	Jun DISC
	@	EQ 2GM BASE/VIAL	A 090354	004	Dec 28, 2009	Jun DISC
	@	EQ 250MG BASE/VIAL	A 090354	001	Dec 28, 2009	Jun DISC
	@	EQ 500MG BASE/VIAL	A 090354	002	Dec 28, 2009	Jun DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN

>A>	AP	+	PFIZER	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 062901	002	Feb 27, 1992	Jul NEWA
>D>	AP			EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 062901	001	Nov 23, 1988	Jul CRLD
>A>	AP	+		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 062901	001	Nov 23, 1988	Jul CRLD

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	ACCORD HLTHCARE	1MG	A 090568	001	Jun 28, 2010	Apr CAHN
	@ KUDCO IRELAND	1MG	A 091331	001	Jan 05, 2011	Feb DISC

ARIPIPIRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

	OTSUKA PHARM CO LTD	300MG/VIAL	N 202971	001	Feb 28, 2013	Feb NEWA
+		400MG/VIAL	N 202971	002	Feb 28, 2013	Feb NEWA

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

@	PRINSTON INC	385MG;30MG;25MG	A 075141	001	May 29, 1998	Apr CAHN
	ORPHENGESIC FORTE					
@	PRINSTON INC	770MG;60MG;50MG	A 075141	002	May 29, 1998	Apr CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

@	WATSON LABS	50MG	A 073352	001	Dec 27, 1991	Mar DISC
@		100MG	A 073353	001	Dec 27, 1991	Mar DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	KUDCO IRELAND	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar NEWA
AB		EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar NEWA
AB		EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar NEWA
AB		EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

	MERCK SHARP DOHME	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	May NEWA
		EQ 20MG BASE;10MG	N200153	002	May 03, 2013	May NEWA
		EQ 40MG BASE;10MG	N200153	003	May 03, 2013	May NEWA
+		EQ 80MG BASE;10MG	N200153	004	May 03, 2013	May NEWA

AZELAIC ACID

GEL; TOPICAL

FINACEA

+	BAYER HLTHCARE	15%	N021470	001	Dec 24, 2002	Jun CAHN
---	----------------	-----	---------	-----	--------------	----------

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

AP	SUN PHARM INDS LTD	EQ 500MG BASE/VIAL	A090923	001	Apr 02, 2013	Mar NEWA
----	--------------------	--------------------	---------	-----	--------------	----------

BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

+	PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001		Jun CAHN
---	----------------------	--------------	---------	-----	--	----------

POWDER; FOR RX COMPOUNDING

BACI-RX

@	X GEN PHARMS	5,000,000 UNITS/BOT	A061580	001		Mar DISC
---	--------------	---------------------	---------	-----	--	----------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	PERRIGO CO TENNESSEE	400 UNITS/GM;EQ 3.5MG BASE;10,000 UNITS/GM	A060764	002		Jun CAHN
----	----------------------	--	---------	-----	--	----------

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	PERRIGO CO TENNESSEE	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Jun CAHN
----	----------------------	------------------------------	---------	-----	--------------	----------

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+	PERRIGO CO TENNESSEE	400 UNITS/GM;1%;EQ 3.5MG BASE;10,000 UNITS/GM	A062166	002		Jun CAHN
---	----------------------	---	---------	-----	--	----------

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP	MALLINCKRODT INC	0.05MG/ML	N022462	001	Nov 19, 2010	May CAHN
AP		0.5MG/ML	N022462	002	Nov 19, 2010	May CAHN
		1MG/ML	N022462	004	Jun 22, 2012	May CAHN
AP		2MG/ML	N022462	003	Nov 19, 2010	May CAHN

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	CARACO	100MG	A040587	001	Mar 19, 2008	May CAHN
AA		200MG	A040587	002	Mar 19, 2008	May CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

	GEL; TOPICAL								
	ACANYA								
	+	DOW PHARM	2.5%;1.2%		N050819	001	Oct 23, 2008	Apr	CAHN
		BENZACLIN							
AB		VALEANT BERMUDA	5%;EQ 1% BASE		N050756	001	Dec 21, 2000	Apr	CAHN
BT	+		5%;EQ 1% BASE		N050756	002	Apr 20, 2007	Apr	CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

	GEL; TOPICAL								
	BENZAMYCIN PAK								
	+	VALEANT LUXEMBOURG	5%;3%		N050769	001	Nov 27, 2000	Jun	CAHN

BENZPHETAMINE HYDROCHLORIDE

	TABLET; ORAL								
	BENZPHETAMINE HYDROCHLORIDE								
	@ COREPHARMA	50MG			A040714	001	Oct 29, 2007	Feb	DISC

BENZTROPINE MESYLATE

	INJECTABLE; INJECTION								
	BENZTROPINE MESYLATE								
AP		NAVINTA LLC	1MG/ML		A091525	001	Feb 05, 2013	Jan	NEWA
	TABLET; ORAL								
	BENZTROPINE MESYLATE								
	@ PROSAM LABS	0.5MG			A040699	001	Feb 14, 2008	Mar	DISC
	@	1MG			A040705	001	Feb 14, 2008	Mar	DISC
	@	2MG			A040706	001	Feb 14, 2008	Mar	DISC

BETAMETHASONE

	SYRUP; ORAL								
	CELESTONE								
	@ MERCK SHARP DOHME	0.6MG/5ML			N014215	002		Apr	CAHN

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

	INJECTABLE; INJECTION								
	CELESTONE SOLUSPAN								
AB	+	MERCK SHARP DOHME	3MG/ML;EQ 3MG BASE/ML		N014602	001		Apr	CAHN

BETAMETHASONE VALERATE

	AEROSOL, FOAM; TOPICAL								
	BETAMETHASONE VALERATE								
AB		PERRIGO	0.12%		A078337	001	Nov 26, 2012	Apr	CPOT
		LUXIQ							
AB	+	STIEFEL	0.12%		N020934	001	Feb 28, 1999	Apr	CPOT

BETAXOLOL HYDROCHLORIDE

	SOLUTION/DROPS; OPHTHALMIC								
	BETAXOLOL HYDROCHLORIDE								
	@ APOTEX INC	EQ 0.5% BASE			A075446	001	Sep 28, 2000	Apr	DISC

BETHANECHOL CHLORIDE

	TABLET; ORAL								
	BETHANECHOL CHLORIDE								
AA		CARACO	5MG		A040897	001	Apr 22, 2009	Jun	CAHN
AA			10MG		A040897	002	Apr 22, 2009	Jun	CAHN
AA			25MG		A040897	003	Apr 22, 2009	Jun	CAHN
AA			50MG		A040897	004	Apr 22, 2009	Jun	CAHN
	@ LANNETT HOLDINGS INC	5MG			A040703	001	Mar 27, 2008	Jun	DISC
	@	50MG			A040677	001	Mar 27, 2008	Jun	DISC

BEXAROTENE

	CAPSULE; ORAL								
	TARGRETIN								
	+	VALEANT LUXEMBOURG	75MG		N021055	001	Dec 29, 1999	Jun	CAHN
	GEL; TOPICAL								
	TARGRETIN								
	+	VALEANT LUXEMBOURG	1%		N021056	001	Jun 28, 2000	Jun	CAHN
	+	VALEANT PHARMS INC	1%		N021056	001	Jun 28, 2000	Feb	CAHN

BICALUTAMIDE

TABLET; ORAL						
BICALUTAMIDE						
AB	ACCORD HLTHCARE	50MG	A078917	001	Jul 06, 2009	Apr CAHN

BLEOMYCIN SULFATE

INJECTABLE; INJECTION						
BLEOMYCIN SULFATE						
	@ PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	A065201	001	Dec 13, 2007	Feb DISC

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC						
SIMBRINZA						
+	ALCON RES LTD	0.2%;1%	N204251	001	Apr 19, 2013	Apr NEWA

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC						
BROMDAY						
+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Apr CPOT
BROMFENAC SODIUM						
AT	COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Apr CPOT
AT	LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Apr CPOT
AT		0.09%	A202030	001	Jan 09, 2013	Feb CAHN
PROLENSA						
+	BAUSCH AND LOMB	EQ 0.07% ACID	N203168	001	Apr 05, 2013	Apr NEWA
XIBROM						
+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	001	Mar 24, 2005	Apr CPOT

BUDESONIDE

SUSPENSION; INHALATION						
BUDESONIDE						
	@ APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Apr DISC
	@	0.5MG/2ML	A078202	002	Mar 30, 2009	Apr DISC
TABLET, EXTENDED RELEASE; ORAL						
UCERIS						
+	SANTARUS	9MG	N203634	001	Jan 14, 2013	Jan NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION						
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE						
	@ INTL MEDICATED	0.25%	A076012	001	Jan 09, 2002	Jun DISC
	@	0.5%	A076012	002	Jan 09, 2002	Jun DISC
	@	0.75%	A076012	003	Jan 09, 2002	Jun DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; SUBLINGUAL							
SUBOXONE							
>D>	+	RECKITT BENCKISER	EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	Jul CRLD
>A>			EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	Jul CRLD
>D>			EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	Jul CRLD
>A>	+		EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	Jul CRLD
TABLET; SUBLINGUAL							
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
>A>	AB	ACTAVIS ELIZABETH	EQ 2MG BASE;EQ 0.5MG BASE	A091422	001	Feb 22, 2013	Jul CTNA
>A>	AB	+	EQ 8MG BASE;EQ 2MG BASE	A091422	002	Feb 22, 2013	Jul CTNA
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE							
	AB	ACTAVIS ELIZABETH	EQ 2MG BASE;EQ 0.5MG BASE	A091422	001	Feb 22, 2013	Feb NEWA
>D>	AB		EQ 2MG BASE;EQ 0.5MG BASE	A091422	001	Feb 22, 2013	Jul CTNA
	AB	+	EQ 8MG BASE;EQ 2MG BASE	A091422	002	Feb 22, 2013	Apr CRLD
	AB		EQ 8MG BASE;EQ 2MG BASE	A091422	002	Feb 22, 2013	Feb NEWA
>D>	AB	+	EQ 8MG BASE;EQ 2MG BASE	A091422	002	Feb 22, 2013	Jul CTNA
	AB	AMNEAL PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A203136	001	Feb 22, 2013	Feb NEWA
	AB		EQ 8MG BASE;EQ 2MG BASE	A203136	002	Feb 22, 2013	Feb NEWA
SUBOXONE							
	@	RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N020733	001	Oct 08, 2002	Mar DISC
	AB		EQ 2MG BASE;EQ 0.5MG BASE	N020733	001	Oct 08, 2002	Feb CFTG
	@		EQ 8MG BASE;EQ 2MG BASE	N020733	002	Oct 08, 2002	Mar DISC
	AB	+	EQ 8MG BASE;EQ 2MG BASE	N020733	002	Oct 08, 2002	Feb CFTG
>A>		ZUBSOLV					
>A>		OREXO AB	EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013	Jul NEWA
>A>	+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jul NEWA

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL
APLENZIN

VALEANT BERMUDA 174MG
+ 348MG
522MG

N022108 001 Apr 23, 2008 Apr CAHN
N022108 002 Apr 23, 2008 Apr CAHN
N022108 003 Apr 23, 2008 Apr CAHN

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

@ TEVA 75MG
@ 100MG

A075310 001 Nov 29, 1999 Feb CDFR
A075310 002 Nov 29, 1999 Feb DISC

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

@ IMPAX LABS 300MG
AB1 WATSON LABS INC 100MG
AB3 150MG
AB1 150MG
AB1 200MG
AB3 300MG

A077415 002 Dec 15, 2006 Apr DISC
A077455 001 Jul 19, 2010 Apr CAHN
A077285 001 Nov 26, 2008 Apr CAHN
A077455 002 Mar 12, 2008 Apr CAHN
A077455 003 Jul 19, 2010 Apr CAHN
A077285 002 Aug 15, 2008 Apr CAHN

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

+ PERRIGO ISRAEL 2%
GYNAZOLE-1
@ KV PHARM 2%

A200923 001 May 18, 2012 Mar CRLD
N019881 001 Feb 07, 1997 Mar DISC

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

@ APOTEX INC 2MG/ML
BUTORPHANOL TARTRATE PRESERVATIVE FREE
@ APOTEX INC 1MG/ML
@ 2MG/ML

A075697 001 Oct 23, 2001 Apr DISC
A075695 001 Oct 23, 2001 Apr DISC
A075695 002 Oct 23, 2001 Apr DISC

STADOL

@ APOTHECON 2MG/ML
STADOL PRESERVATIVE FREE

N017857 004 Jun DISC

@ APOTHECON 1MG/ML
@ 2MG/ML

N017857 001 Jun DISC
N017857 002 Jun DISC

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB APOTEX CORP 0.5MG

A201503 001 Mar 08, 2013 Feb NEWA

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

AA MIKART 100MG;1MG
@ 100MG;1MG

A040590 001 Sep 16, 2005 Mar CMFD
A040590 001 Sep 16, 2005 Jan DISC

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

AB BANNER PHARMACAPS 0.25MCG
AB 0.5MCG

A091174 001 May 24, 2013 May NEWA
A091174 002 May 24, 2013 May NEWA

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB INVAGEN PHARMS EQ 169MG CALCIUM

A203135 001 Feb 07, 2013 Jan NEWA

TABLET; ORAL

CALCIUM ACETATE

AB INVAGEN PHARMS EQ 169MG CALCIUM

A202420 001 Feb 05, 2013 Jan NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74	N019867	001	Dec 20, 1993	Mar DISC
	MG/100ML;640MG/100ML;500MG/100ML;7				
	4MG/100ML				

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML;1.5GM/100ML;5.08MG/10	N020374	001	Jun 13, 1994	Feb DISC
	0ML;538MG/100ML;448MG/100ML				

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML;2.5GM/100ML;5.08MG/10	N020374	002	Jun 13, 1994	Feb DISC
	0ML;538MG/100ML;448MG/100ML				

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML;3.5GM/100ML;5.08MG/10	N020374	003	Jun 13, 1994	Feb DISC
	0ML;538MG/100ML;448MG/100ML				

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML;4.25GM/100ML;5.08MG/1	N020374	004	Jun 13, 1994	Feb DISC
	00ML;538MG/100ML;448MG/100ML				

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+	LUKARE MEDICAL LLC	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/M	N020577	001	Sep 27, 1996	Jun CAHN
		L;1.9MG/ML;7.3MG/ML;0.2MG/ML				

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

	JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013	Apr CAHN
+		300MG	N204042	002	Mar 29, 2013	Apr CAHN
	JANSSEN RES AND DEV	100MG	N204042	001	Mar 29, 2013	Mar NEWA
+		300MG	N204042	002	Mar 29, 2013	Mar NEWA

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

AB	ASTRAZENECA	4MG	N020838	001	Jun 04, 1998	Apr CFTG
AB		8MG	N020838	002	Jun 04, 1998	Apr CFTG
AB		16MG	N020838	003	Jun 04, 1998	Apr CFTG
AB	+	32MG	N020838	004	Jun 04, 1998	Apr CFTG

CANDESARTAN CILEXETIL

AB	SANDOZ	4MG	A078702	001	May 03, 2013	Apr NEWA
AB		8MG	A078702	002	May 03, 2013	Apr NEWA
AB		16MG	A078702	003	May 03, 2013	Apr NEWA
AB		32MG	A078702	004	May 03, 2013	Apr NEWA

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	APOTEX INC	32MG;25MG	A202884	003	Jun 03, 2013	May NEWA
AB	DR REDDYS LABS LTD	16MG;12.5MG	A202965	001	Jun 03, 2013	May NEWA
AB		32MG;12.5MG	A202965	002	Jun 03, 2013	May NEWA
AB		32MG;25MG	A202965	003	Jun 03, 2013	May NEWA

CAPSAICIN

PATCH; TOPICAL

QUTENZA

>A>	+	ACORDA	8%	N022395	001	Nov 16, 2009	Jul CAHN
>D>	+	NEUROGESX	8%	N022395	001	Nov 16, 2009	Jul CAHN

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@ PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996	Jun DISC
@	25MG	A074477	002	Feb 13, 1996	Jun DISC
@	50MG	A074477	003	Feb 13, 1996	Jun DISC
@	100MG	A074477	004	Feb 13, 1996	Jun DISC
@ TEVA	12.5MG	A074483	001	Feb 13, 1996	Jun DISC
@	25MG	A074483	002	Feb 13, 1996	Jun DISC
@	50MG	A074483	003	Feb 13, 1996	Jun DISC
@	100MG	A074483	004	Feb 13, 1996	Jun DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	TARO	100MG	A201106	001	Jun 21, 2013	Jun NEWA
AB		200MG	A201106	002	Jun 21, 2013	Jun NEWA
AB		300MG	A201106	003	Jun 21, 2013	Jun NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB	ACCORD HLTHCARE	25MG;100MG	A202323	001	Feb 08, 2013	Jan NEWA
AB		50MG;200MG	A202323	002	Feb 08, 2013	Jan NEWA

CARBINOXAMINE MALEATE

SUSPENSION, EXTENDED RELEASE; ORAL

KARBINAL ER

+	TRIS PHARMA INC	4MG/5ML	N022556	001	Mar 28, 2013	Mar NEWA
---	-----------------	---------	---------	-----	--------------	----------

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

@ PLIVA	50MG/VIAL	A076602	001	Nov 16, 2004	Feb DISC
@	150MG/VIAL	A076602	002	Nov 16, 2004	Feb DISC
@	450MG/VIAL	A076602	003	Nov 16, 2004	Feb DISC

INJECTABLE; IV (INFUSION)

CARBOPLATIN

@ FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006	Mar DISC
@	150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006	Mar DISC
@ PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009	Apr DISC
@	150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009	Apr DISC
@	450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009	Apr DISC

PARAPLATIN

@ CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003	Mar CAHN
@	150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003	Mar CAHN
@	450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003	Mar CAHN
@	600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004	Mar CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	ACCELRX LABS	350MG	A040576	001	Jun 07, 2005	May CAHN
	@ COREPHARMA	350MG	A040397	001	Sep 21, 2000	Feb DISC
	@ PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Jun DISC

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+	ARBOR PHARMS LLC	7.7MG	N020637	001	Sep 23, 1996	Mar CAHN
---	------------------	-------	---------	-----	--------------	----------

INJECTABLE; INJECTION

BICNU

+	EMCURE PHARMS LTD	100MG/VIAL	N017422	001		Jan CAHN
---	-------------------	------------	---------	-----	--	----------

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

@ APOTEX INC	1%	A076097	001	Feb 06, 2002	Apr DISC
--------------	----	---------	-----	--------------	----------

CARVEDILOL

TABLET; ORAL

CARVEDILOL

@	WOCKHARDT LTD	3.125MG	A078786	001	Dec 22, 2009	Feb DISC
@		6.25MG	A078786	002	Dec 22, 2009	Feb DISC
@		12.5MG	A078786	003	Dec 22, 2009	Feb DISC
@		25MG	A078786	004	Dec 22, 2009	Feb DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

AB	AUROBINDO	EQ 250MG BASE/5ML	A065349	001	Apr 25, 2013	Apr NEWA
AB		EQ 500MG BASE/5ML	A065349	002	Apr 25, 2013	Apr NEWA
	@ TEVA PHARMS USA	EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006	Mar DISC
	@	EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006	Mar DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	+	HOSPIRA INC	EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Feb CRLD
AP	+		EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Feb CRLD
AP	+		EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005	Feb CRLD
AP	+		EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Feb CRLD
>D> AP		STERI PHARMA	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jul CRLD
>A> AP	+		EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jul CRLD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

@	SANDOZ	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Mar DISC
@		EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Mar DISC
@		EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Mar DISC

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

+	LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Feb CDFR
	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Feb CDFR
		200MG/5ML	A065355	001	Apr 10, 2007	Feb CDFR

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

@	AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516	001	Nov 06, 2009	Jun DISC
---	----------------------	-------------------	---------	-----	--------------	----------

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

@	AUROBINDO PHARMA LTD	1GM/VIAL	A065481	002	May 28, 2010	Jun DISC
@		2GM/VIAL	A065481	003	May 28, 2010	Jun DISC
@		6GM/VIAL	A065482	001	May 28, 2010	Jun DISC
@		500MG/VIAL	A065481	001	May 28, 2010	Jun DISC

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

@	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A065505	003	Jul 31, 2008	May DISC
@		EQ 2GM BASE/VIAL	A065505	004	Jul 31, 2008	May DISC
@		EQ 250MG BASE/VIAL	A065505	001	Jul 31, 2008	May DISC
@		EQ 500MG BASE/VIAL	A065505	002	Jul 31, 2008	May DISC
>D> AP	TEVA	EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006	Jul DISC
>A>	@	EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006	Jul DISC
>D> AP		EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006	Jul DISC
>A>	@	EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006	Jul DISC
AP	TEVA PHARMS USA	EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007	May CAHN
AP		EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007	May CAHN
AP		EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007	May CAHN
AP		EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007	May CAHN

INJECTABLE; INJECTION

CEFTRIAXONE

@	AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065504	001	Jul 31, 2008	May DISC
---	----------------------	-------------------	---------	-----	--------------	----------

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

>A>	@ TEVA PHARMS	EQ 1.5GM BASE/VIAL	A064192	001	Apr 16, 1998	Jul DISC
>D> AB		EQ 750MG BASE/VIAL	A064192	002	Apr 16, 1998	Jul DISC
>A>	@	EQ 750MG BASE/VIAL	A064192	002	Apr 16, 1998	Jul DISC
	INJECTABLE; INJECTION					
	CEFUROXIME SODIUM					
>D> AP	TEVA PHARMS	EQ 1.5GM BASE/VIAL	A064192	001	Apr 16, 1998	Jul DISC
	ZINACEF IN PLASTIC CONTAINER					
	@ COVIS PHARMA SARL	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun DISC

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

	ALKEM LABS LTD	EQ 333MG BASE	A090836	003	Mar 29, 2013	Mar NEWA
AB		EQ 750MG BASE	A090836	004	Mar 29, 2013	Mar NEWA
	KEFLEX					
AB	+ SHIONOGI INC	EQ 750MG BASE	N050405	005	May 12, 2006	Mar CTEC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

	@ APOTEX INC	5MG/5ML	A078412	001	Jun 18, 2008	Apr DISC
	@ AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009	Feb DISC
AA	BIO PHARM INC	5MG/5ML	A078870	001	Apr 27, 2009	May CAHN
AA	CARACO	5MG/5ML	A090191	001	Nov 12, 2009	Jun CAHN

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

	@ EMD SERONO INC	EQ 3MG BASE/ML	N021197	002	Aug 11, 2000	Jun DISC
--	------------------	----------------	---------	-----	--------------	----------

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE HYDROCHLORIDE

AB	ROXANE	30MG	A091591	001	Jul 08, 2013	Jun NEWA
----	--------	------	---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

	@ APOTEX INC	0.12%	A075561	001	Nov 14, 2000	Apr DISC
	PAROEX					
AT	SUNSTAR AMERICAS	0.12%	A076434	001	Nov 29, 2005	Apr CTNA

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

>D> AB	+ MYLAN	250MG	A084388	001		Jul CTEC
>A>	+	250MG	A084388	001		Jul CTEC
>D> AB		500MG	A084217	001		Jul CTEC
>A>		500MG	A084217	001		Jul CTEC
>D> AB	WEST WARD	250MG	A086028	001	Jul 14, 1982	Jul DISC
>A>	@	250MG	A086028	001	Jul 14, 1982	Jul DISC
>D> AB		500MG	A087736	001	Jul 14, 1982	Jul DISC
>A>	@	500MG	A087736	001	Jul 14, 1982	Jul DISC
	DIURIL					
	@ OAK PHARMS AKORN	250MG	N011145	004		Jan CAHN
	@	500MG	N011145	002		Jan CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

AP	LUITPOLD	EQ 500MG BASE/VIAL	A202561	001	Apr 22, 2013	Jun CAHN
AP	PHARMAFORCE	EQ 500MG BASE/VIAL	A202561	001	Apr 22, 2013	Apr NEWA
	DIURIL					
AP	+ OAK PHARMS AKORN	EQ 500MG BASE/VIAL	N011145	005		Jan CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

VITUZ

+	CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013	Feb NEWA
---	---------------	-----------------	---------	-----	--------------	----------

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@	WATSON LABS INC	100MG	A088852	001	Sep 26, 1984	Jan DISC
---	-----------------	-------	---------	-----	--------------	----------

@		250MG	A088826	001	Sep 26, 1984	Jan DISC
---	--	-------	---------	-----	--------------	----------

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

>A>	AB	ANCHEN PHARMS	EQ 45MG FENOFIBRIC ACID	A201573	002	Jul 18, 2013	Jul NEWA
-----	----	---------------	-------------------------	---------	-----	--------------	----------

>A>	AB		EQ 135MG FENOFIBRIC ACID	A201573	001	Jul 18, 2013	Jul NEWA
-----	----	--	--------------------------	---------	-----	--------------	----------

AB		MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913	001	Mar 25, 2013	Mar NEWA
----	--	------------------	-------------------------	---------	-----	--------------	----------

AB			EQ 135MG FENOFIBRIC ACID	A200913	002	Mar 25, 2013	Mar NEWA
----	--	--	--------------------------	---------	-----	--------------	----------

TRILIPIX

AB		ABBVIE	EQ 45MG FENOFIBRIC ACID	N022224	001	Dec 15, 2008	Mar CFTG
----	--	--------	-------------------------	---------	-----	--------------	----------

AB	+		EQ 135MG FENOFIBRIC ACID	N022224	002	Dec 15, 2008	Mar CFTG
----	---	--	--------------------------	---------	-----	--------------	----------

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

@	APOTEX INC	8%	A078172	001	Sep 18, 2007	Apr DISC
---	------------	----	---------	-----	--------------	----------

@	TEVA PHARMS	8%	A078079	001	Sep 18, 2007	Jan DISC
---	-------------	----	---------	-----	--------------	----------

PENLAC

AT	+	VALEANT BERMUDA	8%	N021022	001	Dec 17, 1999	May CAHN
----	---	-----------------	----	---------	-----	--------------	----------

AT	+	VALEANT INTL	8%	N021022	001	Dec 17, 1999	Feb CAHN
----	---	--------------	----	---------	-----	--------------	----------

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@	WATSON LABS INC	200MG	A074349	001	Aug 30, 1996	May DISC
---	-----------------	-------	---------	-----	--------------	----------

@		300MG	A074349	002	Aug 30, 1996	May DISC
---	--	-------	---------	-----	--------------	----------

@		400MG	A074349	003	Aug 30, 1996	May DISC
---	--	-------	---------	-----	--------------	----------

@		800MG	A074316	001	Feb 28, 1996	Jun DISC
---	--	-------	---------	-----	--------------	----------

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@	APOTEX INC	EQ 300MG BASE/5ML	A075560	001	Mar 15, 2000	Apr DISC
---	------------	-------------------	---------	-----	--------------	----------

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

@	TEVA PHARMS USA	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006	Apr CAHN
---	-----------------	----------------------	---------	-----	--------------	----------

@		400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006	Apr CAHN
---	--	----------------------	---------	-----	--------------	----------

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

@	APOTEX INC	EQ 0.3% BASE	A075928	001	Jun 09, 2004	Apr DISC
---	------------	--------------	---------	-----	--------------	----------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

@	BAYER HLTHCARE	212.6MG;EQ 287.5MG BASE	N021473	001	Dec 13, 2002	May DISC
---	----------------	-------------------------	---------	-----	--------------	----------

@		425.2MG;EQ 574.9MG BASE	N021473	002	Aug 28, 2003	May DISC
---	--	-------------------------	---------	-----	--------------	----------

CIPROFLOXACIN EXTENDED RELEASE

@	DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701	002	Oct 31, 2007	Jun DISC
---	--------------------	-------------------------	---------	-----	--------------	----------

AB	+	MYLAN PHARMS INC	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007	May CRLD
----	---	------------------	-------------------------	---------	-----	--------------	----------

AB	+		425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007	May CRLD
----	---	--	-------------------------	---------	-----	--------------	----------

CISPLATININJECTABLE; INJECTION
PLATINOL

@ HQ SPCLT PHARMA	10MG/VIAL	N018057	001		Jan CAHN
@	50MG/VIAL	N018057	002		Jan CAHN
PLATINOL-AQ					
@ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984	Jan CAHN
@	1MG/ML	N018057	004	Nov 08, 1988	Jan CAHN

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

@ APOTEX INC	EQ 10MG BASE/5ML	A077601	001	Nov 15, 2005	Apr DISC
--------------	------------------	---------	-----	--------------	----------

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@ COREPHARMA	EQ 10MG BASE	A077036	001	Oct 28, 2004	Feb DISC
@	EQ 20MG BASE	A077036	002	Oct 28, 2004	Feb DISC
@	EQ 40MG BASE	A077036	003	Oct 28, 2004	Feb DISC
@ NATCO PHARMA LTD	EQ 20MG BASE	A077141	002	Apr 10, 2008	Jun DISC
@	EQ 40MG BASE	A077141	001	Apr 10, 2008	Jun DISC

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB	ALLIED PHARMA INC	250MG	A202710	001	Jun 10, 2013	May NEWA
AB		500MG	A202710	002	Jun 10, 2013	May NEWA

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

@ APOTEX INC	EQ 0.5MG BASE/5ML	A075703	001	Nov 27, 2000	Apr DISC
@ SILARX	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997	Mar DISC

CLEVIDIPINE

EMULSION; INTRAVENOUS

CLEVIPREX

+	MEDICINES CO	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008	Feb CAIN
+		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008	Feb CAIN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	AUROBINDO PHARMA LTD	EQ 75MG BASE/5ML	A202409	001	Apr 30, 2013	Apr NEWA
----	----------------------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP	AKORN INC	EQ 6MG BASE/ML	A203048	001	Apr 04, 2013	Mar NEWA
AP		EQ 12MG BASE/ML	A203048	002	Apr 04, 2013	Mar NEWA
AP		EQ 18MG BASE/ML	A203048	003	Apr 04, 2013	Mar NEWA

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

@ ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988	May CAHN
@ PERRIGO NEW YORK	EQ 1% BASE	A064050	001	Nov 30, 1995	Feb DISC

CLOBAZAM

TABLET; ORAL

ONFI

>D>	LUNDBECK LLC	5MG	N202067	001	Oct 21, 2011	Jul DISC
>A>	@	5MG	N202067	001	Oct 21, 2011	Jul DISC

CLOBETASOL PROPIONATEAEROSOL, FOAM; TOPICAL
OLUX E

AB2 + DELCOR ASSET 0.05% N022013 001 Jan 12, 2007 Jun CAHN

CREAM; TOPICAL

CLOBETASOL PROPIONATE

@ TEVA PHARMS USA 0.05%

A074087 001 Feb 16, 1994 Jun DISC

SOLUTION; TOPICAL

EMBELINE

>D> AT HI TECH PHARMA 0.05%

A074222 001 Dec 06, 1995 Jul CRLD

>A> AT + 0.05%

A074222 001 Dec 06, 1995 Jul CRLD

>D> TEMOVATE

>D> AT + FOUGERA PHARMS 0.05%

N019966 001 Feb 22, 1990 Jul DISC

>A> @ 0.05%

N019966 001 Feb 22, 1990 Jul DISC

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

AB ACCORD HLTHCARE 0.5MG

A077147 001 May 02, 2005 Apr CAHN

AB 1MG

A077147 002 May 02, 2005 Apr CAHN

AB 2MG

A077147 003 May 02, 2005 Apr CAHN

@ APOTEX INC 0.5MG

A075468 001 Oct 06, 2000 Feb DISC

@ 1MG

A075468 002 Oct 06, 2000 Feb DISC

@ 2MG

A075468 003 Oct 06, 2000 Feb DISC

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

AB CARLSBAD 0.1MG

A202297 001 Jun 13, 2013 May NEWA

AB 0.2MG

A202297 002 Jun 13, 2013 May NEWA

AB 0.3MG

A202297 003 Jun 13, 2013 May NEWA

TABLET, EXTENDED RELEASE; ORAL

JENLOGA

@ CONCORDIA PHARMS INC 0.1MG

N022331 001 Sep 30, 2009 May CAHN

@ 0.2MG

N022331 002 May 25, 2010 May CAHN

KAPVAY

+ CONCORDIA PHARMS INC 0.1MG

N022331 003 Sep 28, 2010 May CAHN

0.2MG

N022331 004 Sep 28, 2010 May CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB ACCORD HLTHCARE EQ 75MG BASE

A202925 001 Mar 27, 2013 Mar NEWA

AB EQ 300MG BASE

A202925 002 Mar 27, 2013 Mar NEWA

AB ACTAVIS TOTOWA EQ 75MG BASE

A090307 001 May 28, 2013 May NEWA

AB MUTUAL PHARM EQ 75MG BASE

A078133 001 Jun 10, 2013 May NEWA

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

@ RECORDATI RARE 3.75MG

N017105 001 May CAHN

@ 7.5MG

N017105 002 May CAHN

@ 15MG

N017105 003 May CAHN

TABLET; ORAL

TRANXENE

AB RECORDATI RARE 3.75MG

N017105 006 May CAHN

AB 7.5MG

N017105 007 May CAHN

AB + 15MG

N017105 008 May CAHN

TRANXENE SD

@ RECORDATI RARE 11.25MG

N017105 005 May CAHN

@ 22.5MG

N017105 004 May CAHN

CLOZAPINE

SUSPENSION; ORAL

VERSACLOZ

+ DOUGLAS PHARMS 50MG/ML

N203479 001 Feb 06, 2013 Feb NEWA

+ JAZZ PHARMS III 50MG/ML

N203479 001 Feb 06, 2013 Mar CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	AMNEAL PHARMS	10MG/5ML;6.25MG/5ML	A200894	001	Apr 24, 2013	Apr NEWA
AA	CARACO	10MG/5ML;6.25MG/5ML	A090180	001	Mar 17, 2010	May CAHN

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

AP	MYLAN LLC	0.25MG/VIAL	A090574	001	Dec 17, 2009	Feb CAHN
----	-----------	-------------	---------	-----	--------------	----------

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

AA	MICRO LABS LTD INDIA	100MG/5ML	A202745	001	Apr 04, 2013	Mar NEWA
----	----------------------	-----------	---------	-----	--------------	----------

SOLUTION; INHALATION

CROMOLYN SODIUM

@ APOTEX INC

10MG/ML

A075333	001	Apr 30, 2002	Apr DISC
---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

@ APOTEX INC

4%

A075615	001	Jan 26, 2001	Apr DISC
---------	-----	--------------	----------

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB	IVAX INTL	15MG	N021777	001	Feb 01, 2007	Jan CAHN
AB	+	30MG	N021777	002	Feb 01, 2007	Jan CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

AB	TWI PHARMS INC	15MG	A091281	001	Jan 31, 2013	Jan NEWA
AB		30MG	A091281	002	Jan 31, 2013	Jan NEWA

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	7.5MG	A073144	003	Mar 25, 2013	Mar NEWA
	@ PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Mar DISC
	@ SANDOZ	5MG	A072854	002	Feb 03, 2006	Apr DISC
	@	10MG	A072854	001	Nov 19, 1991	Apr DISC

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

@ AKORN

2%

A040165	001	Jan 13, 1997	Mar DISC
---------	-----	--------------	----------

CYCLOGYL

+ ALCON LABS INC 2%

A084108	001		Mar CTEC
---------	-----	--	----------

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN (LYOPHILIZED)

AP	+	BAXTER HLTHCARE	1GM/VIAL	N012142	004	Aug 30, 1982	Mar CTNA
	@		1GM/VIAL	N012142	010	Sep 24, 1985	Jan CTNA
AP	+		2GM/VIAL	N012142	005	Aug 30, 1982	Mar CTNA
	@		2GM/VIAL	N012142	009	Dec 10, 1985	Jan CTNA
AP	+		500MG/VIAL	N012142	003		Mar CTNA
	@		500MG/VIAL	N012142	008	Jan 04, 1984	Jan CTNA

CYCLOSPORINE

SOLUTION; ORAL

CYCLOSPORINE

@ APOTEX INC

100MG/ML

A065167	001	Jan 05, 2005	Apr DISC
---------	-----	--------------	----------

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013	Mar NEWA
----	-------------	---------	---------	-----	--------------	----------

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE; ORAL

PROCYSBI

RAPTOR PHARMS

EQ 25MG BASE

N203389	001	Apr 30, 2013	Apr NEWA
---------	-----	--------------	----------

+ EQ 75MG BASE

N203389	002	Apr 30, 2013	Apr NEWA
---------	-----	--------------	----------

CYTARABINE

INJECTABLE; INJECTION							
CYTOSAR-U							
AP	+	TEVA PHARMS USA	1GM/VIAL	A075206	004	Dec 30, 1998	Jun CAHN
AP	+		2GM/VIAL	A075206	003	Dec 30, 1998	Jun CAHN
AP			100MG/VIAL	A075206	001	Dec 30, 1998	Jun CAHN
AP	+		500MG/VIAL	A075206	002	Dec 30, 1998	Jun CAHN

DABRAFENIB MESYLATE

CAPSULE; ORAL							
TAFINLAR							
		GLAXOSMITHKLINE	EQ 50MG BASE	N202806	001	May 29, 2013	May NEWA
	+		EQ 75MG BASE	N202806	002	May 29, 2013	May NEWA

DACARBAZINE

INJECTABLE; INJECTION							
DACARBAZINE							
AP		TEVA PHARMS USA	200MG/VIAL	A075259	002	Aug 27, 1998	Apr CAHN
AP	+		500MG/VIAL	A075259	001	Sep 22, 2000	Apr CAHN

DACTINOMYCIN

INJECTABLE; INJECTION							
COSMEGEN							
AP	+	RECORDATI RARE	0.5MG/VIAL	N050682	001		May CAHN

DALTEPARIN SODIUM

INJECTABLE; SUBCUTANEOUS							
FRAGMIN							
		@ EISAI INC	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Jun DISC
		@	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Jun DISC

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION							
DAUNORUBICIN HYDROCHLORIDE							
AP		TEVA PHARMS USA	EQ 5MG BASE/ML	A065035	001	Jan 24, 2000	Apr CAHN

DECITABINE

INJECTABLE; INTRAVENOUS							
DACOGEN							
>D>	+	EISAI INC	50MG/VIAL	N021790	001	May 02, 2006	Jul CFTG
>A>	AP		50MG/VIAL	N021790	001	May 02, 2006	Jul CFTG
>A>		DECITABINE					
>A>	AP	DR REDDYS LABS LTD	50MG/VIAL	A203131	001	Jul 11, 2013	Jul NEWA

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION							
DESMOPRESSIN ACETATE							
AP		SUN PHARM INDS LTD	0.004MG/ML	A091280	001	Jan 25, 2013	Jan NEWA
AP		TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Apr CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28							
DESOGESTREL AND ETHINYL ESTRADIOL							
>A>	AB	NOVAST LABS LTD	0.15MG;0.03MG	A091234	001	Jul 12, 2013	Jul NEWA
		ENSKYCE					
	AB	LUPIN LTD	0.15MG;0.03MG	A201887	001	Mar 07, 2013	Feb NEWA
>A>		PIMTREA					
>A>	AB	NOVAST LABS LTD	0.15MG,N/A;0.02MG,0.01MG	A091247	001	Aug 01, 2013	Jul NEWA

DESONIDE

GEL; TOPICAL							
DESONATE							
	+	BAYER HLTHCARE	0.05%	N021844	001	Oct 20, 2006	Jun CAHN

DESOXIMETASONE

SPRAY; TOPICAL							
TOPICORT							
	+	TARO	0.25%	N204141	001	Apr 11, 2013	Apr NEWA

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL
DESVENLAFAXINE

	+	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013	Apr CRLD
			50MG	N204150	001	Mar 04, 2013	Mar NEWA
>D>	+		50MG	N204150	001	Mar 04, 2013	Jul CTEC
>A> BC	+		50MG	N204150	001	Mar 04, 2013	Jul CTEC
	+		100MG	N204150	002	Mar 04, 2013	Mar NEWA
>D>	+		100MG	N204150	002	Mar 04, 2013	Jul CTEC
>A> BC	+		100MG	N204150	002	Mar 04, 2013	Jul CTEC
>A>		KHEDEZLA					
>A> BC		OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013	Jul NEWA
>A> BC			100MG	N204683	002	Jul 10, 2013	Jul NEWA

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE

AA		WOCKHARDT EU OPERATN	0.5MG/5ML	A088254	001	Jul 27, 1983	May CRLD
----	--	----------------------	-----------	---------	-----	--------------	----------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

AT		NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE					
		PERRIGO CO TENNESSEE	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jun CAHN

SUSPENSION/DROPS; OPHTHALMIC

		NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE					
		@ ALCON PHARMS LTD	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062721	001	Nov 17, 1986	Jan DISC

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
PRECEDEX

	+	HOSPIRA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038	002	Mar 13, 2013	Mar NEWA
	+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038	003	Mar 13, 2013	Mar NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION
TOTECT

	+	BIOCODEX INC	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	May CAHN
--	---	--------------	--------------------	---------	-----	--------------	----------

DEXTROAMPHETAMINE SULFATE

SOLUTION; ORAL
DEXTROAMPHETAMINE SULFATE

AA	+	OUTLOOK PHARMS	5MG/5ML	A040776	001	Jan 29, 2008	May CFTG
AA		TRIS PHARMA INC	5MG/5ML	A203644	001	May 29, 2013	May NEWA

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

>A> AA		AUROLIFE PHARMA LLC	5MG	A202893	001	Jul 31, 2013	Jul NEWA
>A> AA			10MG	A202893	002	Jul 31, 2013	Jul NEWA

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER
@ B BRAUN

		5GM/100ML;220MG/100ML	N018744	003	Nov 09, 1982	Jan DISC
--	--	-----------------------	---------	-----	--------------	----------

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

		@ WATSON LABS	5MG/ML	A070296	001	Feb 12, 1986	Jun DISC
--	--	---------------	--------	---------	-----	--------------	----------

DIAZOXIDE

SUSPENSION; ORAL
PROGLYCEM

	+	TEVA BRANDED PHARM	50MG/ML	N017453	001		Apr CAHN
--	---	--------------------	---------	---------	-----	--	----------

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM

		@ APOTEX INC	0.1%	A077600	001	Nov 13, 2008	Apr DISC
--	--	--------------	------	---------	-----	--------------	----------

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB SANDOZ 50MG;0.2MG
 AB 75MG;0.2MG

A200158 001 May 09, 2013 Apr NEWA
 A200158 002 May 09, 2013 Apr NEWA

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HYDROCHLORIDE

>D> AB WEST WARD 10MG
 >A> @ 10MG

A040204 001 Feb 28, 1997 Jul DISC
 A040204 001 Feb 28, 1997 Jul DISC

DIDANOSINE

TABLET, FOR SUSPENSION; ORAL

DIDANOSINE

AUROBINDO 100MG
 150MG
 + 200MG

A077275 001 Aug 14, 2012 Apr CDFR
 A077275 002 Aug 14, 2012 Apr CDFR
 A077275 003 Aug 14, 2012 Apr CDFR

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX @ FOUGERA PHARMS 0.05%
 + TARO 0.05%
 PSORCON
 @ TARO PHARMS NORTH 0.05%

A075187 001 Mar 30, 1998 May DISC
 A075508 001 Apr 24, 2000 May CRLD
 N020205 001 Nov 20, 1992 Jun CAHN

DIGOXIN

TABLET; ORAL

DIGOXIN

@ CARACO 0.125MG
 @ 0.25MG

A076363 001 Jan 31, 2003 Jun DISC
 A076363 002 Jan 31, 2003 Jun DISC

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

AB3 PAR PHARM 120MG
 AB3 180MG
 AB3 240MG
 AB3 300MG
 AB4 SANDOZ 120MG
 AB4 180MG
 AB4 240MG
 AB4 300MG
 AB4 360MG
 AB4 420MG

A074984 001 Dec 20, 1999 Jan CAHN
 A074984 002 Dec 20, 1999 Jan CAHN
 A074984 003 Dec 20, 1999 Jan CAHN
 A074984 004 Dec 20, 1999 Jan CAHN
 A091022 001 Sep 28, 2012 Feb CAHN
 A091022 002 Sep 28, 2012 Feb CAHN
 A091022 003 Sep 28, 2012 Feb CAHN
 A091022 004 Sep 28, 2012 Feb CAHN
 A091022 005 Sep 28, 2012 Feb CAHN
 A091022 006 Sep 28, 2012 Feb CAHN

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

>A> AP AKORN INC 5MG/ML
 @ APOTEX INC 5MG/ML
 >D> AP TAYLOR PHARMA 5MG/ML
 @ TEVA PHARMS USA 5MG/ML
 + 10MG/ML

A075086 001 Apr 09, 1998 Jul CAHN
 A075375 001 Sep 30, 1999 Apr DISC
 A075086 001 Apr 09, 1998 Jul CAHN
 A074894 001 Aug 26, 1997 Apr CAHN
 A074894 002 Apr 19, 2002 Apr CAHN

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

@ DAVA PHARMS INC 30MG
 @ 60MG
 @ 90MG
 @ 120MG

A074093 001 Nov 05, 1992 Jan DISC
 A074093 002 Nov 05, 1992 Jan DISC
 A074093 003 Nov 05, 1992 Jan DISC
 A074093 004 Nov 05, 1992 Jan DISC

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

+ FRESENIUS KABI USA 50MG/ML
 @ WATSON LABS 50MG/ML

A040519 001 Jun 23, 2004 Apr CRLD
 A080615 001 Apr DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

TECFIDERA

BIOGEN IDEC INC 120MG
 + 240MG

N204063 001 Mar 27, 2013 Mar NEWA
 N204063 002 Mar 27, 2013 Mar NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION							
DIPHENHYDRAMINE HYDROCHLORIDE							
	@ WATSON LABS INC	10MG/ML	A080873	001		Mar	DISC
	@	50MG/ML	A080873	002		Mar	DISC
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE							
AP	BD RX	50MG/ML	A091526	001	Mar 26, 2013	Mar	NEWA
	@ WATSON LABS INC	50MG/ML	A080873	003		Mar	DISC

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

@ APOTEX INC	5MG/ML	A075769	001	Nov 27, 2002	Apr	DISC
@ TEVA PHARMS USA	5MG/ML	A074952	001	Nov 26, 1997	May	CAHN

TABLET; ORAL

DIPYRIDAMOLE

@ PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Jun	DISC
@	50MG	A040542	002	Apr 21, 2006	Jun	DISC
@	75MG	A040542	003	Apr 21, 2006	Jun	DISC

DISULFIRAM

TABLET; ORAL

DISULFIRAM

>A> AB	ALVOGEN PINE BROOK	250MG	A091681	001	Aug 08, 2013	Jul	NEWA
--------	--------------------	-------	---------	-----	--------------	-----	------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

@ TEVA PHARMS USA	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009	Mar	DISC
-------------------	------------------------	---------	-----	--------------	-----	------

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ACTAVIS INC	20MG/ML (20MG/ML)	N203551	001	Apr 12, 2013	Apr	NEWA
AP		80MG/4ML (20MG/ML)	N203551	002	Apr 12, 2013	Apr	NEWA
		140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013	Apr	NEWA
	@ APOTEX INC	20MG/0.5ML (40MG/ML)	N022312	001	Jan 11, 2012	May	DISC
	@	80MG/2ML (40MG/ML)	N022312	002	Jan 11, 2012	May	DISC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPT

>D>	+	EISAI INC	23MG	N022568	001	Jul 23, 2010	Jul	CTEC
>A> AB	+		23MG	N022568	001	Jul 23, 2010	Jul	CTEC

DONEPEZIL HYDROCHLORIDE

	@ ACCORD HLTHCARE	5MG	A201335	001	Aug 29, 2011	Jan	DISC
	@	10MG	A201335	002	Aug 29, 2011	Jan	DISC
AB	ACTAVIS GRP PTC	5MG	A090551	001	May 31, 2011	Apr	CAHN
AB		10MG	A090551	002	May 31, 2011	Apr	CAHN
AB	ALEMBIC PHARMS LTD	5MG	A201724	001	Feb 25, 2013	Feb	NEWA
AB		10MG	A201724	002	Feb 25, 2013	Feb	NEWA
AB	ALVOGEN PINE BROOK	5MG	A202114	001	Jul 05, 2013	Jun	NEWA
AB		10MG	A202114	002	Jul 05, 2013	Jun	NEWA
>A> AB	DR REDDYS LABS LTD	23MG	A202723	001	Jul 24, 2013	Jul	NEWA
>A> AB	PAR PHARM	23MG	A202542	001	Jul 24, 2013	Jul	NEWA

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

@ APOTEX INC	EQ 2% BASE	A078395	001	Oct 28, 2008	Apr	DISC
--------------	------------	---------	-----	--------------	-----	------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@ APOTEX INC	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008	Apr	DISC
--------------	-------------------------	---------	-----	--------------	-----	------

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

>D> AP	+	BAXTER HLTHCARE	20MG/ML	N014879	001		Jul	CAHN
>A> AP	+	HIKMA MAPLE	20MG/ML	N014879	001		Jul	CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@	WATSON LABS INC	EQ 1MG BASE	A075426	001	Oct 18, 2000	Jan	DISC
@		EQ 2MG BASE	A075426	002	Oct 18, 2000	Jan	DISC
@		EQ 4MG BASE	A075426	003	Oct 18, 2000	Jan	DISC
@		EQ 8MG BASE	A075426	004	Oct 18, 2000	Jan	DISC

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 10MG BASE	A070791	002	May 13, 1986	Jun	CRLD
AB		EQ 10MG BASE	A070791	002	May 13, 1986	May	CRLD
AB	+	EQ 25MG BASE	A070791	003	May 13, 1986	Jun	CRLD
	@ PAR PHARM	EQ 10MG BASE	A071697	001	Nov 09, 1987	May	DISC
	@	EQ 25MG BASE	A071437	001	Nov 09, 1987	May	DISC
	@	EQ 50MG BASE	A071595	001	Nov 09, 1987	May	DISC
	@	EQ 75MG BASE	A071608	001	Nov 09, 1987	May	DISC
	@	EQ 100MG BASE	A071422	001	Nov 09, 1987	May	DISC
	@ WATSON LABS	EQ 10MG BASE	A071485	001	Apr 30, 1987	May	DISC
	@	EQ 25MG BASE	A071486	001	Apr 30, 1987	May	DISC
	@	EQ 50MG BASE	A071238	001	Apr 30, 1987	May	DISC
	@	EQ 75MG BASE	A071326	001	Apr 30, 1987	May	DISC
	@	EQ 100MG BASE	A071239	001	Apr 30, 1987	May	DISC

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

@	PHARM ASSOC	EQ 10MG BASE/ML	A075924	001	Jan 15, 2004	Mar	DISC
---	-------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	EQ 3MG BASE	A201951	001	Jul 26, 2013	Jul	NEWA
>A>	AB		EQ 6MG BASE	A201951	002	Jul 26, 2013	Jul	NEWA
		SILENOR						
		PERNIX THERAPS LLC	EQ 3MG BASE	N022036	001	Mar 17, 2010	Apr	CAHN
>D>			EQ 3MG BASE	N022036	001	Mar 17, 2010	Jul	CFTG
>A>	AB		EQ 3MG BASE	N022036	001	Mar 17, 2010	Jul	CFTG
	+		EQ 6MG BASE	N022036	002	Mar 17, 2010	Apr	CAHN
>D>	+		EQ 6MG BASE	N022036	002	Mar 17, 2010	Jul	CFTG
>A>	AB	+	EQ 6MG BASE	N022036	002	Mar 17, 2010	Jul	CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	SAGENT PHARMS	2MG/ML	A091495	001	Mar 18, 2013	Mar	NEWA
AP	TEVA PHARMS USA	2MG/ML	A064140	001	Jul 28, 1995	Jun	CAHN
AP		200MG/100ML	A064140	002	Jul 28, 1995	Jun	CAHN

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

AB	+	JANSSEN RES AND DEV	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Jan	CFTG
AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Jan	CFTG

DOXIL (LIPOSOMAL)

AB		JANSSEN RES AND DEV	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Jun	CRLD
AB	+		20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Apr	CTNA
AB			50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Jun	CRLD
AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Apr	CTNA

DOXORUBICIN HYDROCHLORIDE

AB		SUN PHARMA GLOBAL	20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013	Jan	NEWA
AB			50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013	Jan	NEWA

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	+	SUN PHARMA GLOBAL	20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013	Jun	CRLD
AB	+		20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013	Apr	CTNA
AB	+		50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013	Jun	CRLD
AB	+		50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013	Apr	CTNA

DOXYCYCLINE

FOR SUSPENSION; ORAL

DOXYCYCLINE

AB	LUPIN LTD	EQ 25MG BASE/5ML	A201678	001	Mar 18, 2013	Mar	NEWA
----	-----------	------------------	---------	-----	--------------	-----	------

DOXYCYCLINE HYCLATE

CAPSULE; ORAL						
DOXYCYCLINE HYCLATE						
AB	HIKMA PHARMS	EQ 50MG BASE	A062396	002	Nov 07, 1984	May CAHN
AB		EQ 100MG BASE	A062396	001	May 07, 1984	May CAHN
TABLET; ORAL						
DOXYCYCLINE HYCLATE						
	@ BLU CARIBE INC	EQ 50MG BASE	A062269	003		Mar CAHN
	@	EQ 100MG BASE	A062269	002	Nov 08, 1982	Mar CAHN
AB	+ HIKMA PHARMS	EQ 100MG BASE	A065095	001	Jul 02, 2003	May CAHN
TABLET, DELAYED RELEASE; ORAL						
DORYX						
	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr NEWA
		EQ 200MG BASE	N050795	005	Apr 11, 2013	Apr NEWA
DOXYCYCLINE HYCLATE						
AB	HERITAGE PHARMS INC	EQ 75MG BASE	A200856	001	Apr 30, 2013	Apr NEWA
AB		EQ 100MG BASE	A200856	002	Apr 30, 2013	Apr NEWA
AB		EQ 150MG BASE	A200856	003	Apr 30, 2013	Apr NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE; ORAL						
DICLEGIS						
+	DUCHESNAY	10MG;10MG	N021876	001	Apr 08, 2013	Apr NEWA

DUTASTERIDE

CAPSULE; ORAL						
DUTASTERIDE						
AB	BANNER PHARMACAPS	0.5MG	A200899	001	May 30, 2013	May NEWA

ECONAZOLE NITRATE

CREAM; TOPICAL						
ECONAZOLE NITRATE						
AB	IGI LABS INC	1%	A076574	001	Dec 17, 2004	Mar CAHN

EDROPHONIUM CHLORIDE

		INJECTABLE; INJECTION					
		TENSILON					
>D>	AP	+	VALEANT PHARM INTL	10MG/ML	N007959	001	Jul CAHN
>A>	AP	+	VALEANT PHARMS	10MG/ML	N007959	001	Jul CAHN
		TENSILON PRESERVATIVE FREE					
>D>	AP	+	VALEANT PHARM INTL	10MG/ML	N007959	002	Jul CAHN
>A>	AP	+	VALEANT PHARMS	10MG/ML	N007959	002	Jul CAHN

ENALAPRILAT

INJECTABLE; INJECTION							
ENALAPRILAT							
AP	TEVA PHARMS USA	1.25MG/ML	A075578	001	Aug 22, 2000	May	CAHN

ENTACAPONE

TABLET; ORAL						
ENTACAPONE						
AB	MYLAN PHARMS INC	200MG	A202394	001	May 13, 2013	Apr NEWA

EPINEPHRINE

		INJECTABLE; IM-SC						
		EPIPEN						
>A>	BX	+	MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N019430	001	Dec 22, 1987	Jul CDFR
		EPIPEN JR.						
>A>	BX	+	MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Jul CDFR
		INJECTABLE; INTRAMUSCULAR						
		EPIPEN						
>D>	BX	+	MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N019430	001	Dec 22, 1987	Jul CDFR
		EPIPEN JR.						
>D>	BX	+	MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Jul CDFR

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION						
EPIRUBICIN HYDROCHLORIDE						
	@ MYLAN LLC	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007	Feb DISC
	@	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007	Feb DISC
AP	TEVA PHARMS USA	50MG/25ML (2MG/ML)	A065331	001	Aug 09, 2007	Apr CAHN
AP		200MG/100ML (2MG/ML)	A065331	002	Aug 09, 2007	Apr CAHN

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION						
EPOPROSTENOL SODIUM						
AP	TEVA PHARMS USA	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Apr CAHN
AP		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Apr CAHN

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)						
INVANZ						
+	MERCK SHARP DOHME	EQ 1GM BASE/VIAL	N021337	001	Nov 21, 2001	Jun CAHN

ERYTHROMYCIN

	CAPSULE, DELAYED REL PELLETS; ORAL					
	ERYC					
AB	+	MAYNE PHARMA	250MG	N050536	001	Mar CAHN
	@	WARNER CHILCOTT LLC	250MG	A062338	001	Apr DISC
	GEL; TOPICAL					
	ERYGEL					
>A>	AT	+	DELCOR ASSET CORP	2%	N050617	001 Oct 21, 1987 Jul CAHN
>D>	AT	+	MERZ PHARMS	2%	N050617	001 Oct 21, 1987 Jul CAHN
	OINTMENT; OPHTHALMIC					
	ERYTHROMYCIN					
AT	+	PERRIGO CO TENNESSEE	0.5%	A062447	001 Sep 26, 1983 Jun CAHN	
	SOLUTION; TOPICAL					
	SANSAC					
	@	DOW PHARM	2%	A062522	001 Jan 24, 1985 Apr CAHN	

ESCITALOPRAM OXALATE

SOLUTION; ORAL						
ESCITALOPRAM OXALATE						
AA	SILARX PHARMS INC	EQ 5MG BASE/5ML	A090477	001	Jun 12, 2013	May NEWA

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS						
ESOMEPRAZOLE SODIUM						
AP	SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Mar NEWA
AP		EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	Mar NEWA
NEXIUM IV						
AP	+ ASTRAZENECA	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	Mar CFTG
AP	+	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	Mar CFTG

ESTRADIOL VALERATE

INJECTABLE; INJECTION					
ESTRADIOL VALERATE					
@ WATSON LABS	40MG/ML	A083714	001		Jun DISC
@ WATSON LABS INC	20MG/ML	A083547	001		Jun DISC

ESTRONE

INJECTABLE; INJECTION					
ESTRONE					
@ WATSON LABS	5MG/ML	A085239	001		Jun DISC

ESTROPIPATE

TABLET; ORAL						
ORTHO-EST						
@	CARACO	0.75MG	A089567	001	Feb 27, 1991	Apr DISC
@		1.5MG	A089582	001	Jul 17, 1991	Apr DISC

ESZOPICLONETABLET; ORAL
ESZOPICLONE

AB	MYLAN PHARMS INC	1MG	A091151	001	Mar 26, 2013	Mar NEWA
AB		2MG	A091151	002	Mar 26, 2013	Mar NEWA
AB		3MG	A091151	003	Mar 26, 2013	Mar NEWA
AB	SUN PHARMA GLOBAL	1MG	A091103	001	Apr 03, 2013	Mar NEWA
AB		2MG	A091103	002	Apr 03, 2013	Mar NEWA
AB		3MG	A091103	003	Apr 03, 2013	Mar NEWA
	LUNESTA					
AB	SUNOVION PHARMS INC	1MG	N021476	001	Dec 15, 2004	Mar CTEC
AB		2MG	N021476	002	Dec 15, 2004	Mar CTEC
AB	+	3MG	N021476	003	Dec 15, 2004	Mar CTEC

ETHAMBUTOL HYDROCHLORIDETABLET; ORAL
ETHAMBUTOL HYDROCHLORIDE

>D> AB	WEST WARD	100MG	A075095	001	Nov 30, 1999	Jul DISC
>A>	@	100MG	A075095	001	Nov 30, 1999	Jul DISC
>D> AB	+	400MG	A075095	002	Nov 30, 1999	Jul DISC
>A>	@	400MG	A075095	002	Nov 30, 1999	Jul DISC
	MYAMBUTOL					
>D> AB	STI PHARMA LLC	400MG	N016320	003		Jul CRLD
>A> AB	+	400MG	N016320	003		Jul CRLD

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET; ORAL
DAYSEE

AB	LUPIN LTD	0.03MG,0.01MG;0.15MG,N/A	A091467	001	Apr 10, 2013	Mar NEWA
	QUARTETTE					
+	TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar NEWA

TABLET; ORAL-28

	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB1	LUPIN LTD	0.02MG;0.1MG	A091425	001	Jan 18, 2013	Jan NEWA

ETHINYL ESTRADIOL; NORETHINDRONETABLET; ORAL-28
NORETHINDRONE AND ETHINYL ESTRADIOL

>A> AB	FAMY CARE LTD	0.05MG;1MG	A203006	001	Aug 05, 2013	Jul NEWA
	OVCON-50					
>D>	+	WARNER CHILCOTT LLC	0.05MG;1MG	N017576	001	Jul CFTG
>A> AB	+		0.05MG;1MG	N017576	001	Jul CFTG
	PIRMELLA 1/35					
AB	LUPIN LTD	0.035MG;1MG	A201512	001	Apr 24, 2013	Apr NEWA
	PIRMELLA 7/7/7					
AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A201510	001	Apr 24, 2013	Apr NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATECAPSULE; ORAL
MINASTRIN 24 FE

+	WARNER CHILCOTT	0.02MG;1MG	N204426	001	Apr 19, 2013	Apr NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
@	WARNER CHILCOTT	0.02MG;1MG	N204426	001	Apr 19, 2013	May DISC

TABLET; ORAL

FEMHRT

@	WARNER CHILCOTT LLC	0.005MG;1MG	N021065	002	Oct 15, 1999	Jan DISC
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
+	BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009	Jan CRLD

TABLET, CHEWABLE; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
+	WARNER CHILCOTT LLC	0.02MG;1MG	N203667	001	May 08, 2003	May	NEWA
TABLET, CHEWABLE, TABLET; ORAL							
LO MINASTRIN FE							
+	WARNER CHILCOTT	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jul	NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28							
ESTARYLLA							
AB	SANDOZ	0.035MG;0.25MG	A090794	001	Jan 30, 2013	Jan	NEWA
	TRI LO SPRINTC						
	@ BARR LABS INC	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A076784	001	Jun 29, 2009	Apr	DISC
		15MG,0.25MG					
	TRI-ESTARYLLA						
AB	SANDOZ	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A090793	001	Jan 30, 2013	Jan	NEWA
		15MG,0.25MG					

ETHOTOIN

TABLET; ORAL							
PEGANONE							
+	RECORDATI RARE	250MG	N010841	001		May	CAHN

ETODOLAC

TABLET; ORAL							
ETODOLAC							
	@ PROSAM LABS	400MG	A074819	001	Feb 28, 1997	Mar	DISC
	@	500MG	A074819	002	Apr 28, 1998	Mar	DISC

ETOPOSIDE

INJECTABLE; INJECTION							
ETOPOSIDE							
AP	ACCORD HLTHCARE	20MG/ML	A074513	001	Mar 14, 1996	Apr	CAHN
	@ PHARMACHEMIE	20MG/ML	A074227	001	Feb 22, 1996	Apr	DISC
AP	TEVA PHARMS USA	20MG/ML	A074284	001	Feb 10, 1994	May	CAHN
AP		20MG/ML	A074529	001	Jul 24, 1996	Apr	CAHN

FAMCICLOVIR

TABLET; ORAL							
FAMCICLOVIR							
>A> AB	CIPLA LTD	125MG	A078278	001	Mar 21, 2011	Jul	CAHN
>A> AB		250MG	A078278	002	Mar 21, 2011	Jul	CAHN
>A> AB		500MG	A078278	003	Mar 21, 2011	Jul	CAHN
>D> AB	WATSON LABS	125MG	A078278	001	Mar 21, 2011	Jul	CAHN
>D> AB		250MG	A078278	002	Mar 21, 2011	Jul	CAHN
>D> AB		500MG	A078278	003	Mar 21, 2011	Jul	CAHN

FAMOTIDINE

INJECTABLE; INJECTION							
FAMOTIDINE							
	@ APOTEX INC	10MG/ML	A075942	001	Aug 02, 2002	Apr	DISC
	FAMOTIDINE PRESERVATIVE FREE						
AP	AKORN INC	10MG/ML	A076324	001	Nov 27, 2002	Mar	CAHN
	@ APOTEX INC	10MG/ML	A076324	001	Nov 27, 2002	Apr	DISC
	FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)						
AP	AKORN INC	10MG/ML	A076322	001	Nov 27, 2002	Mar	CAHN
	@ APOTEX INC	10MG/ML	A076322	001	Nov 27, 2002	Apr	DISC
	PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER						
	@ MERCK SHARP DOHME	0.4MG/ML	N020249	001	Feb 18, 1994	Apr	CAHN

FENOFIBRATE

CAPSULE; ORAL							
FENOFIBRATE (MICRONIZED)							
>A> AB	APOTEX INC	43MG	A202252	001	Jul 26, 2013	Jul	NEWA
>A> AB		130MG	A202252	002	Jul 26, 2013	Jul	NEWA

FENOFIBRIC ACID

TABLET; ORAL							
FIBRICOR							
	MUTUAL PHARM CO INC	35MG	N022418	001	Aug 14, 2009	Feb	CAHN
+		105MG	N022418	002	Aug 14, 2009	Feb	CAHN

FENOPROFEN CALCIUM

TABLET; ORAL							
FENOPROFEN CALCIUM							
	@ IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557	001	Aug 29, 1988	Mar	DISC
+	MYLAN PHARMS INC	EQ 600MG BASE	A072267	001	Aug 17, 1988	Mar	CTEC

FENTANYL CITRATEFILM; BUCCAL
ONSOLIS

@	MEDA PHARMS	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	May DISC
@		EQ 0.4MG BASE	N022266	002	Jul 16, 2009	May DISC
@		EQ 0.6MG BASE	N022266	003	Jul 16, 2009	May DISC
@		EQ 0.8MG BASE	N022266	004	Jul 16, 2009	May DISC
@		EQ 1.2MG BASE	N022266	005	Jul 16, 2009	May DISC

INJECTABLE; INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

>D>	AP	+	BAXTER HLTHCARE	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Jul CAHN
>A>	AP	+	HIKMA MAPLE	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Jul CAHN

TABLET; BUCCAL, SUBLINGUAL

FENTORA

AB			CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Feb CDFR
AB				EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Feb CDFR
		@		EQ 0.3MG BASE	N021947	006	Mar 02, 2007	Feb CDFR
AB	+			EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Feb CDFR
AB				EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Feb CDFR
AB				EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Feb CDFR

TABLET; SUBLINGUAL

ABSTRAL

			GALENA BIOPHARMA	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	May CAHN
				EQ 0.2MG BASE	N022510	002	Jan 07, 2011	May CAHN
				EQ 0.3MG BASE	N022510	003	Jan 07, 2011	May CAHN
		+		EQ 0.4MG BASE	N022510	004	Jan 07, 2011	May CAHN
				EQ 0.6MG BASE	N022510	005	Jan 07, 2011	May CAHN
				EQ 0.8MG BASE	N022510	006	Jan 07, 2011	May CAHN

>A> FERRIC CARBOXYMALTOSE

>A> INJECTABLE; IV

>A> INJECTAFER

>A>		+	LUITPOLD	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013	Jul NEWA
-----	--	---	----------	--------------------------------	---------	-----	--------------	----------

FERUMOXSI

SUSPENSION; ORAL

GASTROMARK

@	AMAG PHARMS INC	EQ 0.175MG IRON/ML	N020410	001	Dec 06, 1996	Feb DISC
---	-----------------	--------------------	---------	-----	--------------	----------

FINASTERIDE

TABLET; ORAL

FINASTERIDE

AB			ACCORD HLTHCARE	5MG	A090121	001	Feb 23, 2010	Apr CAHN
AB			HETERO LABS LTD III	1MG	A090060	001	Jul 01, 2013	Jun NEWA
AB				5MG	A090061	001	Jun 07, 2010	Apr CAHN
AB			SUN PHARMA GLOBAL	1MG	A090508	001	Jul 01, 2013	Jun NEWA

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

		@	APOTEX INC	50MG	A079164	001	Jul 09, 2009	Apr DISC
		@		100MG	A079164	002	Jul 09, 2009	Apr DISC
		@		150MG	A079164	003	Jul 09, 2009	Apr DISC
AB	+		ROXANE	150MG	A076278	003	Jan 14, 2003	May CRLD
			TAMBOCOR					
		@	MEDICIS	50MG	N018830	004	Aug 23, 1988	May DISC
		@		100MG	N018830	001	Oct 31, 1985	May DISC
		@		150MG	N018830	003	Jun 03, 1988	May DISC

FLUCONAZOLE

FOR SUSPENSION; ORAL							
FLUCONAZOLE							
	@ TARO PHARM INDS	50MG/5ML	A076918	001	Dec 18, 2006	Mar	DISC
	@	200MG/5ML	A076918	002	Dec 18, 2006	Mar	DISC
INJECTABLE; INJECTION							
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER							
	@ APOTEX INC	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Apr	DISC
	@	400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Apr	DISC
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%							
AP	TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	May	CAHN
AP		400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	May	CAHN
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	@ APOTEX INC	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Apr	DISC
	@	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Apr	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION							
FLUDARABINE PHOSPHATE							
AP	+ FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan	CRLD
AP	TEVA PARENTERAL	50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Jan	CRLD
AP	TEVA PHARMS USA	50MG/VIAL	A076349	001	Aug 28, 2003	Apr	CAHN
AP		50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Apr	CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS							
FLUDEOXYGLUCOSE F18							
	+ HOUSTON CYCLOTRON	20-500mCi/ML	A203665	001	Feb 14, 2013	Jun	CRLD
	+	20-500mCi/ML	A203665	001	Feb 14, 2013	Jan	NEWA
>A>	MCPRF	20-240mCi/ML	A203612	001	Aug 05, 2013	Jul	NEWA
	+ UCLA BIOMEDICAL	4-40mCi/ML	A203811	001	Jun 27, 2013	Jun	NEWA

FLUMAZENIL

INJECTABLE; INJECTION							
FLUMAZENIL							
	@ APOTEX INC	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr	DISC
	@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr	DISC
	@ TEVA PHARMS USA	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	Apr	CAHN
	@	1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	Apr	CAHN

FLUOCINOLONE ACETONIDE

OIL; TOPICAL							
FLUOCINOLONE ACETONIDE							
>A> AT	PERRIGO ISRAEL	0.01%	A202847	001	Aug 09, 2013	Jul	NEWA
>A> AT		0.01%	A202848	001	Aug 09, 2013	Jul	NEWA

FLUOCINONIDE

CREAM; TOPICAL							
LIDEX							
	@ CNTY LINE PHARMS	0.05%	N016908	002		Jan	CAHN
LIDEX-E							
	@ CNTY LINE PHARMS	0.05%	N016908	003		Jan	CAHN
GEL; TOPICAL							
FLUOCINONIDE							
AB	+ TARO	0.05%	A074935	001	Jul 29, 1997	Jan	CRLD
	LIDEX						
	@ CNTY LINE PHARMS	0.05%	N017373	001		Jan	CAHN
OINTMENT; TOPICAL							
FLUOCINONIDE							
AB	+ TARO	0.05%	A075008	001	Jun 30, 1999	Jan	CRLD
	LIDEX						
	@ CNTY LINE PHARMS	0.05%	N016909	002		Jan	CAHN
SOLUTION; TOPICAL							
FLUOCINONIDE							
AT	ACTAVIS MID ATLANTIC	0.05%	A071535	001	Dec 02, 1988	May	CAHN
AT	+ TARO	0.05%	A074799	001	Dec 31, 1996	Jan	CRLD
LIDEX							
	@ CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	May	CAHN
	@ MEDICIS	0.05%	N018849	001	Apr 06, 1984	Jan	DISC

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

AP	+	MYLAN LLC	1GM/20ML (50MG/ML)	A040743	001	Apr 26, 2007	Feb CAHN
AP	+		500MG/10ML (50MG/ML)	A040743	002	Apr 26, 2007	Feb CAHN
AP	+	TEVA PHARMS USA	2.5GM/50ML (50MG/ML)	A040334	001	Feb 25, 2000	May CAHN
AP	+		5GM/100ML (50MG/ML)	A040334	002	Feb 25, 2000	May CAHN
AP	+		500MG/10ML (50MG/ML)	A040333	001	Jan 27, 2000	May CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

		@ CARLSBAD	EQ 10MG BASE	A076022	001	Jan 30, 2002	Mar DISC
		@	EQ 20MG BASE	A076022	002	Jan 30, 2002	Mar DISC
		@ CR DOUBLE CRANE	EQ 10MG BASE	A076165	001	Feb 01, 2002	Apr DISC
AB1			EQ 10MG BASE	A076165	001	Feb 01, 2002	Mar CAHN
		@	EQ 20MG BASE	A076165	002	Feb 01, 2002	Apr DISC
AB1			EQ 20MG BASE	A076165	002	Feb 01, 2002	Mar CAHN
>D>	AB1	PLIVA	EQ 10MG BASE	A076001	001	Jan 29, 2002	Jul CAHN
>D>	AB1		EQ 20MG BASE	A076001	002	Jan 29, 2002	Jul CAHN
>A>	AB1	TEVA PHARMS USA	EQ 10MG BASE	A076001	001	Jan 29, 2002	Jul CAHN
>A>	AB1		EQ 20MG BASE	A076001	002	Jan 29, 2002	Jul CAHN
		@ WOCKHARDT LTD	EQ 10MG BASE	A078143	001	Jan 16, 2008	Feb DISC
		@	EQ 20MG BASE	A078143	002	Jan 16, 2008	Feb DISC
		@	EQ 40MG BASE	A078143	003	Jan 16, 2008	Feb DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

		@ APOTEX INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	Apr DISC
--	--	--------------	------------------	---------	-----	--------------	----------

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB		TEVA PHARMS	EQ 25MG BASE;EQ 3MG BASE	A202074	001	Mar 25, 2013	Mar NEWA
----	--	-------------	--------------------------	---------	-----	--------------	----------

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

		@ APOTEX INC	25MG/ML	A075918	001	Aug 17, 2001	Apr DISC
--	--	--------------	---------	---------	-----	--------------	----------

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

>D>	AB	WEST WARD	15MG	A071107	001	Dec 08, 1986	Jul DISC
>A>		@	15MG	A071107	001	Dec 08, 1986	Jul DISC
>D>	AB		30MG	A071108	001	Dec 08, 1986	Jul DISC
>A>		@	30MG	A071108	001	Dec 08, 1986	Jul DISC

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREO ELLIPTA

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.025MG BASE/INH	N204275	001	May 10, 2013	May NEWA
---	---------------	-------------------------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

LOTION; TOPICAL

FLUTICASONE PROPIONATE

>A>	AB	PERRIGO ISRAEL	0.05%	A091553	001	Jul 30, 2013	Jul NEWA
-----	----	----------------	-------	---------	-----	--------------	----------

POWDER; INHALATION

FLOVENT DISKUS 100

+	GLAXO GRP LTD	0.1MG/INH	N020833	002	Sep 29, 2000	May CAHN
---	---------------	-----------	---------	-----	--------------	----------

FLOVENT DISKUS 250

+	GLAXO GRP LTD	0.25MG/INH	N020833	003	Sep 29, 2000	May CAHN
---	---------------	------------	---------	-----	--------------	----------

FLOVENT DISKUS 50

+	GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000	May CAHN
---	---------------	------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION
ADV AIR HFA

+	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006	May CAHN
+		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006	May CAHN
+		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006	May CAHN

POWDER; INHALATION

	ADV AIR DISKUS 100/50					
+	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000	May CAHN
	ADV AIR DISKUS 250/50					
+	GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000	May CAHN
	ADV AIR DISKUS 500/50					
+	GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000	May CAHN

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL
FLUVOXAMINE MALEATE

AB	ACTAVIS ELIZABETH	100MG	A091482	001	Apr 23, 2013	Apr NEWA
AB	ANCHEN PHARMS	100MG	A091476	001	Mar 13, 2013	Mar NEWA
AB		150MG	A091476	002	Mar 13, 2013	Mar NEWA
	LUVOX CR					
AB	JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Mar CFTG
AB	+	150MG	N022033	002	Feb 28, 2008	Mar CFTG

TABLET; ORAL

FLUVOXAMINE MALEATE

@	CARACO	25MG	A075900	001	Feb 23, 2006	Jun DISC
@		50MG	A075900	002	Feb 23, 2006	Jun DISC
@		100MG	A075900	003	Feb 23, 2006	Jun DISC

FOLIC ACID

TABLET; ORAL
FOLIC ACID

>A> AA	BICON PHARM	1MG	A091145	001	Jul 12, 2013	Jul NEWA
--------	-------------	-----	---------	-----	--------------	----------

FOSINOPRIL SODIUM

TABLET; ORAL
FOSINOPRIL SODIUM

@	WATSON LABS	10MG	A076987	001	Dec 23, 2004	Mar DISC
@		20MG	A076987	002	Dec 23, 2004	Mar DISC
@		40MG	A076987	003	Dec 23, 2004	Mar DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION
FOSPHENYTOIN SODIUM

AP	AMNEAL PHARMS	EQ 50MG PHENYTOIN NA/ML	A078476	001	Mar 18, 2008	May CAHN
	@ APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126	001	Aug 06, 2007	Apr DISC
	@ TEVA PHARMS USA	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	May CAHN

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

@	INTL MEDICATION	10MG/ML	N018025	001		Jan DISC
---	-----------------	---------	---------	-----	--	----------

TABLET; ORAL

FUROSEMIDE

@	DAVA PHARMS INC	20MG	N018415	001	Jul 27, 1982	Feb DISC
@		40MG	N018415	002	Jul 27, 1982	Feb DISC
@		80MG	N018415	003	Nov 26, 1984	Feb DISC

GABAPENTINCAPSULE; ORAL
GABAPENTIN

>A>	AB	TARO	100MG	A077261	001	Aug 02, 2013	Jul NEWA
>A>	AB		300MG	A077261	002	Aug 02, 2013	Jul NEWA
>A>	AB		400MG	A077261	003	Aug 02, 2013	Jul NEWA

SOLUTION; ORAL
GABAPENTIN

AA		TARO	250MG/5ML	A076672	001	Jul 03, 2013	Jun NEWA
----	--	------	-----------	---------	-----	--------------	----------

TABLET; ORAL
GABAPENTIN

>A>	AB	ALLIED PHARMA INC	600MG	A203244	002	Jul 12, 2013	Jul NEWA
>A>	AB		800MG	A203244	001	Jul 12, 2013	Jul NEWA

GABAPENTIN ENACARBILTABLET, EXTENDED RELEASE; ORAL
HORIZANT

		XENOPORT INC	300MG	N022399	002	Dec 13, 2011	May CAHN
+			600MG	N022399	001	Apr 06, 2011	May CAHN

GADOTERATE MEGLUMINESOLUTION; INTRAVENOUS
DOTAREM

+		GUERBET	3.769GM/10ML (376.9MG/ML)	N204781	002	Mar 20, 2013	Mar NEWA
+			5.6535GM/15ML (376.9MG/ML)	N204781	003	Mar 20, 2013	Mar NEWA
+			7.538GM/20ML (376.9MG/ML)	N204781	004	Mar 20, 2013	Mar NEWA
+			37.69GM/100ML (376.9MG/ML)	N204781	001	Mar 20, 2013	Mar NEWA

GADOXETATE DISODIUMSOLUTION; INTRAVENOUS
EOVIST

		BAYER HLTHCARE	2.72145GM/15ML (181.43MG/ML)	N022090	002	Feb 04, 2013	Feb NEWA
--	--	----------------	------------------------------	---------	-----	--------------	----------

GALLIUM NITRATEINJECTABLE; INJECTION
GANITE

>A>		@ CHAPTER 7 TRUSTEE	25MG/ML	N019961	002	Jan 17, 1991	Jul CAHN
		@ GENTA	25MG/ML	N019961	002	Jan 17, 1991	Jul DISC
>D>		+	25MG/ML	N019961	002	Jan 17, 1991	Jul DISC
>A>		@	25MG/ML	N019961	002	Jan 17, 1991	Jul DISC

GANCICLOVIRIMPLANT; IMPLANTATION
VITRASERT

		@ BAUSCH AND LOMB	4.5MG	N020569	001	Mar 04, 1996	May DISC
--	--	-------------------	-------	---------	-----	--------------	----------

GATIFLOXACINSOLUTION/DROPS; OPHTHALMIC
GATIFLOXACIN

		@ APOTEX INC	0.3%	A079084	001	Aug 19, 2011	Apr DISC
--	--	--------------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

>A>	AP	CIPLA LTD	EQ 1GM BASE/VIAL	A078759	002	Jul 25, 2011	Jul CAHN
>A>	AP		EQ 200MG BASE/VIAL	A078759	001	Jul 25, 2011	Jul CAHN
	AP	DR REDDYS LABS LTD	EQ 2GM BASE/VIAL	A202997	001	May 07, 2013	Apr NEWA
	AP	JIANGSU HANSON PHARM	EQ 1GM BASE/VIAL	A202485	002	May 07, 2013	Apr NEWA
	AP		EQ 200MG BASE/VIAL	A202485	001	May 07, 2013	Apr NEWA
	AP	PHARMAFORCE	EQ 1GM BASE/VIAL	A202031	002	May 07, 2013	Apr NEWA
	AP		EQ 200MG BASE/VIAL	A202031	001	May 07, 2013	Apr NEWA
	AP	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091597	002	May 07, 2013	Apr NEWA
	AP		EQ 200MG BASE/VIAL	A091597	001	May 07, 2013	Apr NEWA
>D>	AP	WATSON LABS	EQ 1GM BASE/VIAL	A078759	002	Jul 25, 2011	Jul CAHN
>D>	AP		EQ 200MG BASE/VIAL	A078759	001	Jul 25, 2011	Jul CAHN

GEMFIBROZILTABLET; ORAL
GEMFIBROZIL

AB		CARACO	600MG	A079239	001	Dec 29, 2008	Jun CAHN
----	--	--------	-------	---------	-----	--------------	----------

GENTAMICIN SULFATE

		OINTMENT; OPHTHALMIC					
		GENTAMICIN SULFATE					
AT		PERRIGO CO TENNESSEE	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Jun CAHN
		SOLUTION/DROPS; OPHTHALMIC					
		GENTAMICIN SULFATE					
AT		PERRIGO CO TENNESSEE	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Jun CAHN

GLATIRAMER ACETATE

		FOR SOLUTION; SUBCUTANEOUS					
		COPAXONE					
		@ TEVA PHARMS USA	20MG/VIAL	N020622	001	Dec 20, 1996	Apr CAHN
		INJECTABLE; SUBCUTANEOUS					
		COPAXONE					
		+ TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Apr CAHN

GLIMEPIRIDE

		TABLET; ORAL					
		GLIMEPIRIDE					
		@ COREPHARMA	1MG	A077274	001	Oct 06, 2005	Feb DISC
		@	2MG	A077274	002	Oct 06, 2005	Feb DISC
		@	4MG	A077274	003	Oct 06, 2005	Feb DISC
>A>	AB	HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Jul NEWA
>A>	AB		2MG	A078952	002	Aug 01, 2013	Jul NEWA
>A>	AB		4MG	A078952	003	Aug 01, 2013	Jul NEWA
	AB	INDOCO REMEDIES	1MG	A202112	001	Apr 17, 2013	Apr NEWA
	AB		2MG	A202112	002	Apr 17, 2013	Apr NEWA
	AB		4MG	A202112	003	Apr 17, 2013	Apr NEWA
>A>	AB	MICRO LABS LTD INDIA	1MG	A091220	001	Jun 29, 2012	Jul CAHN
>A>	AB		2MG	A091220	002	Jun 29, 2012	Jul CAHN
>A>			3MG	A091220	003	Jun 29, 2012	Jul CAHN
>A>	AB		4MG	A091220	004	Jun 29, 2012	Jul CAHN
>A>			6MG	A091220	005	Jun 29, 2012	Jul CAHN
>A>	AB		8MG	A091220	006	Jun 29, 2012	Jul CAHN
>D>	AB	MICRO LABS USA	1MG	A091220	001	Jun 29, 2012	Jul CAHN
>D>	AB		2MG	A091220	002	Jun 29, 2012	Jul CAHN
>D>			3MG	A091220	003	Jun 29, 2012	Jul CAHN
>D>	AB		4MG	A091220	004	Jun 29, 2012	Jul CAHN
>D>			6MG	A091220	005	Jun 29, 2012	Jul CAHN
>D>	AB		8MG	A091220	006	Jun 29, 2012	Jul CAHN

GLIPIZIDE

		TABLET; ORAL					
		GLIPIZIDE					
AB		ACCORD HLTHCARE	5MG	A074550	001	Sep 11, 1997	Apr CAHN
AB			10MG	A074550	002	Sep 11, 1997	Apr CAHN
		@ BARR LABS INC	5MG	A074619	001	Apr 04, 1997	May CAHN
		@	10MG	A074619	002	Apr 04, 1997	May CAHN

GLYCEROL PHENYLBUTYRATE

		LIQUID; ORAL					
		RAVICTI					
		+ HYPERION THERAP INC	1.1GM/ML	N203284	001	Feb 01, 2013	Feb NEWA

GLYCOPYRROLATE

		INJECTABLE; INJECTION					
		ROBINUL					
AP		+ HIKMA MAPLE	0.2MG/ML	N017558	001		Apr CAHN
		TABLET; ORAL					
		GLYCOPYRROLATE					
AA		AUROLIFE PHARMA LLC	1MG	A202675	001	Apr 15, 2013	Apr NEWA
		@ COREPHARMA	1MG	A040568	001	Dec 22, 2004	Mar DISC
		@	2MG	A040568	002	Dec 22, 2004	Mar DISC
>D>	AA	WEST WARD	1MG	A040836	001	Mar 05, 2009	Jul DISC
>A>		@	1MG	A040836	001	Mar 05, 2009	Jul DISC
>D>	AA		2MG	A040836	002	Mar 05, 2009	Jul DISC
>A>		@	2MG	A040836	002	Mar 05, 2009	Jul DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

	@	APOTEX INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	Apr DISC
	@		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr DISC
	@		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr DISC
	@	EBEWE PHARMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008	Feb DISC
AP	+	TEVA PHARMS USA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078392	001	Dec 31, 2007	May CAHN
AP	+		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963	001	Jan 03, 2008	May CAHN
AP	+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077297	001	Jun 30, 2008	May CAHN
			GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE				
	@	TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007	May CAHN

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRIFULVIN V

AB	+	VALEANT LUXEMBOURG	125MG/5ML	A062483	001	Jan 26, 1984	Apr CAHN
			TABLET; ORAL				
			GRISEOFULVIN				
>A>		SANDOZ	250MG	A091592	001	Aug 07, 2013	Jul NEWA
>A>	AB		500MG	A091592	002	Aug 07, 2013	Jul NEWA

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

	@	EPIC PHARMA LLC	EQ 1MG BASE	A074673	001	Feb 28, 1997	Jun DISC
	@		EQ 2MG BASE	A074673	002	Feb 28, 1997	Jun DISC

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

	@	FOUGERA PHARMS	0.05%	A076903	001	Dec 16, 2004	Apr DISC
	@	G AND W LABS INC	0.05%	A077109	001	Jun 14, 2005	Jun CAHN
	@	TARO	0.05%	A076994	001	Dec 16, 2004	Mar DISC

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

	@	APOTEX INC	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Apr DISC
	@		EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Apr DISC
AO		TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999	Jun CAHN
AO			EQ 100MG BASE/ML	A075393	002	May 11, 1999	Jun CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

	@	APOTEX INC	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr DISC
	@		EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	Apr DISC
AP		TEVA PHARMS USA	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001	Jun CAHN

HYALURONIDASE

INJECTABLE; INJECTION

VITRASE

	+	BAUSCH AND LOMB	200 UNITS/VIAL	N021640	002	Dec 02, 2004	May CAHN
	@		6,200 UNITS/VIAL	N021640	001	May 05, 2004	May CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HYDROCHLORIDE

AP	NAVINTA LLC	20MG/ML	A202938	001	Mar 28, 2013	Mar NEWA
	TABLET; ORAL					
	HYDRALAZINE HYDROCHLORIDE					
AA	ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr CAHN
AA		25MG	A091679	002	Mar 04, 2013	Apr CAHN
AA		50MG	A091679	003	Mar 04, 2013	Apr CAHN
AA		100MG	A091679	004	Mar 04, 2013	Apr CAHN
AA	ACTAVIS PHARMA	10MG	A091679	001	Mar 04, 2013	Feb NEWA
AA		25MG	A091679	002	Mar 04, 2013	Feb NEWA
AA		50MG	A091679	003	Mar 04, 2013	Feb NEWA
AA		100MG	A091679	004	Mar 04, 2013	Feb NEWA
AA	ALKEM LABS LTD	10MG	A200737	001	Dec 07, 2012	Apr CTEC
AA		25MG	A200737	002	Dec 07, 2012	Apr CTEC
AA		50MG	A200737	003	Dec 07, 2012	Apr CTEC
AA		100MG	A200737	004	Dec 07, 2012	Apr CTEC
AA	HETERO LABS LTD III	10MG	A040901	001	Sep 12, 2008	Apr CAHN
AA		25MG	A040901	002	Sep 12, 2008	Apr CAHN
AA		50MG	A040901	003	Sep 12, 2008	Apr CAHN
AA		100MG	A040901	004	Sep 12, 2008	Apr CAHN
AA	STRIDES ARCOLAB LTD	25MG	A200770	001	May 03, 2013	Apr NEWA
AA		50MG	A200770	002	May 03, 2013	Apr NEWA
AA		100MG	A200770	003	May 03, 2013	Apr NEWA
	@ ZYDUS PHARMS USA	10MG	A040858	001	Feb 26, 2010	Jun DISC
	@	25MG	A040858	002	Feb 26, 2010	Jun DISC
	@	50MG	A040858	003	Feb 26, 2010	Jun DISC
	@	100MG	A040858	004	Feb 26, 2010	Jun DISC

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

@	WATSON LABS	25MG	A081189	001	Jan 24, 1992	Mar DISC
---	-------------	------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	12.5MG;150MG	A203630	001	Feb 22, 2013	Feb NEWA
AB		12.5MG;300MG	A203630	002	Feb 22, 2013	Feb NEWA
AB	LUPIN LTD	12.5MG;150MG	A201524	001	Feb 27, 2013	Feb NEWA
AB		12.5MG;300MG	A201524	002	Feb 27, 2013	Feb NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	IPCA LABS LTD	12.5MG;50MG	A201682	001	Mar 01, 2013	Feb NEWA
AB		12.5MG;100MG	A201682	002	Mar 01, 2013	Feb NEWA
AB		25MG;100MG	A201682	003	Mar 01, 2013	Feb NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
INDERIDE-40/25

>D>	AB	+	AKRIMAX PHARMS	25MG;40MG	N018031	001	Jul CAHN
>A>	AB	+	WYETH PHARMS INC	25MG;40MG	N018031	001	Jul CAHN
			INDERIDE-80/25				
>D>		@	AKRIMAX PHARMS	25MG;80MG	N018031	002	Jul CAHN
>A>		@	WYETH PHARMS INC	25MG;80MG	N018031	002	Jul CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX CORP	12.5MG;EQ 10MG BASE	A091524	001	Mar 12, 2013	Mar NEWA
AB		12.5MG;EQ 20MG BASE	A091524	002	Mar 12, 2013	Mar NEWA
AB		25MG;EQ 20MG BASE	A091524	003	Mar 12, 2013	Mar NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENETABLET; ORAL
MAXZIDE

AB	+	MYLAN PHARMS INC	50MG;75MG	N019129	001	Oct 22, 1984	May CAHN
AB		MAXZIDE-25					
AB		MYLAN PHARMS INC	25MG;37.5MG	N019129	003	May 13, 1988	May CAHN
		TRIAMTERENE AND HYDROCHLOROTHIAZIDE					
		@ WATSON LABS	50MG;75MG	A071969	001	Apr 17, 1988	Jan DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC LTD	12.5MG;80MG	A201662	001	Mar 21, 2013	Mar NEWA
AB			12.5MG;160MG	A201662	002	Mar 21, 2013	Mar NEWA
AB			12.5MG;320MG	A201662	003	Mar 21, 2013	Mar NEWA
AB			25MG;160MG	A201662	004	Mar 21, 2013	Mar NEWA
AB			25MG;320MG	A201662	005	Mar 21, 2013	Mar NEWA
AB		APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013	Mar NEWA
AB			12.5MG;160MG	A203026	002	Mar 21, 2013	Mar NEWA
AB			12.5MG;320MG	A203026	003	Mar 21, 2013	Mar NEWA
AB			25MG;160MG	A203026	004	Mar 21, 2013	Mar NEWA
AB			25MG;320MG	A203026	005	Mar 21, 2013	Mar NEWA
AB		AUROBINDO PHARMA LTD	12.5MG;80MG	A202519	001	Mar 21, 2013	Mar NEWA
AB			12.5MG;160MG	A202519	002	Mar 21, 2013	Mar NEWA
AB			12.5MG;320MG	A202519	003	Mar 21, 2013	Mar NEWA
AB			25MG;160MG	A202519	004	Mar 21, 2013	Mar NEWA
AB			25MG;320MG	A202519	005	Mar 21, 2013	Mar NEWA
AB		LUPIN LTD	12.5MG;80MG	A078946	003	Mar 21, 2013	Mar NEWA
AB			12.5MG;160MG	A078946	004	Mar 21, 2013	Mar NEWA
AB			12.5MG;320MG	A078946	001	Mar 21, 2013	Mar NEWA
AB			25MG;160MG	A078946	005	Mar 21, 2013	Mar NEWA
AB			25MG;320MG	A078946	002	Mar 21, 2013	Mar NEWA
AB		MACLEODS PHARMS LTD	12.5MG;80MG	A203145	001	Apr 19, 2013	Apr NEWA
AB			12.5MG;160MG	A203145	002	Apr 19, 2013	Apr NEWA
AB			12.5MG;320MG	A203145	003	Apr 19, 2013	Apr NEWA
AB			25MG;160MG	A203145	004	Apr 19, 2013	Apr NEWA
AB			25MG;320MG	A203145	005	Apr 19, 2013	Apr NEWA
AB		WATSON LABS INC	12.5MG;80MG	A091519	001	Mar 21, 2013	Mar NEWA
AB			12.5MG;160MG	A091519	002	Mar 21, 2013	Mar NEWA
AB			12.5MG;320MG	A091519	003	Mar 21, 2013	Mar NEWA
AB			25MG;160MG	A091519	004	Mar 21, 2013	Mar NEWA
AB			25MG;320MG	A091519	005	Mar 21, 2013	Mar NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB		SUN PHARM INDS INC	2.5MG;200MG	A091633	001	May 28, 2013	May NEWA
AB			5MG;200MG	A091633	002	May 28, 2013	May NEWA
AB			7.5MG;200MG	A091633	003	May 28, 2013	May NEWA
AB			10MG;200MG	A091633	004	May 28, 2013	May NEWA
		REPREXAIN					
AB		AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007	May CFTG
AB			10MG;200MG	A076642	004	Oct 19, 2007	May CFTG

HYDROCORTISONE

LOTION; TOPICAL

STIE-CORT

@ PERRIGO CO

1%

A089066 001 Nov 25, 1985 Feb DISC

OINTMENT; TOPICAL

HYDROCORTISONE

@ TARO

2.5%

A040310 001 Dec 29, 2000 Mar DISC

HYDROCORTISONE ACETATE

PASTE; TOPICAL

ORABASE HCA

@ COLGATE

0.5%

A083205 001 Mar DISC

HYDROCORTISONE VALERATE

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

@	FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001	Feb DISC
+	TARO	0.2%	A075043	001	Aug 25, 1998	Feb CRLD
	WESTCORT					
@	RANBAXY	0.2%	N018726	001	Aug 08, 1983	Feb DISC

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EXALGO

	MALLINCKRODT INC	16MG	N021217	003	Mar 01, 2010	Jan CRLD
+		32MG	N021217	004	Aug 24, 2012	Jan CRLD

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

@	BARR LABS INC	250MG	A075020	002	Jun 26, 2000	Jun CAHN
@		500MG	A075020	001	Jul 30, 1998	Jun CAHN

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

>A> AA	SILARX PHARMS INC	10MG/5ML	A201674	001	Aug 21, 2013	Jul NEWA
--------	-------------------	----------	---------	-----	--------------	----------

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB	CARACO	10MG	A040899	001	Jun 10, 2008	Jun CAHN
AB		25MG	A040899	002	Jun 10, 2008	Jun CAHN
AB		50MG	A040899	003	Jun 10, 2008	Jun CAHN
AB	HETERO LABS LTD III	10MG	A040805	001	May 29, 2008	Apr CAHN
AB		25MG	A040805	002	May 29, 2008	Apr CAHN
AB		50MG	A040805	003	May 29, 2008	Apr CAHN

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB	EMCURE PHARMS USA	25MG	A201507	001	Jun 03, 2013	May NEWA
AB		50MG	A201507	002	Jun 03, 2013	May NEWA

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

@	CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348	001	Jun 11, 2009	May DISC
---	-------------------	----------------------	---------	-----	--------------	----------

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+	RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	May CAHN
---	----------------	------------------------------------	---------	-----	--------------	----------

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+	AMARIN PHARMS	1GM	N202057	001	Jul 26, 2012	Jun NEWA
---	---------------	-----	---------	-----	--------------	----------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE PFS

AP	TEVA PHARMS USA	1MG/ML	A065036	001	May 01, 2002	Apr CAHN
----	-----------------	--------	---------	-----	--------------	----------

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

AP	+	TEVA PHARMS USA	1GM/20ML (50MG/ML)	A076657	001	Apr 04, 2007	May CAHN
AP	+		3GM/60ML (50MG/ML)	A076657	002	Apr 04, 2007	May CAHN

IFOSFAMIDE; MESNAINJECTABLE; INTRAVENOUS
IFOSFAMIDE/MESNA KIT

+	TEVA PHARMS USA	1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	001	Feb 26, 2002	May CAHN
+		3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	002	Feb 26, 2002	May CAHN

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

@	PROSAM LABS	10MG	A040753	001	Feb 28, 2008	Mar DISC
@		25MG	A040752	001	Feb 28, 2008	Mar DISC
@		50MG	A040751	001	Feb 28, 2008	Mar DISC

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

AB	MYLAN PHARMS INC	EQ 75MG HCL	A202338	001	Jun 28, 2013	Jun NEWA
AB		EQ 100MG HCL	A202338	002	Jun 28, 2013	Jun NEWA
AB		EQ 125MG HCL	A202338	003	Jun 28, 2013	Jun NEWA
AB		EQ 150MG HCL	A202338	004	Jun 28, 2013	Jun NEWA

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

@	MERCK SHARP DOHME	EQ 100MG BASE	N020685	006	Apr 19, 2000	Jun DISC
---	-------------------	---------------	---------	-----	--------------	----------

INDOMETHACIN

CAPSULE; ORAL

INDOCIN

@	ICEUTICA OPERATIONS	25MG	N016059	001		Mar CAHN
@		50MG	N016059	002		Mar CAHN

INDOMETHACIN

AB	CARACO	25MG	A091401	001	Mar 28, 2013	Jun CAHN
AB		50MG	A091401	002	Mar 28, 2013	Jun CAHN
AB	HETERO LABS LTD III	25MG	A091240	001	Apr 12, 2011	Apr CAHN
AB		50MG	A091240	002	Apr 12, 2011	Apr CAHN
AB	SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013	Mar NEWA
AB		50MG	A091401	002	Mar 28, 2013	Mar NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP	+	RECORDATI RARE	EQ 1MG BASE/VIAL	N018878	001	Jan 30, 1985	May CAHN
----	---	----------------	------------------	---------	-----	--------------	----------

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

@	APOTEX INC	0.02%	A075441	001	Mar 28, 2001	Apr DISC
@	TEVA PHARMS USA	0.02%	A075313	001	Feb 07, 2000	Mar DISC

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

@	APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003	Apr DISC
@		0.042MG/SPRAY	A076155	001	Apr 18, 2003	Apr DISC

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD

EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013	Mar NEWA
--	---------	-----	--------------	----------

ISONIAZID

TABLET; ORAL

ISONIAZID

@	WATSON LABS	300MG	A080521	001		Jun DISC
---	-------------	-------	---------	-----	--	----------

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE

+ SANOFI AVENTIS US 150MG;300MG

A061884 001

Apr CTEC

RIFAMPIN AND ISONIAZID

@ WEST WARD PHARM CORP 150MG;300MG

A065221 001

Jul 29, 2005

Apr DISC

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

@ INTL MEDICATION 0.2MG/ML

A083724 001

Mar DISC

ISUPREL

+ HOSPIRA 0.2MG/ML

N010515 001

Mar CTEC

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

+ ACTIENT PHARMS 40MG

N019790 001

Sep 02, 1988

May CAHN

TABLET; ORAL

ISORDIL

AB VALEANT BERMUDA 5MG

N012093 007

Jul 29, 1988

Apr CAHN

AB 10MG

N012093 002

Jul 29, 1988

Apr CAHN

AB 20MG

N012093 006

Jul 29, 1988

Apr CAHN

AB + 30MG

N012093 005

Jul 29, 1988

Apr CAHN

+ 40MG

N012093 001

Jul 29, 1988

Apr CAHN

AB VALEANT PHARM NORTH 5MG

N012093 007

Jul 29, 1988

Mar CAHN

AB 10MG

N012093 002

Jul 29, 1988

Mar CAHN

AB 20MG

N012093 006

Jul 29, 1988

Mar CAHN

AB + 30MG

N012093 005

Jul 29, 1988

Mar CAHN

+ 40MG

N012093 001

Jul 29, 1988

Mar CAHN

ISOSORBIDE DINITRATE

AB PAR PHARM 5MG

A086923 001

Mar 12, 1987

Apr CMFD

@ 5MG

A086923 001

Mar 12, 1987

Feb DISC

@ WATSON LABS 5MG

A086034 001

Jan 06, 1988

Apr DISC

@ 10MG

A086032 001

Jan 07, 1988

Apr DISC

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

@ WATSON LABS 2.5MG

A086033 001

Feb 26, 1988

Jun DISC

@ 5MG

A086031 001

Sep 29, 1987

Jun DISC

AB + WEST WARD PHARM CORP 5MG

A086055 001

Nov 02, 1987

Jun CRLD

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

BX RANBAXY 10MG

N021951 001

May 25, 2012

Feb CAHN

BX 20MG

N021951 002

May 25, 2012

Feb CAHN

BX 30MG

N021951 003

May 25, 2012

Feb CAHN

BX 40MG

N021951 004

May 25, 2012

Feb CAHN

AMNESTEEM

AB MYLAN PHARMS INC 20MG

A075945 002

Nov 08, 2002

Apr CRLD

CLARAVIS

AB TEVA PHARMS USA 10MG

A076356 001

Apr 11, 2003

May CAHN

AB 30MG

A076135 003

May 11, 2006

Apr CRLD

AB + 40MG

A076135 001

Apr 11, 2003

Apr CRLD

ZENATANE

AB DR REDDYS LABS LTD 10MG

A202099 001

Mar 25, 2013

Mar NEWA

AB 20MG

A202099 002

Mar 25, 2013

Mar NEWA

AB 40MG

A202099 003

Mar 25, 2013

Mar NEWA

ISRADIPINE

TABLET, EXTENDED RELEASE; ORAL

DYNACIRC CR

@ GLAXOSMITHKLINE LLC 5MG

N020336 001

Jun 01, 1994

Jun DISC

@ 10MG

N020336 002

Jun 01, 1994

Jun DISC

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

@ APOTEX INC	15MG/ML	A075631	002	Jun 29, 2001	Apr	DISC
@	30MG/ML	A075626	001	Jul 24, 2001	Apr	DISC
@	30MG/ML	A075631	001	Jun 29, 2001	Apr	DISC
@	30MG/ML	A077201	001	Oct 14, 2005	Apr	DISC
@ LUITPOLD	15MG/ML	A078145	001	Jan 14, 2008	Jun	DISC
@	30MG/ML	A078145	002	Jan 14, 2008	Jun	DISC

SOLUTION/DROPS; OPHTHALMIC

ACULAR PRESERVATIVE FREE

@ ALLERGAN	0.5%	N020811	001	Nov 03, 1997	May	DISC
------------	------	---------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

>A> AP	AKORN INC	5MG/ML	A075431	001	Nov 29, 1999	Jul	CAHN
>A> AP		5MG/ML	A075524	001	Nov 29, 1999	Jul	CAHN
	@ APOTEX INC	5MG/ML	A076051	001	Jul 05, 2002	Apr	DISC
>D> AP	TAYLOR	5MG/ML	A075431	001	Nov 29, 1999	Jul	CAHN
>D> AP		5MG/ML	A075524	001	Nov 29, 1999	Jul	CAHN

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	+	SANDOZ	200MG	A075113	002	Aug 04, 1998	Jan	CRLD
		TRANDATE						
		@ PROMETHEUS LABS	100MG	N018716	001	May 24, 1985	Jan	DISC
		@	200MG	N018716	002	Aug 01, 1984	Jan	DISC

LACTULOSE

SOLUTION; ORAL

LACTULOSE

@ APOTEX INC	10GM/15ML	A075911	001	Feb 21, 2002	Apr	DISC
--------------	-----------	---------	-----	--------------	-----	------

SOLUTION; ORAL, RECTAL

LACTULOSE

@ APOTEX INC	10GM/15ML	A076645	001	Jul 28, 2003	Apr	DISC
--------------	-----------	---------	-----	--------------	-----	------

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

AB	+	GLAXOSMITHKLINE LLC	25MG	N020241	005	Dec 27, 1994	Mar CAHN
	@		50MG	N020241	006	Dec 27, 1994	Mar CAHN
AB			100MG	N020241	001	Dec 27, 1994	Mar CAHN
AB			150MG	N020241	002	Dec 27, 1994	Mar CAHN
AB			200MG	N020241	003	Dec 27, 1994	Mar CAHN
	@		250MG	N020241	004	Dec 27, 1994	Mar CAHN

LAMOTRIGINE

AB		ALKEM LABS LTD	25MG	A200694	001	Jun 14, 2013	Jun NEWA
AB			100MG	A200694	002	Jun 14, 2013	Jun NEWA
AB			150MG	A200694	003	Jun 14, 2013	Jun NEWA
AB			200MG	A200694	004	Jun 14, 2013	Jun NEWA

TABLET, CHEWABLE; ORAL

LAMICTAL CD

AB		GLAXOSMITHKLINE LLC	2MG	N020764	004	Sep 08, 2000	Mar CAHN
AB			5MG	N020764	001	Aug 24, 1998	Mar CAHN
AB	+		25MG	N020764	002	Aug 24, 1998	Mar CAHN
	@		100MG	N020764	003	Aug 24, 1998	Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

AB		GLAXOSMITHKLINE LLC	25MG	N022115	001	May 29, 2009	Mar CAHN
AB	+		50MG	N022115	002	May 29, 2009	Mar CAHN
AB			100MG	N022115	003	May 29, 2009	Mar CAHN
AB			200MG	N022115	004	May 29, 2009	Mar CAHN
AB			250MG	N022115	006	Jun 21, 2011	Mar CAHN
AB			300MG	N022115	005	Apr 14, 2010	Mar CAHN

LAMOTRIGINE

AB		DR REDDYS LABS LTD	25MG	A202383	001	Jun 19, 2013	Jun NEWA
AB			50MG	A202383	002	Jun 19, 2013	Jun NEWA
AB			100MG	A202383	003	Jun 19, 2013	Jun NEWA
AB			200MG	A202383	004	Jun 19, 2013	Jun NEWA
AB			300MG	A202383	005	Jun 19, 2013	Jun NEWA
AB		PAR PHARM	25MG	A201791	001	Jan 18, 2013	Jan NEWA
AB			50MG	A201791	002	Jan 18, 2013	Jan NEWA
AB			100MG	A201791	003	Jan 18, 2013	Jan NEWA
AB			200MG	A201791	004	Jan 18, 2013	Jan NEWA
AB			250MG	A201791	005	Jan 18, 2013	Jan NEWA
AB			300MG	A201791	006	Jan 18, 2013	Jan NEWA
AB		WILSHIRE PHARMS INC	25MG	A202887	001	Jun 17, 2013	Jun NEWA
AB			50MG	A202887	002	Jun 17, 2013	Jun NEWA
AB			100MG	A202887	003	Jun 17, 2013	Jun NEWA
AB			200MG	A202887	004	Jun 17, 2013	Jun NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

LAMICTAL ODT

		GLAXOSMITHKLINE LLC	25MG	N022251	001	May 08, 2009	Mar CAHN
>D>			25MG	N022251	001	May 08, 2009	Jul CFTG
>A>	AB		25MG	N022251	001	May 08, 2009	Jul CFTG
	+		50MG	N022251	002	May 08, 2009	Mar CAHN
>D>	+		50MG	N022251	002	May 08, 2009	Jul CFTG
>A>	AB	+	50MG	N022251	002	May 08, 2009	Jul CFTG
			100MG	N022251	002	May 08, 2009	Jul CFTG
>D>			100MG	N022251	003	May 08, 2009	Mar CAHN
>A>	AB		100MG	N022251	003	May 08, 2009	Jul CFTG
			200MG	N022251	004	May 08, 2009	Mar CAHN
>D>			200MG	N022251	004	May 08, 2009	Jul CFTG
>A>	AB		200MG	N022251	004	May 08, 2009	Jul CFTG
>A>		LAMOTRIGINE					
>A>	AB	WATSON LABS INC	25MG	A200828	001	Jul 15, 2013	Jul NEWA
>A>	AB		50MG	A200828	002	Jul 15, 2013	Jul NEWA
>A>	AB		100MG	A200828	003	Jul 15, 2013	Jul NEWA
>A>	AB		200MG	A200828	004	Jul 15, 2013	Jul NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

>A>	AB	ZYDUS HLTHCARE	15MG	A202366	001	Aug 19, 2013	Jul NEWA
>A>	AB		30MG	A202366	002	Aug 19, 2013	Jul NEWA

LATANOPROSTSOLUTION/DROPS; OPHTHALMIC
LATANOPROST

	@ APOTEX INC	0.005%	A077697	001	Mar 22, 2011	Apr DISC
AT	DR REDDYS LABS LTD	0.005%	A202077	001	Feb 11, 2013	Jan NEWA

LENALIDOMIDECAPSULE; ORAL
REVLIMID

	CELGENE	20MG	N021880	006	Jun 05, 2013	Jun NEWA
--	---------	------	---------	-----	--------------	----------

LEPIRUDIN RECOMBINANTINJECTABLE; INJECTION
REFLUDAN

	@ BAYER HLTHCARE	50MG/VIAL	N020807	001	Mar 06, 1998	Jun DISC
--	------------------	-----------	---------	-----	--------------	----------

LETROZOLETABLET; ORAL
LETROZOLE

AB	JIANGSU HENGRUI MED	2.5MG	A202716	001	May 16, 2013	Apr NEWA
----	---------------------	-------	---------	-----	--------------	----------

LEUCOVORIN CALCIUMINJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP	TEVA PHARMS USA	EQ 100MG BASE/VIAL	A081277	001	Sep 28, 1993	Mar CAHN
AP		EQ 350MG BASE/VIAL	A040174	001	Jun 12, 1997	Mar CAHN
	LEUCOVORIN CALCIUM PRESERVATIVE FREE					
	@ LUITPOLD	EQ 50MG BASE/VIAL	A040338	001	Jan 31, 2001	Jun DISC

LEUPROLIDE ACETATEINJECTABLE; INJECTION
LEUPROLIDE ACETATE

AP	TEVA PHARMS USA	1MG/0.2ML	A075471	001	Oct 25, 2000	Mar CAHN
----	-----------------	-----------	---------	-----	--------------	----------

LUPRON

>D>	@ ABBOTT LABS	1MG/0.2ML	N019010	001	Apr 09, 1985	Jul CAHN
>A>	@ ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985	Jul CAHN

LUPRON DEPOT

>D>	+	ABBOTT ENDOCRINE	7.5MG/VIAL	N019732	001	Jan 26, 1989	Jul CAHN
>D>	+		11.25MG/VIAL	N020708	001	Mar 07, 1997	Jul CAHN
>D>	+		22.5MG/VIAL	N020517	001	Dec 22, 1995	Jul CAHN
>D>	+		30MG/VIAL	N020517	002	May 30, 1997	Jul CAHN
>D>	+		45MG/VIAL	N020517	003	Jun 17, 2011	Jul CAHN
	+	ABBVIE ENDOCRINE INC	3.75MG/VIAL	N020011	001	Oct 22, 1990	Apr CAHN
>A>	+		7.5MG/VIAL	N019732	001	Jan 26, 1989	Jul CAHN
>A>	+		11.25MG/VIAL	N020708	001	Mar 07, 1997	Jul CAHN
>A>	+		22.5MG/VIAL	N020517	001	Dec 22, 1995	Jul CAHN
>A>	+		30MG/VIAL	N020517	002	May 30, 1997	Jul CAHN
>A>	+		45MG/VIAL	N020517	003	Jun 17, 2011	Jul CAHN

LUPRON DEPOT-PED

>D>	@ ABBOTT ENDOCRINE	3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	Jul CAHN
>D>	@	7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	Jul CAHN
>D>	+	7.5MG/VIAL	N020263	002	Apr 16, 1993	Jul CAHN
>D>	+	11.25MG/VIAL	N020263	005	Jan 21, 1994	Jul CAHN
>D>	+	11.25MG/VIAL	N020263	007	Aug 15, 2011	Jul CAHN
>D>	+	15MG/VIAL	N020263	006	Jan 21, 1994	Jul CAHN
>D>	+	30MG/VIAL	N020263	008	Aug 15, 2011	Jul CAHN
>A>	@ ABBVIE ENDOCRINE INC	3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	Jul CAHN
>A>	@	7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	Jul CAHN
>A>	+	7.5MG/VIAL	N020263	002	Apr 16, 1993	Jul CAHN
>A>	+	11.25MG/VIAL	N020263	005	Jan 21, 1994	Jul CAHN
>A>	+	11.25MG/VIAL	N020263	007	Aug 15, 2011	Jul CAHN
>A>	+	15MG/VIAL	N020263	006	Jan 21, 1994	Jul CAHN
>A>	+	30MG/VIAL	N020263	008	Aug 15, 2011	Jul CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	DEY	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Mar NEWA
AN		EQ 0.021% BASE	A077800	002	Mar 15, 2013	Mar NEWA
AN		EQ 0.042% BASE	A077800	003	Mar 15, 2013	Mar NEWA
AN	TEVA PHARMS USA	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr NEWA
AN		EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr NEWA
AN		EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr NEWA

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	SAGENT PHARMS	500MG/5ML (100MG/ML)	A091627	001	Jun 26, 2013	Jun NEWA
----	---------------	----------------------	---------	-----	--------------	----------

SOLUTION; ORAL

LEVETIRACETAM

	@ APOTEX INC	100MG/ML	A090187	001	Aug 05, 2011	Apr DISC
AA	HETERO DRUGS LTD	100MG/ML	A203052	001	Feb 28, 2013	Feb NEWA
AA	HETERO LABS LTD III	100MG/ML	A203052	001	Feb 28, 2013	Apr CAHN
AA	ORIT LABS LLC	100MG/ML	A203067	001	May 09, 2013	Apr NEWA

TABLET; ORAL

LEVETIRACETAM

AB	HETERO LABS LTD III	1GM	A090515	004	Oct 08, 2010	Apr CAHN
AB		250MG	A090515	001	Oct 08, 2010	Apr CAHN
AB		500MG	A090515	002	Oct 08, 2010	Apr CAHN
AB		750MG	A090515	003	Oct 08, 2010	Apr CAHN
AB	PRINSTON INC	1GM	A078106	004	Feb 10, 2009	Apr CAHN
AB		250MG	A078106	001	Feb 10, 2009	Apr CAHN
AB		500MG	A078106	002	Feb 10, 2009	Apr CAHN
AB		750MG	A078106	003	Feb 10, 2009	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	@ SANDOZ	500MG	A091668	001	Nov 01, 2012	Mar DISC
	@	750MG	A091668	002	Nov 01, 2012	Mar DISC
AB	VINTAGE PHARMS LLC	500MG	A202533	001	Jul 20, 2012	Jan NEWA
AB		750MG	A202533	002	Jul 20, 2012	Jan NEWA

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

	@ APOTEX INC	0.25%	A075473	001	Aug 03, 2000	Apr DISC
	@	0.5%	A075475	001	Aug 03, 2000	Apr DISC

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

AP	TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	May CAHN
----	-----------------	----------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

>A> AA	TARO PHARM INDS	2.5MG/5ML	A202673	001	Jul 26, 2013	Jul NEWA
--------	-----------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	SANDOZ	5MG	A090486	001	Mar 26, 2013	Mar NEWA
AB	SUN PHARMA GLOBAL	5MG	A090362	001	Jan 31, 2013	Jan NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AP	AUROBINDO PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Jan NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Jan NEWA
AP	CLARIS LIFESCIENCES	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	May NEWA
AP	EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013	Jan NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013	Jan NEWA
	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
>A> AP	CLARIS LIFESCIENCES	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Jul NEWA
>A> AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Jul NEWA
>A> AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Jul NEWA
AP	FRESENIUS KABI USA	EQ 250MG/50ML (EQ 5MG/ML)	A200674	001	Jun 19, 2013	Jun NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A200674	002	Jun 19, 2013	Jun NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A200674	003	Jun 19, 2013	Jun NEWA
	SOLUTION/DROPS; OPHTHALMIC					
	LEVOFLOXACIN					
	@ APOTEX INC	0.5%	A078282	001	Dec 20, 2010	Apr DISC

>A> LEVOMILNACIPRAN HYDROCHLORIDE

>A> CAPSULE, EXTENDED RELEASE; ORAL

>A> FETZIMA

>A>	FOREST LABS INC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jul NEWA
>A>		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jul NEWA
>A>		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jul NEWA
>A>	+	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jul NEWA

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

@ NOVOCOL

0.05MG/ML;2%

A084697 001

Jun DISC

SCANDONEST L

+ DEPROCO

0.05MG/ML;2%

A088388 001

Oct 10, 1984

Jun CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

SKYLA

+ BAYER HLTHCARE

13.5MG

N203159 001

Jan 09, 2013

Jan NEWA

TABLET; ORAL

LEVONORGESTREL

AB LUPIN LTD

0.75MG

A091328 001

Jan 23, 2013

Jan NEWA

AB NOVEL LABS INC

1.5MG

A202508 001

Feb 22, 2013

Feb NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHYROXINE SODIUM

>D>	AB2, AB3	MERCK KGAA	0.025MG	A076752	001	Jun 16, 2005	Jul DISC
>A>	@		0.025MG	A076752	001	Jun 16, 2005	Jul DISC
>D>	AB2, AB3		0.05MG	A076752	002	Jun 16, 2005	Jul DISC
>A>	@		0.05MG	A076752	002	Jun 16, 2005	Jul DISC
>D>	AB2, AB3		0.075MG	A076752	003	Jun 16, 2005	Jul DISC
>A>	@		0.075MG	A076752	003	Jun 16, 2005	Jul DISC
>D>	AB2, AB3		0.088MG	A076752	004	Jun 16, 2005	Jul DISC
>A>	@		0.088MG	A076752	004	Jun 16, 2005	Jul DISC
>D>	AB2, AB3		0.1MG	A076752	005	Jun 16, 2005	Jul DISC
>A>	@		0.1MG	A076752	005	Jun 16, 2005	Jul DISC
>D>	AB2, AB3		0.112MG	A076752	006	Jun 16, 2005	Jul DISC
>A>	@		0.112MG	A076752	006	Jun 16, 2005	Jul DISC
>D>	AB2, AB3		0.125MG	A076752	007	Jun 16, 2005	Jul DISC
>A>	@		0.125MG	A076752	007	Jun 16, 2005	Jul DISC
>D>	AB2, AB3		0.15MG	A076752	008	Jun 16, 2005	Jul DISC
>A>	@		0.15MG	A076752	008	Jun 16, 2005	Jul DISC
>D>	AB2, AB3		0.175MG	A076752	009	Jun 16, 2005	Jul DISC
>A>	@		0.175MG	A076752	009	Jun 16, 2005	Jul DISC
>D>	AB2, AB3		0.2MG	A076752	010	Jun 16, 2005	Jul DISC
>A>	@		0.2MG	A076752	010	Jun 16, 2005	Jul DISC
>D>	AB2, AB3		0.3MG	A076752	011	Jun 16, 2005	Jul DISC
>A>	@		0.3MG	A076752	011	Jun 16, 2005	Jul DISC

LEVOXYL

AB1, AB3	KING PHARMS R AND D	0.025MG	N021301	001	May 25, 2001	Mar CAHN
AB1, AB3		0.05MG	N021301	002	May 25, 2001	Mar CAHN
AB1, AB3		0.075MG	N021301	003	May 25, 2001	Mar CAHN
AB1, AB3		0.088MG	N021301	004	May 25, 2001	Mar CAHN
AB1, AB3		0.1MG	N021301	005	May 25, 2001	Mar CAHN
AB1, AB3		0.112MG	N021301	006	May 25, 2001	Mar CAHN
AB1, AB3		0.125MG	N021301	007	May 25, 2001	Mar CAHN
AB1, AB3		0.137MG	N021301	008	May 25, 2001	Mar CAHN
AB1, AB3		0.15MG	N021301	009	May 25, 2001	Mar CAHN
AB1, AB3		0.175MG	N021301	010	May 25, 2001	Mar CAHN
AB1, + AB3		0.2MG	N021301	011	May 25, 2001	Mar CAHN
@		0.3MG	N021301	012	May 25, 2001	Mar CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

@	LUITPOLD	2%	A083198	001		Mar DISC
	LIDOCAINE HYDROCHLORIDE	PRESERVATIVE FREE				
AP	AUROBINDO PHARMA LTD	1%	A203040	001	Mar 14, 2013	Mar NEWA
AP		1%	A203082	001	Mar 14, 2013	Mar NEWA
AP		2%	A203040	002	Mar 14, 2013	Mar NEWA
AP		2%	A203082	002	Mar 14, 2013	Mar NEWA

JELLY; TOPICAL

ANESTACON

@	POLYMEDICA	2%	A080429	001		May DISC
	LIDOCAINE HYDROCHLORIDE					
@	TEVA PHARMS USA	2%	A081318	001	Apr 29, 1993	Jun DISC

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

AB	KING PHARMS R AND D	EQ 0.005MG BASE	N010379	001		Mar	CAHN
AB		EQ 0.025MG BASE	N010379	002		Mar	CAHN
AB	+	EQ 0.05MG BASE	N010379	003		Mar	CAHN

LISINOPRIL

TABLET; ORAL

LISINOPRIL

>A>	AB	ACCORD HLTHCARE	2.5MG	A202554	001	Jul 30, 2013	Jul	NEWA
>A>	AB		5MG	A202554	002	Jul 30, 2013	Jul	NEWA
>A>	AB		10MG	A202554	003	Jul 30, 2013	Jul	NEWA
>A>	AB		20MG	A202554	004	Jul 30, 2013	Jul	NEWA
>A>	AB		30MG	A202554	005	Jul 30, 2013	Jul	NEWA
>A>	AB		40MG	A202554	006	Jul 30, 2013	Jul	NEWA
		@ SANDOZ	2.5MG	A075999	001	Jul 01, 2002	Jan	CAHN
		@	5MG	A075999	002	Jul 01, 2002	Jan	CAHN
		@	10MG	A075999	003	Jul 01, 2002	Jan	CAHN
		@	20MG	A075999	004	Jul 01, 2002	Jan	CAHN
		@	30MG	A075999	005	Jul 01, 2002	Jan	CAHN
		@	40MG	A075999	006	Jul 01, 2002	Jan	CAHN

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

		@ APOTEX INC	300MG	A076795	001	Nov 22, 2004	Feb	DISC
AB		HETERO LABS LTD III	150MG	A090702	001	Sep 25, 2009	Apr	CAHN
AB			300MG	A090702	002	Sep 25, 2009	Apr	CAHN
AB			600MG	A090702	003	Sep 25, 2009	Apr	CAHN

LOMUSTINE

CAPSULE; ORAL

CEENU

		CORDEN PHARMA	10MG	N017588	001		Apr	CAHN
			40MG	N017588	002		Apr	CAHN
		+	100MG	N017588	003		Apr	CAHN

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA		LUPIN LTD	2MG/ML	A091407	001	Feb 19, 2013	Feb	NEWA
----	--	-----------	--------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

LORAZEPAM

>A>	AP	AKORN	2MG/ML	A075025	001	Jul 23, 1998	Jul	CAHN
>D>	AP	TAYLOR	2MG/ML	A075025	001	Jul 23, 1998	Jul	CAHN

TABLET; ORAL

LORAZEPAM

		@ SANDOZ	0.5MG	A071193	001	Apr 15, 1988	Apr	DISC
		@	1MG	A071194	001	Apr 15, 1988	Apr	DISC
		@	2MG	A071195	001	Apr 15, 1988	Apr	DISC

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB		ACTAVIS GRP PTC	25MG	A090382	001	Oct 06, 2010	Mar	CAHN
AB			50MG	A090382	002	Oct 06, 2010	Mar	CAHN
AB			100MG	A090382	003	Oct 06, 2010	Mar	CAHN

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB	+	CARLSBAD	40MG	A075991	003	Jun 05, 2002	Feb	CRLD
		MEVACOR						
		@ MERCK	20MG	N019643	003	Aug 31, 1987	Feb	DISC
		@	40MG	N019643	004	Dec 14, 1988	Feb	DISC

LOXAPINEPOWDER; INHALATION
ADASUVE

>D>	+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Jul CAHN
>A>	+	TEVA PHARMS USA INC	10MG	N022549	001	Dec 21, 2012	Jul CAHN

LOXAPINE SUCCINATECAPSULE; ORAL
LOXAPINE SUCCINATE

AB		MIKAH PHARMA	EQ 5MG BASE	A076868	001	Aug 04, 2005	May CMFD
AB			EQ 10MG BASE	A076868	002	Aug 04, 2005	May CMFD
AB			EQ 25MG BASE	A076868	003	Aug 04, 2005	May CMFD
AB			EQ 50MG BASE	A076868	004	Aug 04, 2005	May CMFD

LURASIDONE HYDROCHLORIDETABLET; ORAL
LATUDA

>A>		SUNOVION PHARMS INC	60MG	N200603	005	Jul 12, 2013	Jul NEWA
-----	--	---------------------	------	---------	-----	--------------	----------

MAFENIDE ACETATECREAM; TOPICAL
SULFAMYLON

	+	MYLAN INSTITUTIONAL	EQ 85MG BASE/GM	N016763	001		May CAHN
		FOR SOLUTION; TOPICAL					
		MAFENIDE ACETATE					
AB		PAR FORM	5%	A201511	001	Feb 12, 2013	Jan NEWA
		SULFAMYLON					
AB	+	MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998	May CAHN
AB	+	MYLAN LLC	5%	N019832	003	Jun 05, 1998	Jan CFTG

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATESOLUTION; ORAL
SUCLEAR

+	BRAINTREE LABS	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM	N203595	001	Jan 18, 2013	Jan NEWA
---	----------------	---	---------	-----	--------------	----------

MANNITOLINJECTABLE; INJECTION
MANNITOL 20%

@ B BRAUN	20GM/100ML	N014738	001		Jan DISC
-----------	------------	---------	-----	--	----------

MECAMYLAMINE HYDROCHLORIDETABLET; ORAL
MECAMYLAMINE HYDROCHLORIDE

NEXGEN PHARMA	2.5MG	A204054	001	Mar 19, 2013	Mar NEWA
---------------	-------	---------	-----	--------------	----------

MECHLORETHAMINE HYDROCHLORIDEINJECTABLE; INJECTION
MUSTARGEN

+	RECORDATI RARE	10MG/VIAL	N006695	001		May CAHN
---	----------------	-----------	---------	-----	--	----------

MEDROXYPROGESTERONE ACETATEINJECTABLE; INJECTION
MEDROXYPROGESTERONE ACETATE

AB	@ TEVA PHARMS USA	150MG/ML	A076552	001	Oct 27, 2004	May CAHN
		150MG/ML	A076553	001	Jul 28, 2004	May CAHN

MEFENAMIC ACIDCAPSULE; ORAL
MEFENAMIC ACID

AB	CYPRESS PHARM	250MG	A090359	001	Feb 05, 2013	Jan NEWA
----	---------------	-------	---------	-----	--------------	----------

MEFLOQUINE HYDROCHLORIDETABLET; ORAL
MEFLOQUINE HYDROCHLORIDE

@ WEST WARD PHARM CORP	250MG	A077699	001	Apr 21, 2010	Jun DISC
------------------------	-------	---------	-----	--------------	----------

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

@ APOTEX INC	40MG/ML	A077404	001	Feb 16, 2006	Apr DISC
--------------	---------	---------	-----	--------------	----------

MELOXICAM

TABLET; ORAL

MELOXICAM

@ COREPHARMA	7.5MG	A077930	001	Jul 19, 2006	Feb DISC
@	15MG	A077930	002	Jul 19, 2006	Feb DISC
@ CR DOUBLE CRANE	7.5MG	A078039	001	Dec 14, 2006	Apr DISC
AB	7.5MG	A078039	001	Dec 14, 2006	Mar CAHN
@	15MG	A078039	002	Dec 14, 2006	Apr DISC
AB	15MG	A078039	002	Dec 14, 2006	Mar CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

@ TARO	200MG	A200998	001	May 23, 2011	Jan DISC
@	400MG	A200998	002	May 23, 2011	Jan DISC

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

+ WARNER CHILCOTT LLC	400MG	N204412	001	Feb 01, 2013	Feb NEWA
SUPPOSITORY; RECTAL					
CANASA					
+ APTALIS PHARMA US	1GM	N021252	002	Nov 05, 2004	Feb CRLD

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	TEVA PHARMS USA	100MG/ML	A075764	001	Apr 27, 2001	May CAHN
----	-----------------	----------	---------	-----	--------------	----------

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

@ APOTEX INC	0.4%	A075402	001	Feb 28, 2001	Apr DISC
@	0.6%	A075403	001	Feb 28, 2001	Apr DISC

SYRUP; ORAL

METAPROTERENOL SULFATE

@ APOTEX INC	10MG/5ML	A075235	001	Jan 27, 2000	Apr DISC
@ NOVEX	10MG/5ML	A075235	001	Jan 27, 2000	Feb DISC
+ SILARX	10MG/5ML	A073632	001	Jul 22, 1992	Feb CTEC
TABLET; ORAL					
METAPROTERENOL SULFATE					
PAR PHARM	10MG	A072024	001	Jun 28, 1988	Mar CTEC
+	20MG	A072025	001	Jun 28, 1988	Mar CTEC
@ WATSON LABS	10MG	A073013	001	Jan 31, 1991	Mar DISC
@	20MG	A072795	001	Jan 31, 1991	Mar DISC

METAXALONE

TABLET; ORAL

METAXALONE

AB	AMNEAL PHARMS	800MG	A203399	001	Jun 21, 2013	Jun NEWA
----	---------------	-------	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	SANDOZ	1GM	A075965	003	Jan 25, 2002	May CMFD
	@	1GM	A075965	003	Jan 25, 2002	Mar DISC
AB		500MG	A075965	001	Jan 25, 2002	May CMFD
	@	500MG	A075965	001	Jan 25, 2002	Mar DISC
AB		850MG	A075965	002	Jan 25, 2002	May CMFD
	@	850MG	A075965	002	Jan 25, 2002	Mar DISC

TABLET, EXTENDED RELEASE; ORAL
FORTAMET

>D> AB	+	ANDRX LABS LLC	1GM	N021574	002	Apr 27, 2004	Jul CTEC
>A> AB2	+		1GM	N021574	002	Apr 27, 2004	Jul CTEC

GLUMETZA

>D> BX	+	SANTARUS	1GM	N021748	002	Jun 03, 2005	Jul CTEC
>A> AB3	+		1GM	N021748	002	Jun 03, 2005	Jul CTEC
>D> BX			500MG	N021748	001	Jun 03, 2005	Jul CTEC
>A> AB3			500MG	N021748	001	Jun 03, 2005	Jul CTEC

METFORMIN HYDROCHLORIDE

>D> AB		LUPIN LTD	1GM	A090692	002	Jun 29, 2011	Jul CTEC
>A> AB2			1GM	A090692	002	Jun 29, 2011	Jul CTEC
>A> AB3			1GM	A091664	002	Jul 19, 2013	Jul NEWA
>A> AB3			500MG	A091664	001	Jul 19, 2013	Jul NEWA
>D> AB		MYLAN PHARMS INC	1GM	A200690	002	Aug 01, 2012	Jul CTEC
>A> AB2			1GM	A200690	002	Aug 01, 2012	Jul CTEC
	@	TORRENT PHARMS LTD	750MG	A079226	001	Feb 18, 2010	Jun DISC
	@	WATSON LABS INC	500MG	A076818	001	Dec 14, 2004	Mar DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	500MG;EQ 15MG BASE	A200823	001	Feb 13, 2013	Jan NEWA
AB		850MG;EQ 15MG BASE	A200823	002	Feb 13, 2013	Jan NEWA
AB	SANDOZ	500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013	Apr NEWA
AB		850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013	Apr NEWA
AB	TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	Jan NEWA
AB		850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	Jan NEWA

METHADONE HYDROCHLORIDE

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDE

AA	MALLINCKRODT INC	40MG	A077142	001	Jul 12, 2005	Mar CDFR
AA	+ ROXANE	40MG	N017058	001		Mar CDFR
AA	SANDOZ	40MG	A075082	001	Mar 25, 1998	Mar CDFR
	METHADOSE					
AA	MALLINCKRODT	40MG	A074184	001	Apr 29, 1993	Mar CDFR

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

AA	+	RECORDATI RARE	5MG	N005378	002		May CAHN
----	---	----------------	-----	---------	-----	--	----------

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

>D> AP		WATSON LABS	100MG/ML	A086459	001		Jul DISC
>A>		@	100MG/ML	A086459	001		Jul DISC
		ROBAXIN					
>D> AP	+	BAXTER HLTHCARE CORP	100MG/ML	N011790	001		Jul CTEC
>A>	+		100MG/ML	N011790	001		Jul CTEC

TABLET; ORAL

METHOCARBAMOL

AA	AUSTARPHARMA LLC	500MG	A200958	001	Oct 21, 2011	May CMFD
	@	500MG	A200958	001	Oct 21, 2011	Jan DISC
AA		750MG	A200958	002	Oct 21, 2011	May CMFD
AA	HETERO LABS LTD III	500MG	A090200	001	Nov 06, 2009	Apr CAHN
AA		750MG	A090200	002	Nov 06, 2009	Apr CAHN
AA	PRINSTON INC	500MG	A086989	001		Feb CMFD
AA		750MG	A086988	001		Feb CAHN
	@ SOLCO HLTHCARE	500MG	A086989	001		Jan DISC

METHOXSALLENCAPSULE; ORAL
OXSORALEN-ULTRA

+ DOW PHARM 10MG

N019600 001 Oct 30, 1986 Apr CAHN

METHYLCLOTHIAZIDETABLET; ORAL
METHYLCLOTHIAZIDE+ MYLAN PHARMS INC 5MG
@ WATSON LABS 5MGA087672 001 Aug 17, 1982 Jan CTEC
A088724 001 Sep 06, 1984 Jan DISCMETHYL AMINOLEVULINATE HYDROCHLORIDECREAM; TOPICAL
METVIXIA

@ GALDERMA LABS LP EQ 16.8% BASE

N021415 001 Jul 27, 2004 Jun DISC

METHYLDOPATABLET; ORAL
METHYLDOPAAB @ ACCORD HLTHCARE 125MG
AB 250MG
AB 500MGA070070 003 Oct 15, 1985 Apr CAHN
A070084 001 Oct 15, 1985 Apr CAHN
A070085 001 Oct 15, 1985 Apr CAHNMETHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
METHYLPHENIDATE HYDROCHLORIDEAB1 WATSON LABS INC 20MG
AB1 30MG
AB1 40MGA078458 001 Dec 01, 2011 Apr CAHN
A078458 002 Dec 01, 2011 Apr CAHN
A078458 003 Dec 01, 2011 Apr CAHN

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB CARACO 5MG
AB 10MG
AB 20MGA090710 001 Mar 15, 2012 May CAHN
A090710 002 Mar 15, 2012 May CAHN
A090710 003 Mar 15, 2012 May CAHNTABLET, EXTENDED RELEASE; ORAL
CONCERTAAB JANSSEN PHARMS 18MG
METHYLIN ER
MALLINCKRODT INC 10MG
METHYLPHENIDATE HYDROCHLORIDE
AB KUDCO IRELAND 18MG
AB 27MGN021121 001 Aug 01, 2000 Jun CTEC
A075629 001 May 09, 2000 Feb CTEC
A091695 001 Jul 09, 2013 Jun NEWA
A091695 002 Jul 09, 2013 Jun NEWAMETHYLPREDNISOLONE ACETATEINJECTABLE; INJECTION
METHYLPREDNISOLONE ACETATEAB TEVA PHARMS USA 40MG/ML
AB 40MG/ML
AB 80MG/ML
AB 80MG/MLA040557 001 Feb 23, 2005 May CAHN
A040620 001 Oct 27, 2006 May CAHN
A040557 002 Feb 23, 2005 May CAHN
A040620 002 Oct 27, 2006 May CAHNMETOCLOPRAMIDE HYDROCHLORIDEINJECTABLE; INJECTION
METOCLOPRAMIDE HYDROCHLORIDEAP BD RX EQ 5MG BASE/ML
@ TEVA PARENTERAL EQ 5MG BASE/ML
@ TEVA PHARMS USA EQ 5MG BASE/MLA091392 001 Apr 19, 2013 Apr NEWA
A073135 001 Nov 27, 1991 Feb DISC
A073135 001 Nov 27, 1991 May CAHNTABLET, ORALLY DISINTEGRATING; ORAL
METOZOLV ODT>D> SALIX PHARMS EQ 5MG BASE
>A> + EQ 5MG BASE
>D> + EQ 10MG BASE
>A> @ EQ 10MG BASEN022246 001 Sep 04, 2009 Jul CRLD
N022246 001 Sep 04, 2009 Jul CRLD
N022246 002 Sep 04, 2009 Jul DISC
N022246 002 Sep 04, 2009 Jul DISCMETOLAZONETABLET; ORAL
METOLAZONE@ TEVA 2.5MG
@ 5MG
@ 10MGA076600 001 Jan 06, 2004 Mar DISC
A076833 001 Mar 01, 2004 Jun DISC
A075543 003 Dec 24, 2003 May DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
METOPROLOL SUCCINATE

@ NESHER PHARMS	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008	Feb DISC
@	EQ 50MG TARTRATE	A077176	001	May 14, 2008	May DISC

METOPROLOL TARTRATE

INJECTABLE; INJECTION
METOPROLOL TARTRATE

AP	CLARIS LIFESCIENCES	1MG/ML	A078950	001	Apr 29, 2013	Apr NEWA
	@ WATSON LABS	1MG/ML	A074032	001	Dec 21, 1993	Mar DISC

TABLET; ORAL

METOPROLOL TARTRATE

AB	ALEMBIC PHARMS LTD	25MG	A202871	001	May 28, 2013	May NEWA
AB		50MG	A202871	002	May 28, 2013	May NEWA
AB		100MG	A202871	003	May 28, 2013	May NEWA
	@ PRINSTON INC	50MG	A074453	001	Apr 27, 1995	Mar CAHN
	@	100MG	A074453	002	Apr 27, 1995	Mar CAHN

METRONIDAZOLE

TABLET; ORAL
METRONIDAZOLE

AB	TEVA PHARMS USA	250MG	A070027	001	Nov 06, 1984	Mar CAHN
----	-----------------	-------	---------	-----	--------------	----------

METYROSLINE

CAPSULE; ORAL
DEMSER

+	ATON PHARMA VPNA	250MG	N017871	001		Jun CAHN
---	------------------	-------	---------	-----	--	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

>A>	AP	AKORN INC	EQ 1MG BASE/ML	A075494	001	Jun 30, 2000	Jul CAHN
>A>	AP		EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Jul CAHN
>A>	AP		EQ 5MG BASE/ML	A075494	002	Jun 30, 2000	Jul CAHN
		@ APOTEX INC	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr DISC
		@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr DISC
		@ CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Jan DISC
		@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Jan DISC
		@ INTL MEDICATED	EQ 1MG BASE/ML	A076144	001	Jan 26, 2005	Jun DISC
		@	EQ 5MG BASE/ML	A076144	002	Jan 26, 2005	Jun DISC
		@ INTL MEDICATION	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004	May DISC
		@	EQ 5MG BASE/ML	A076020	002	Jul 16, 2004	May DISC
>D>	AP	TAYLOR	EQ 1MG BASE/ML	A075494	001	Jun 30, 2000	Jul CAHN
>D>	AP		EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Jul CAHN
>D>	AP		EQ 5MG BASE/ML	A075494	002	Jun 30, 2000	Jul CAHN

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

@ APOTEX INC	EQ 2MG BASE/ML	A077115	001	Sep 09, 2005	Apr DISC
--------------	----------------	---------	-----	--------------	----------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

@ APOTEX INC	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004	Apr DISC
--------------	----------------	---------	-----	--------------	----------

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

@ APOTEX INC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Apr DISC
--------------	---------------------------------------	---------	-----	--------------	----------

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	CARACO	EQ 50MG BASE	A090867	001	May 13, 2013	Apr NEWA
AB		EQ 75MG BASE	A090867	002	May 13, 2013	Apr NEWA
AB		EQ 100MG BASE	A090867	003	May 13, 2013	Apr NEWA

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

@	RANBAXY LABS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	May DISC
@		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	May DISC
@		EQ 90MG BASE	N201922	003	Jul 11, 2012	May DISC
@		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	May DISC
@		EQ 135MG BASE	N201922	005	Jul 11, 2012	May DISC

TABLET, EXTENDED RELEASE; ORAL

SOLODYN

@	MEDICIS	EQ 45MG BASE	N050808	001	May 08, 2006	Apr DISC
+		EQ 55MG BASE	N050808	008	Aug 27, 2010	Apr CRLD
+		EQ 80MG BASE	N050808	007	Aug 27, 2010	Apr CRLD
@		EQ 135MG BASE	N050808	003	May 08, 2006	Apr DISC

MIPOMERSEN SODIUM

SOLUTION; SUBCUTANEOUS

KYNAMRO

+	GENZYME CORP	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jan NEWA
---	--------------	---------------------	---------	-----	--------------	----------

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

@	ACTAVIS ELIZABETH	15MG	A077959	001	Feb 14, 2011	Jun DISC
@		30MG	A077959	002	Feb 14, 2011	Jun DISC
@		45MG	A077959	003	Feb 14, 2011	Jun DISC

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP	ONCO THERAPIES LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012	Mar CAIN
AP	TEVA PHARMS USA	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A077356	001	Apr 11, 2006	May CAHN
AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A077356	002	Apr 11, 2006	May CAHN
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A077356	003	Apr 11, 2006	May CAHN

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

AB	MERCK SHARP DOHME	0.1%	N019625	002	Apr 19, 2013	Apr NEWA
----	-------------------	------	---------	-----	--------------	----------

OINTMENT; TOPICAL

MOMETASONE FUROATE

@	TARO	0.1%	A076624	001	Dec 03, 2004	May DISC
---	------	------	---------	-----	--------------	----------

MORPHINE SULFATECAPSULE, EXTENDED RELEASE; ORAL
KADIAN

AB1	+	WATSON LABS INC	10MG	N020616	008	Apr 20, 2007	May	CTEC
	+		10MG	N020616	008	Apr 20, 2007	Apr	CAHN
AB1			20MG	N020616	001	Jul 03, 1996	Apr	CAHN
AB1			30MG	N020616	004	Mar 09, 2001	Apr	CAHN
			40MG	N020616	009	Jul 09, 2012	Apr	CAHN
AB1			50MG	N020616	002	Jul 03, 1996	Apr	CAHN
AB1			60MG	N020616	005	Mar 09, 2001	Apr	CAHN
			70MG	N020616	010	Jul 09, 2012	Apr	CAHN
AB1			80MG	N020616	006	Oct 27, 2006	Apr	CAHN
AB1	+		100MG	N020616	003	Jul 03, 1996	Apr	CAHN
			130MG	N020616	011	Jul 09, 2012	Apr	CAHN
			150MG	N020616	012	Jul 09, 2012	Apr	CAHN
AB1	+		200MG	N020616	007	Feb 27, 2007	May	CTEC
	+		200MG	N020616	007	Feb 27, 2007	Apr	CAHN

MORPHINE SULFATE

AB1		PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Apr	CTEC
AB1			30MG	A200812	002	Nov 10, 2011	Apr	CTEC
AB1			50MG	A200812	003	Nov 10, 2011	Apr	CTEC
AB1			60MG	A200812	004	Nov 10, 2011	Apr	CTEC
AB1			80MG	A200812	005	Nov 10, 2011	Apr	CTEC
AB1			100MG	A200812	006	Nov 10, 2011	Apr	CTEC
AB1		UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	May	NEWA
AB1			20MG	A202104	002	Jun 03, 2013	May	NEWA
AB1			30MG	A202104	003	Jun 03, 2013	May	NEWA
AB1			50MG	A202104	004	Jun 03, 2013	May	NEWA
AB1			60MG	A202104	005	Jun 03, 2013	May	NEWA
AB1			80MG	A202104	006	Jun 03, 2013	May	NEWA
AB1			100MG	A202104	007	Jun 03, 2013	May	NEWA

SOLUTION; ORAL

MORPHINE SULFATE

>D>		LANNETT HOLDINGS INC	20MG/ML	N201517	001	Jun 23, 2011	Jul	CPOT
>A>			100MG/5ML	N201517	001	Jun 23, 2011	Jul	CPOT

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EMBEDA

>D>		ALPHARMA KING	60MG; 2.4MG	N022321	004	Aug 13, 2009	Jul	CRLD
>A>	+		60MG; 2.4MG	N022321	004	Aug 13, 2009	Jul	CRLD
>D>	+		100MG; 4MG	N022321	006	Aug 13, 2009	Jul	CRLD
>A>			100MG; 4MG	N022321	006	Aug 13, 2009	Jul	CRLD

MUPIROCIN CALCIUM

CREAM; TOPICAL

BACTROBAN

AB	+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan	CFTG
		MUPIROCIN						
AB		GLENMARK GENERICS	EQ 2% BASE	A201587	001	Jan 24, 2013	Jan	NEWA

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

AB		ACCORD HLTHCARE	250MG	A090253	001	May 04, 2009	Apr	CAHN
AB		ALKEM LABS LTD	250MG	A200197	001	Jun 13, 2013	Jun	NEWA

NABUMETONE

TABLET; ORAL

NABUMETONE

@ DR REDDYS LABS LTD

@

@ PROSAM LABS

@

500MG

750MG

500MG

750MG

A078420 001 Sep 24, 2008 Apr DISC

A078420 002 Sep 24, 2008 Apr DISC

A079093 001 Feb 27, 2009 Mar DISC

A079093 002 Feb 27, 2009 Mar DISC

NAFTIFINE HYDROCHLORIDE

GEL; TOPICAL

NAFTIN

+ MERZ PHARMS

2%

N204286 001 Jun 27, 2013 Jun NEWA

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

@ SANDOZ

50MG

A075434 001 Mar 08, 2000 Apr DISC

REVIA

>D> AB + DURAMED 50MG

N018932 001 Nov 20, 1984 Jul CAHN

>A> AB + TEVA WOMENS 50MG

N018932 001 Nov 20, 1984 Jul CAHN

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE

>A> AT AKORN INC 0.1%

A083590 001 Jul CAHN

>D> AT TAYLOR 0.1%

A083590 001 Jul CAHN

NAPROXEN

TABLET; ORAL

NAPROXEN

AB WEST WARD PHARM CORP 250MG

A076494 001 Jan 14, 2004 Apr CAHN

AB 375MG

A076494 002 Jan 14, 2004 Apr CAHN

AB 500MG

A076494 003 Jan 14, 2004 Apr CAHN

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

AMERGE

AB GLAXOSMITHKLINE LLC EQ 1MG BASE

N020763 002 Feb 10, 1998 Mar CAHN

AB + EQ 2.5MG BASE

N020763 001 Feb 10, 1998 Mar CAHN

NELFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

@ AGOURON

EQ 50MG BASE/SCOOPFUL

N020778 001 Mar 14, 1997 Jun DISC

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

@ X GEN PHARMS

100%

A061579 001 Mar DISC

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

POLY-PRED

@ ALLERGAN

EQ 0.35% BASE;10,000 UNITS/ML;0.5%

N050081 002 May DISC

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

+ ECLAT PHARMS LLC 5MG/10ML (0.5MG/ML)

N204078 001 May 31, 2013 May NEWA

+ 10MG/10ML (1MG/ML)

N204078 002 May 31, 2013 May NEWA

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB ACTAVIS ELIZABETH 20MG

A072556 001 Sep 20, 1990 Apr CTEC

@ CATALENT 10MG

A073250 001 Oct 08, 1991 Apr DISC

AB EMCURE PHARMS USA 10MG

A202644 001 Apr 25, 2013 Apr NEWA

AB 20MG

A202644 002 Apr 25, 2013 Apr NEWA

NILUTAMIDE

TABLET; ORAL

NILANDRON

@ COVIS PHARMA SARL 50MG

N020169 001 Sep 19, 1996 Apr CAHN

+ 150MG

N020169 002 Apr 30, 1999 Apr CAHN

NIMODIPINECAPSULE; ORAL
NIMODIPINE

>D>	AB	BANNER PHARMACAPS	30MG	A076740	001	Jan 17, 2008	Jul	CRLD
>A>	AB	+	30MG	A076740	001	Jan 17, 2008	Jul	CRLD
>D>	AB	+	SUN PHARM INDS INC	30MG	A077067	001	Apr 17, 2007	Jul
>A>	AB		30MG	A077067	001	Apr 17, 2007	Jul	CRLD

SOLUTION; ORAL
NYMALIZE

+	ARBOR PHARMS INC	60MG/20ML	N203340	001	May 10, 2013	May	NEWA
---	------------------	-----------	---------	-----	--------------	-----	------

NISOLDIPINETABLET, EXTENDED RELEASE; ORAL
NISOLDIPINE

>D>	+	MYLAN	20MG	A079051	001	Jul 25, 2008	Jul	CRLD
>A>			20MG	A079051	001	Jul 25, 2008	Jul	CRLD

NITISINONECAPSULE; ORAL
ORFADIN

	SWEDISH ORPHAN	2MG	N021232	001	Jan 18, 2002	May	CAHN
		5MG	N021232	002	Jan 18, 2002	May	CAHN
+		10MG	N021232	003	Jan 18, 2002	May	CAHN

NITROFURANTOINSUSPENSION; ORAL
NITROFURANTOIN

>A>	AB	CARACO	25MG/5ML	A201355	001	Aug 14, 2013	Jul	NEWA
-----	----	--------	----------	---------	-----	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINECAPSULE; ORAL
MACRODANTIN

	ALVOGEN INC	25MG	N016620	003		Mar	CTEC
AB		25MG	N016620	003		Feb	CAHN
AB		50MG	N016620	001		Feb	CAHN
AB	+	100MG	N016620	002		Feb	CAHN
	NITROFURANTOIN						
	@ WATSON LABS	25MG	A073696	001	Dec 31, 1992	Mar	DISC
	@	50MG	A073696	002	Dec 31, 1992	Mar	DISC
	@	100MG	A073696	003	Dec 31, 1992	Mar	DISC

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINECAPSULE; ORAL
MACROBID

AB	+	ALVOGEN INC	75MG;25MG	N020064	001	Dec 24, 1991	Mar	CAHN
----	---	-------------	-----------	---------	-----	--------------	-----	------

NITROGLYCERINFILM, EXTENDED RELEASE; TRANSDERMAL
NITRO-DUR

AB1	+	MERCK SHARP DOHME	0.1MG/HR	N020145	001	Apr 04, 1995	Mar	CAHN
AB1	+		0.2MG/HR	N020145	002	Apr 04, 1995	Mar	CAHN
	+		0.3MG/HR	N020145	003	Apr 04, 1995	Mar	CAHN
AB1	+		0.4MG/HR	N020145	004	Apr 04, 1995	Mar	CAHN
AB1	+		0.6MG/HR	N020145	005	Apr 04, 1995	Mar	CAHN
	+		0.8MG/HR	N020145	006	Apr 04, 1995	Mar	CAHN

INJECTABLE; INJECTION
NITROGLYCERIN

>D>	AP	+	HOSPIRA	5MG/ML	N018531	001		Jul	DISC
>A>			@	5MG/ML	N018531	001		Jul	DISC
>D>	AP	+	LUITPOLD	5MG/ML	A072034	001	May 24, 1988	Jul	CTEC
>A>		+		5MG/ML	A072034	001	May 24, 1988	Jul	CTEC

NIZATIDINECAPSULE; ORAL
NIZATIDINE

@	APOTEX INC	150MG	A076383	001	Jan 23, 2003	Feb	DISC
@		300MG	A076383	002	Jan 23, 2003	Feb	DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
NOREPINEPHRINE BITARTRATE

AP	TEVA PHARMS USA	EQ 1MG BASE/ML	A040455	001	Mar 03, 2003	May CAHN
----	-----------------	----------------	---------	-----	--------------	----------

NORETHINDRONE

TABLET; ORAL
NORETHINDRONE

>A>	AB1	HAUPT PHARMA	0.35MG	A202260	001	Aug 01, 2013	Jul NEWA
		TABLET; ORAL-28 JENCYCLA					
	AB2	LUPIN LTD	0.35MG	A091323	001	Mar 28, 2013	Apr CTEC
	AB		0.35MG	A091323	001	Mar 28, 2013	Mar NEWA
		NORETHINDRONE					
	AB2	FAMY CARE LTD	0.35MG	A200980	001	Jun 12, 2013	May NEWA
	AB1		0.35MG	A201483	001	Jun 24, 2013	Jun NEWA

NYSTATIN

SUSPENSION; ORAL
NILSTAT

	@ GLENMARK GENERICS	100,000 UNITS/ML	N050299	001		Feb DISC
--	---------------------	------------------	---------	-----	--	----------

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
OCTREOTIDE ACETATE

AP	TEVA PHARMS USA	EQ 0.05MG BASE/ML	A075957	001	Oct 03, 2005	May CAHN
AP		EQ 0.1MG BASE/ML	A075957	002	Oct 03, 2005	May CAHN
AP		EQ 0.2MG BASE/ML	A075959	001	Nov 21, 2005	May CAHN
AP		EQ 0.5MG BASE/ML	A075957	003	Oct 03, 2005	May CAHN
AP		EQ 1MG BASE/ML	A075959	002	Nov 21, 2005	May CAHN

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
OFLOXACIN

AT	ALTAIRE PHARMS INC	0.3%	A202692	001	Apr 29, 2013	Apr NEWA
	@ APOTEX INC	0.3%	A076513	001	May 14, 2004	Apr DISC

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION; ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Apr NEWA
AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Apr NEWA
	ZEGERID					
AB	SANTARUS	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr CFTG
AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr CFTG

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

	@ APOTEX INC	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006	Apr DISC
AP	CLARIS LIFESCIENCES	2MG/ML	A078288	001	Feb 22, 2013	Feb NEWA
>D>	AP	2MG/ML	A078288	001	Feb 22, 2013	Jul CPOT
>A>	AP	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Jul CPOT
	@ LUITPOLD	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006	Mar DISC
	@ PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544	001	Dec 26, 2006	Feb DISC
	ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER					
	@ CLARIS LIFESCIENCES	EQ 0.64MG BASE/ML	A078308	001	Mar 17, 2008	Jan DISC
	@ HOSPIRA	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007	Jan DISC
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
	@ APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006	Apr DISC
>A>	AP	BD RX	A202253	001	Jul 19, 2013	Jul NEWA
	AP	CLARIS LIFESCIENCES	A078287	001	Feb 22, 2013	Feb NEWA
>D>	AP	2MG/ML	A078287	001	Feb 22, 2013	Jul CPOT
>A>	AP	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Jul CPOT
	@ LUITPOLD	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006	Mar DISC

OSPENIFENE

TABLET; ORAL
OSPENIFENE

	+	SHIONOGI INC	60MG	N203505	001	Feb 26, 2013	Feb NEWA
--	---	--------------	------	---------	-----	--------------	----------

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

AP	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A201539	001	Jan 18, 2013	Jan NEWA
AP		EQ 2GM BASE/VIAL	A201539	002	Jan 18, 2013	Jan NEWA
AP		EQ 10GM BASE/VIAL	A201538	001	Jan 18, 2013	Jan NEWA

OXAPROZIN

TABLET; ORAL
OXAPROZIN
@ CARACO

600MG

A075844 001 Jan 03, 2002 Jan DISC

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

>D> AB	ACTAVIS ELIZABETH	30MG	A072253	001	Apr 14, 1988	Jul CRLD
>A> AB	+	30MG	A072253	001	Apr 14, 1988	Jul CRLD
>D> AB	+	IVAX SUB TEVA PHARMS	A070945	001	Aug 03, 1987	Jul CRLD
>A> AB		30MG	A070945	001	Aug 03, 1987	Jul CRLD

OXCARBAZEPINE

TABLET; ORAL
OXCARBAZEPINE

@ TEVA PHARMS USA 150MG
@ 300MG
@ 600MG

A078005 001 Dec 11, 2007 Mar DISC
A078005 002 Dec 11, 2007 Mar DISC
A078005 003 Dec 11, 2007 Mar DISC

OXYBUTYNIN

GEL, METERED; TRANSDERMAL
GELNIQUE 3%

+ WATSON LABS INC 3%

N202513 001 Dec 07, 2011 Jun CTNA

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE

@ APOTEX INC 5MG/5ML
@ MIKART 5MG/5ML

A074997 001 Oct 15, 1997 Apr DISC
A075039 001 Jan 29, 1999 Jun DISC

TABLET; ORAL

OXYBUTYNIN CHLORIDE

AB	TEVA PHARMS USA	5MG	A071655	001	Nov 14, 1988	Mar CAHN
----	-----------------	-----	---------	-----	--------------	----------

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL
OXYCODONE HYDROCHLORIDE

>A> AA	ROXANE	5MG/5ML	A204037	001	Jul 15, 2013	Jul NEWA
>A> AA		100MG/5ML	A203208	001	Jul 12, 2013	Jul NEWA
>D>	+	VISTAPHARM	N201194	001	Jan 12, 2012	Jul CTEC
>A> AA	+	5MG/5ML	N201194	001	Jan 12, 2012	Jul CTEC

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB	NESHER PHARMS	5MG	A077290	001	Dec 08, 2005	Jun CMFD
	@	5MG	A077290	001	Dec 08, 2005	Mar DISC
AB		10MG	A077290	002	Dec 08, 2005	Jun CMFD
	@	10MG	A077290	002	Dec 08, 2005	Mar DISC
AB		15MG	A077290	003	Dec 08, 2005	Jun CMFD
	@	15MG	A077290	003	Dec 08, 2005	Mar DISC
AB		20MG	A077290	004	Dec 08, 2005	Jun CMFD
	@	20MG	A077290	004	Dec 08, 2005	Mar DISC
AB		30MG	A077290	005	Dec 08, 2005	Jun CMFD
	@	30MG	A077290	005	Dec 08, 2005	Mar DISC

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	AVANTHI INC	5MG	A203601	001	Jan 30, 2013	Jan NEWA
AB		10MG	A203601	002	Jan 30, 2013	Jan NEWA
AB	MALLINCKRODT INC	5MG	A202321	001	Apr 25, 2013	Apr NEWA
AB		10MG	A202321	002	Apr 25, 2013	Apr NEWA

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Jul NEWA
	AB		7.5MG	A079046	001	Dec 13, 2010	Apr CAHN
>A>	AB		10MG	A079046	004	Jul 11, 2013	Jul NEWA
	AB		15MG	A079046	002	Dec 13, 2010	Apr CAHN
>A>	AB		20MG	A079046	005	Jul 11, 2013	Jul NEWA
>A>	AB		30MG	A079046	006	Jul 11, 2013	Jul NEWA
>A>	AB		40MG	A079046	007	Jul 11, 2013	Jul NEWA
>D>		IMPAX LABS	5MG	A079087	001	Jun 14, 2010	Jul CTEC
>A>	AB		5MG	A079087	001	Jun 14, 2010	Jul CTEC
>D>			10MG	A079087	003	Jun 14, 2010	Jul CTEC
>A>	AB		10MG	A079087	003	Jun 14, 2010	Jul CTEC
>D>			20MG	A079087	005	Jun 14, 2010	Jul CTEC
>A>	AB		20MG	A079087	005	Jun 14, 2010	Jul CTEC
>D>			30MG	A079087	006	Jul 22, 2010	Jul CTEC
>A>	AB		30MG	A079087	006	Jul 22, 2010	Jul CTEC
>D>			40MG	A079087	007	Jun 14, 2010	Jul CTEC
>A>	AB		40MG	A079087	007	Jun 14, 2010	Jul CTEC
>A>	AB	ROXANE	5MG	A200822	002	Jul 15, 2013	Jul NEWA
>A>	AB		7.5MG	A200822	003	Jul 15, 2013	Jul NEWA
>A>	AB		10MG	A200822	004	Jul 15, 2013	Jul NEWA
>A>	AB		15MG	A200822	005	Jul 15, 2013	Jul NEWA
>A>	AB		20MG	A200822	006	Jul 15, 2013	Jul NEWA
>A>	AB		30MG	A200822	007	Jul 15, 2013	Jul NEWA
>A>	AB		40MG	A200822	001	Jul 15, 2013	Jul NEWA

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

AP	HIKMA FARMACEUTICA	10USP UNITS/ML (10USP UNITS/ML)	A200219	001	Feb 13, 2013	Jan NEWA
	@ TEVA PHARMS USA	10USP UNITS/ML (10USP UNITS/ML)	A077453	001	Jan 24, 2008	May CAHN
	@	100USP UNITS/10ML (10USP UNITS/ML)	A077453	002	Jan 24, 2008	May CAHN

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

	@ ACCORD HLTHCARE	6MG/ML	A075436	001	Nov 12, 2004	Apr DISC
	@ TEVA PHARMS USA	6MG/ML	A075297	001	Jan 25, 2002	May CAHN
	TAXOL					
AP	HQ SPCLT PHARMA	6MG/ML	N020262	001	Dec 29, 1992	Apr CMFD
	@	6MG/ML	N020262	001	Dec 29, 1992	Jan CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002	Mar CAHN
AP		90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002	Mar CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

	ABBVIE	180,000USP UNITS;36,000USP UNITS;114,000USP UNITS	N020725	005	Mar 14, 2013	Mar NEWA
--	--------	---	---------	-----	--------------	----------

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

AP	+	TEVA PHARMS USA	1MG/ML	A072759	001	Jul 31, 1990	May CAHN
AP	+		2MG/ML	A072760	001	Jul 31, 1990	Mar CAHN

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

	@ APOTEX INC	EQ 10MG BASE/5ML	A077395	001	Dec 05, 2006	Apr DISC
--	--------------	------------------	---------	-----	--------------	----------

PAROXETINE MESYLATECAPSULE; ORAL
BRISDELLE

+	NOVEN THERAP	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Jun NEWA
---	--------------	---------------	---------	-----	--------------	----------

PEGINESATIDE ACETATESOLUTION; INTRAVENOUS, SUBCUTANEOUS
OMONTYS

@	TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012	May DISC
+		EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012	Apr CAHN
@		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012	May DISC
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012	Apr CAHN
OMONTYS PRESERVATIVE FREE						
@	TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012	May DISC
+		EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012	Apr CAHN
@		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012	May DISC
+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012	Apr CAHN
@		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012	May DISC
+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012	Apr CAHN
@		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012	May DISC
+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012	Apr CAHN
@		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012	May DISC
+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012	Apr CAHN
@		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012	May DISC
+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012	Apr CAHN

PHENYLEPHRINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE

	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Mar NEWA
+		10%	N203510	002	Mar 21, 2013	Mar NEWA

PHENYTOIN SODIUMINJECTABLE; INJECTION
PHENYTOIN SODIUM

@	HOSPIRA	50MG/ML	A089744	001	Dec 18, 1987	Mar DISC
---	---------	---------	---------	-----	--------------	----------

PHYTONADIONETABLET; ORAL
MEPHYTON

+	VALEANT PHARMS	5MG	N010104	003		Jun CAHN
---	----------------	-----	---------	-----	--	----------

PINDOLOLTABLET; ORAL
PINDOLOL

	MYLAN PHARMS INC	5MG	A074019	001	Sep 03, 1992	Jun CTEC
+		10MG	A074019	002	Sep 03, 1992	Jun CTEC
@	WATSON LABS	5MG	A074437	001	Feb 27, 1995	Jun DISC
@		10MG	A074437	002	Feb 27, 1995	Jun DISC

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 15MG BASE	A200044	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A200044	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A200044	003	Feb 13, 2013	Jan NEWA
AB	AUROBINDO PHARMA LTD	EQ 15MG BASE	A200268	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A200268	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A200268	003	Feb 13, 2013	Jan NEWA
AB	DR REDDYS LABS LTD	EQ 15MG BASE	A078383	001	Mar 12, 2013	Mar NEWA
AB		EQ 30MG BASE	A078383	002	Mar 12, 2013	Mar NEWA
AB		EQ 45MG BASE	A078383	003	Mar 12, 2013	Mar NEWA
AB	MACLEODS PHARMS LTD	EQ 15MG BASE	A202467	001	Feb 06, 2013	Jan NEWA
AB		EQ 30MG BASE	A202467	002	Feb 06, 2013	Jan NEWA
AB		EQ 45MG BASE	A202467	003	Feb 06, 2013	Jan NEWA
AB	SANDOZ	EQ 15MG BASE	A078670	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A078670	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A078670	003	Feb 13, 2013	Jan NEWA
AB	SYNTHON PHARMS	EQ 15MG BASE	A078472	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A078472	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A078472	003	Feb 13, 2013	Jan NEWA
AB	TORRENT PHARMS LTD	EQ 15MG BASE	A091298	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A091298	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A091298	003	Feb 13, 2013	Jan NEWA
AB	ZYDUS PHARMS USA INC	EQ 15MG BASE	A202456	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A202456	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A202456	003	Feb 13, 2013	Jan NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

>D> AA	+	MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Jul CTEC
>A>			227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Jul CTEC
>D> AA	+		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Jul DISC
>A>	@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Jul DISC
		COLYTE WITH FLAVOR PACKS					
>D> AA	+	MEDA PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jul CTEC
>A>			240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jul CTEC
>D>		COLYTE-FLAVORED					
>D> AA	+	MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Jul DISC
>A>	@		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Jul DISC
>D> AA	+		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Jul DISC
>A>	@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Jul DISC

POLYMYXIN B SULFATE

POWDER; FOR RX COMPOUNDING

POLY-RX

@ X GEN PHARMS

100,000,000 UNITS/BOT

A061578 001

Mar DISC

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

>A> AT	AKORN INC	10,000 UNITS/ML;EQ 1MG BASE/ML	A065006	001	Dec 17, 1998	Jul CAHN
>D> AT	TAYLOR PHARMA	10,000 UNITS/ML;EQ 1MG BASE/ML	A065006	001	Dec 17, 1998	Jul CAHN

POMALIDOMIDE

CAPSULE; ORAL

POMALYST

CELGENE

		1MG	N204026	001	Feb 08, 2013	Feb NEWA
		2MG	N204026	002	Feb 08, 2013	Feb NEWA
		3MG	N204026	003	Feb 08, 2013	Feb NEWA
+		4MG	N204026	004	Feb 08, 2013	Feb NEWA

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

AB	AMNEAL PHARMS	10MEQ	A202128	001	Feb 22, 2013	Feb NEWA
----	---------------	-------	---------	-----	--------------	----------

PRAMIPEXOLE DIHYDROCHLORIDETABLET; ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Mar CAHN
AB		0.25MG	A091254	002	Nov 30, 2010	Mar CAHN
AB		0.5MG	A091254	003	Nov 30, 2010	Mar CAHN
AB		0.75MG	A091254	004	Nov 30, 2010	Mar CAHN
AB		1MG	A091254	005	Nov 30, 2010	Mar CAHN
AB		1.5MG	A091254	006	Nov 30, 2010	Mar CAHN
AB	SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013	Mar NEWA
AB		0.25MG	A091683	002	Mar 27, 2013	Mar NEWA
AB		0.5MG	A091683	003	Mar 27, 2013	Mar NEWA
AB		0.75MG	A091683	004	Mar 27, 2013	Mar NEWA
AB		1MG	A091683	005	Mar 27, 2013	Mar NEWA
AB		1.5MG	A091683	006	Mar 27, 2013	Mar NEWA

PRAMLINTIDE ACETATEINJECTABLE; SUBCUTANEOUS
SYMLIN

	AMYLIN PHARMS	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Jan CAHN
		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Jan CAHN
+		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Jan CAHN
+	AMYLIN PHARMS LLC	EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Jun CRLD
@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Jun DISC

PRAZIOUANTELTABLET; ORAL
BILTRICIDE

+	BAYER HLTHCARE	600MG	N018714	001	Dec 29, 1982	Jun CAHN
---	----------------	-------	---------	-----	--------------	----------

PREDNISOLONESYRUP; ORAL
PREDNISOLONE

@	APOTEX INC	5MG/5ML	A040570	001	Aug 25, 2005	Apr DISC
@		15MG/5ML	A040571	001	Aug 25, 2005	Apr DISC

PREDNISOLONE SODIUM PHOSPHATESOLUTION; ORAL
ORAPRED

AA	+	CONCORDIA PHARMS INC	EQ 15MG BASE/5ML	A075117	001	Dec 14, 2000	May CAHN
		PREDNISOLONE SODIUM PHOSPHATE					
	@	NESHER PHARMS	EQ 15MG BASE/5ML	A076988	001	May 24, 2005	May DISC
	@	PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002	Mar DISC
	@	WE PHARMS	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002	Mar DISC

TABLET, ORALLY DISINTEGRATING; ORAL
ORAPRED ODT

AB		CONCORDIA PHARMS INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	May CAHN
AB			EQ 15MG BASE	N021959	002	Jun 01, 2006	May CAHN
AB	+		EQ 30MG BASE	N021959	003	Jun 01, 2006	May CAHN
AB		SHIONOGI INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	Mar CFTG
AB			EQ 15MG BASE	N021959	002	Jun 01, 2006	Mar CFTG
AB	+		EQ 30MG BASE	N021959	003	Jun 01, 2006	Mar CFTG
		PREDNISOLONE SODIUM PHOSPHATE					
AB		MYLAN PHARMS INC	EQ 10MG BASE	A202179	001	Apr 10, 2013	Mar NEWA
AB			EQ 15MG BASE	A202179	002	Apr 10, 2013	Mar NEWA
AB			EQ 30MG BASE	A202179	003	Apr 10, 2013	Mar NEWA

PREDNISONE

TABLET; ORAL
PREDNISONE

AB	HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010	May CAHN
AB		2.5MG	A040538	001	Jan 08, 2004	May CAHN
AB		5MG	A080292	001		May CAHN
AB		10MG	A088832	001	Dec 04, 1985	May CAHN
AB		20MG	A083677	001		May CAHN
AB		50MG	A088465	001	Jun 01, 1984	May CAHN

PRIMIDONE

TABLET; ORAL
PRIMIDONE

	@ DR REDDYS LABS LTD	50MG	A040862	001	Oct 03, 2008	Apr DISC
	@	250MG	A040862	002	Oct 03, 2008	Apr DISC
>D> AB	WEST WARD	50MG	A040667	001	Jul 27, 2006	Jul DISC
>A>	@	50MG	A040667	001	Jul 27, 2006	Jul DISC

PROBENECID

TABLET; ORAL
PROBENECID

	@ IVAX SUB TEVA PHARMS	500MG	A083740	001	May 09, 1984	May DISC
--	------------------------	-------	---------	-----	--------------	----------

PROGESTERONE

CAPSULE; ORAL
PROGESTERONE

>A> AB	BANNER PHARMACAPS	100MG	A200900	001	Aug 16, 2013	Jul NEWA
>A> AB		200MG	A200900	002	Aug 16, 2013	Jul NEWA
	PROMETRIUM					
AB	ABBVIE INC	100MG	N019781	001	May 14, 1998	May CAHN
AB	+	200MG	N019781	002	Oct 15, 1999	May CAHN
	@	300MG	N019781	003	Oct 15, 1999	May CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HYDROCHLORIDE

AP	+	TEVA PHARMS USA	25MG/ML	A040454	001	Aug 22, 2002	Mar CAHN
AP	+		50MG/ML	A040454	002	Aug 22, 2002	Mar CAHN

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA	CARACO	6.25MG/5ML	A040891	001	Mar 13, 2009	May CAHN
----	--------	------------	---------	-----	--------------	----------

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

AB	CARACO	12.5MG	A040863	001	Dec 30, 2008	May CAHN
AB		25MG	A040863	002	Dec 30, 2008	May CAHN
AB		50MG	A040863	003	Dec 30, 2008	May CAHN

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
PROPARACAINE HYDROCHLORIDE

>A> AT	AKORN INC	0.5%	A040277	001	Mar 16, 2000	Jul CAHN
>D> AT	TAYLOR PHARMA	0.5%	A040277	001	Mar 16, 2000	Jul CAHN

PROPOFOL

INJECTABLE; INJECTION
PROPOFOL

AB	TEVA PHARMS USA	10MG/ML	A075102	001	Jan 04, 1999	Mar CAHN
----	-----------------	---------	---------	-----	--------------	----------

PROPRANOLOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
PROPRANOLOL HYDROCHLORIDE

AB	GLATT AIR	60MG	A078065	001	Jan 26, 2007	Feb CAHN
AB		80MG	A078065	002	Jan 26, 2007	Feb CAHN
AB		120MG	A078065	003	Jan 26, 2007	Feb CAHN
AB		160MG	A078065	004	Jan 26, 2007	Feb CAHN

TABLET; ORAL
INDERAL

>D>	@ AKRIMAX PHARMS	10MG	N016418	001		Jul CAHN
>D>	@	20MG	N016418	003		Jul CAHN
>D> AB		40MG	N016418	002		Jul CAHN
>D> AB		60MG	N016418	009	Oct 18, 1982	Jul CAHN
>D> AB	+	80MG	N016418	004		Jul CAHN
>D>	@	90MG	N016418	010	Oct 18, 1982	Jul CAHN
>A>	@ WYETH PHARMS INC	10MG	N016418	001		Jul CAHN
>A>	@	20MG	N016418	003		Jul CAHN
>A> AB		40MG	N016418	002		Jul CAHN
>A> AB		60MG	N016418	009	Oct 18, 1982	Jul CAHN
>A> AB	+	80MG	N016418	004		Jul CAHN
>A>	@	90MG	N016418	010	Oct 18, 1982	Jul CAHN

PROTRIPTYLINE HYDROCHLORIDETABLET; ORAL
VIVACTIL

@ TEVA WOMENS	5MG	N016012	001		Mar CAHN
@	10MG	N016012	002		Mar CAHN

PYRIMETHAMINETABLET; ORAL
DARAPRIM

+	AMEDRA PHARMS	25MG	N008578	001		Apr CAHN
---	---------------	------	---------	-----	--	----------

QUAZEPAMTABLET; ORAL
DORAL

@ SCIECURE PHARMA INC	7.5MG	N018708	003	Feb 26, 1987	Jun CAHN
+	15MG	N018708	001	Dec 27, 1985	Jun CAHN

QUETIAPINE FUMARATETABLET; ORAL
QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE	EQ 25MG BASE	A202152	001	Mar 27, 2012	Apr CAHN
AB		EQ 50MG BASE	A202152	002	Mar 27, 2012	Apr CAHN
AB		EQ 100MG BASE	A202152	003	Mar 27, 2012	Apr CAHN
AB		EQ 200MG BASE	A202152	004	Mar 27, 2012	Apr CAHN
AB		EQ 300MG BASE	A202152	005	Mar 27, 2012	Apr CAHN
AB		EQ 400MG BASE	A202152	006	Mar 27, 2012	Apr CAHN
AB	ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	May CAHN
AB		EQ 50MG BASE	A201762	002	Feb 27, 2013	May CAHN
AB		EQ 100MG BASE	A201762	003	Feb 27, 2013	May CAHN
AB		EQ 150MG BASE	A201762	004	Feb 27, 2013	May CAHN
AB		EQ 200MG BASE	A201762	005	Feb 27, 2013	May CAHN
AB		EQ 300MG BASE	A201762	006	Feb 27, 2013	May CAHN
AB		EQ 400MG BASE	A201762	007	Feb 27, 2013	May CAHN
AB	ACTAVIS PHARMA	EQ 25MG BASE	A201762	001	Feb 27, 2013	Feb NEWA
AB		EQ 50MG BASE	A201762	002	Feb 27, 2013	Feb NEWA
AB		EQ 100MG BASE	A201762	003	Feb 27, 2013	Feb NEWA
AB		EQ 150MG BASE	A201762	004	Feb 27, 2013	Feb NEWA
AB		EQ 200MG BASE	A201762	005	Feb 27, 2013	Feb NEWA
AB		EQ 300MG BASE	A201762	006	Feb 27, 2013	Feb NEWA
AB		EQ 400MG BASE	A201762	007	Feb 27, 2013	Feb NEWA
AB	ALKEM LABS LTD	EQ 25MG BASE	A201504	001	Feb 12, 2013	Jan NEWA
AB		EQ 50MG BASE	A201504	002	Feb 12, 2013	Jan NEWA
AB		EQ 100MG BASE	A201504	003	Feb 12, 2013	Jan NEWA
AB		EQ 150MG BASE	A201504	004	Feb 12, 2013	Jan NEWA
AB		EQ 200MG BASE	A201504	005	Feb 12, 2013	Jan NEWA
AB		EQ 300MG BASE	A201504	006	Feb 12, 2013	Jan NEWA
AB		EQ 400MG BASE	A201504	007	Feb 12, 2013	Jan NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	@	APOTEX INC	EQ 5MG BASE	A076240	001	Jan 26, 2006	Mar DISC
	@		EQ 10MG BASE	A076240	002	Jan 26, 2006	Mar DISC
	@		EQ 20MG BASE	A076240	003	Jan 26, 2006	Mar DISC
	@		EQ 40MG BASE	A076240	004	Jan 26, 2006	Mar DISC
AB		AUROBINDO PHARMA LTD	EQ 5MG BASE	A202725	001	Apr 29, 2013	Apr NEWA
AB			EQ 10MG BASE	A202725	002	Apr 29, 2013	Apr NEWA
AB			EQ 20MG BASE	A202725	003	Apr 29, 2013	Apr NEWA
AB			EQ 40MG BASE	A202725	004	Apr 29, 2013	Apr NEWA

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

		EISAI INC	5MG	N204736	001	Mar 26, 2013	Mar NEWA
+			10MG	N204736	002	Mar 26, 2013	Mar NEWA

RADIUM RA-223 DICHLORIDE

SOLUTION; INTRAVENOUS

XOFIGO

+		BAYER HLTHCARE	162MCI/6ML (27MCI/ML)	N203971	001	May 15, 2013	May NEWA
---	--	----------------	-----------------------	---------	-----	--------------	----------

RAMELTEON

TABLET; ORAL

>A>		RAMELTEON					
>A>	AB	TEVA PHARMS USA	8MG	A091693	001	Jul 26, 2013	Jul NEWA
		ROZEREM					
>D>	+	TAKEDA PHARMS USA	8MG	N021782	001	Jul 22, 2005	Jul CFTG
>A>	AB	+	8MG	N021782	001	Jul 22, 2005	Jul CFTG

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

>D>	AB	CIPLA	1.25MG	A077004	001	Aug 07, 2008	Jul DISC
>A>		@	1.25MG	A077004	001	Aug 07, 2008	Jul DISC
>D>	AB		2.5MG	A077004	002	Aug 07, 2008	Jul DISC
>A>		@	2.5MG	A077004	002	Aug 07, 2008	Jul DISC
>D>	AB		5MG	A077004	003	Aug 07, 2008	Jul DISC
>A>		@	5MG	A077004	003	Aug 07, 2008	Jul DISC
>D>	AB		10MG	A077004	004	Aug 07, 2008	Jul DISC
>A>		@	10MG	A077004	004	Aug 07, 2008	Jul DISC

RANITIDINE HYDROCHLORIDE

GRANULE, EFFERVESCENT; ORAL							
ZANTAC 150							
	@ GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251	002	Mar 31, 1994	Jun	CAHN
INJECTABLE; INJECTION							
RANITIDINE HYDROCHLORIDE							
AP	ZYDUS PHARMS USA INC	25MG/ML	A091534	001	Feb 22, 2013	Feb	NEWA
ZANTAC IN PLASTIC CONTAINER							
	@ COVIS PHARMA SARL	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jun	DISC
SYRUP; ORAL							
RANITIDINE HYDROCHLORIDE							
	@ APOTEX INC	EQ 15MG BASE/ML	A077602	001	Sep 17, 2007	Apr	DISC
AA	BIO PHARM INC	EQ 15MG BASE/ML	A090102	001	May 26, 2009	Apr	CAHN
AA	CARACO	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Apr	CAHN
ZANTAC							
AA	+ GLAXO GRP LTD	EQ 15MG BASE/ML	N019675	001	Dec 30, 1988	Jun	CAHN
TABLET; ORAL							
RANITIDINE HYDROCHLORIDE							
	@ WATSON LABS	EQ 150MG BASE	A074864	001	Oct 20, 1997	Jan	DISC
	@	EQ 300MG BASE	A074864	002	Oct 20, 1997	Jan	DISC
	@ WATSON LABS INC	EQ 150MG BASE	A077426	001	Dec 19, 2005	Mar	DISC
	@	EQ 300MG BASE	A077426	002	Dec 19, 2005	Mar	DISC
ZANTAC 150							
AB	GLAXO GRP LTD	EQ 150MG BASE	N018703	001	Jun 09, 1983	Jun	CAHN
ZANTAC 300							
AB	+ GLAXO GRP LTD	EQ 300MG BASE	N018703	002	Dec 09, 1985	Jun	CAHN
TABLET, EFFERVESCENT; ORAL							
ZANTAC 150							
	@ GLAXO GRP LTD	EQ 150MG BASE	N020251	001	Mar 31, 1994	Jun	CAHN
ZANTAC 25							
	+ GLAXO GRP LTD	EQ 25MG BASE	N020251	003	Apr 01, 2004	Jun	CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL							
RANEXA							
>D>	+ GILEAD	1GM	N021526	001	Feb 12, 2007	Jul	CFTG
>A>	AB +	1GM	N021526	001	Feb 12, 2007	Jul	CFTG
>D>		500MG	N021526	002	Jan 27, 2006	Jul	CFTG
>A>	AB	500MG	N021526	002	Jan 27, 2006	Jul	CFTG
RANOLAZINE							
>A>	AB LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Jul	NEWA
>A>	AB	1GM	A201046	002	Jul 29, 2013	Jul	NEWA

RASAGILINE MESYLATE

TABLET; ORAL							
AZILECT							
AB	TEVA	EQ 0.5MG BASE	N021641	001	May 16, 2006	Jun	CFTG
AB	+ RASAGILINE MESYLATE	EQ 1MG BASE	N021641	002	May 16, 2006	Jun	CFTG
RASAGILINE MESYLATE							
AB	WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	Jun	NEWA
AB		EQ 1MG BASE	A201823	002	Jul 01, 2013	Jun	NEWA

REPAGLINIDE

TABLET; ORAL							
PRANDIN							
>D>	NOVO NORDISK INC	0.5MG	N020741	001	Dec 22, 1997	Jul	CTEC
>A>	AB	0.5MG	N020741	001	Dec 22, 1997	Jul	CTEC
>D>		1MG	N020741	002	Dec 22, 1997	Jul	CFTG
>A>	AB	1MG	N020741	002	Dec 22, 1997	Jul	CFTG
>D>	+	2MG	N020741	003	Dec 22, 1997	Jul	CFTG
>A>	AB +	2MG	N020741	003	Dec 22, 1997	Jul	CFTG
REPAGLINIDE							
>A>	AB CARACO	1MG	A077571	002	Jul 11, 2013	Jul	NEWA
>A>	AB	2MG	A077571	003	Jul 11, 2013	Jul	NEWA
>A>	AB PADDOCK LLC	0.5MG	A201189	001	Jul 17, 2013	Jul	NEWA

RESERPINE

TABLET; ORAL
SERPALAN

@ LANNETT	0.1MG	N010124	001		May	DISC
@	0.25MG	N010124	002		May	DISC

RIFAMPIN

CAPSULE; ORAL
RIFAMPIN

>A> AB	LUPIN PHARMS	150MG	A090034	001	Aug 21, 2013	Jul NEWA
>A> AB		300MG	A090034	002	Aug 21, 2013	Jul NEWA

RILUZOLE

TABLET; ORAL
RILUTEK

AB	+ COVIS PHARMA SARL	50MG	N020599	001	Dec 12, 1995	Apr CAHN
	RILUZOLE					
AB	APOTEX CORP	50MG	A091300	001	Jun 18, 2013	Jun NEWA
AB	GLENMARK GENERICS	50MG	A091394	001	Jun 18, 2013	Jun NEWA
AB	MYLAN PHARMS INC	50MG	A203042	001	Jul 01, 2013	Jun NEWA
AB	SUN PHARM INDS LTD	50MG	A091417	001	Jun 18, 2013	Jun NEWA

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL
RIMANTADINE HYDROCHLORIDE

@ COREPHARMA	100MG	A075916	001	Nov 02, 2001	Feb	DISC
--------------	-------	---------	-----	--------------	-----	------

RISPERIDONE

SOLUTION; ORAL
RISPERIDONE

AA	BIO PHARM INC	1MG/ML	A078909	001	Jul 29, 2009	May CAHN
	TABLET, ORALLY DISINTEGRATING; ORAL					
	RISPERIDONE					
AB	MYLAN PHARMS INC	0.25MG	A091537	006	Feb 12, 2013	Feb NEWA
AB	PAR PHARM	0.25MG	A077494	001	Apr 30, 2009	Feb CTEC
AB	SUN PHARM INDS LTD	0.5MG	A078464	001	Apr 08, 2013	Mar NEWA
AB		1MG	A078464	002	Apr 08, 2013	Mar NEWA
AB		2MG	A078464	003	Apr 08, 2013	Mar NEWA
AB		3MG	A078464	004	Apr 08, 2013	Mar NEWA
AB		4MG	A078464	005	Apr 08, 2013	Mar NEWA

RIVASTIGMINE TARTRATE

CAPSULE; ORAL
RIVASTIGMINE TARTRATE

AB	APOTEX INC	EQ 1.5MG BASE	A091072	001	May 16, 2013	Apr NEWA
AB		EQ 3MG BASE	A091072	002	May 16, 2013	Apr NEWA
AB		EQ 4.5MG BASE	A091072	003	May 16, 2013	Apr NEWA
AB		EQ 6MG BASE	A091072	004	May 16, 2013	Apr NEWA

RIZATRIPTAN BENZOATE

TABLET; ORAL
RIZATRIPTAN BENZOATE

AB	CIPLA LTD	EQ 5MG BASE	A077526	001	Mar 26, 2013	Mar NEWA
AB		EQ 10MG BASE	A077526	002	Mar 26, 2013	Mar NEWA
AB	INVAGEN PHARMS	EQ 5MG BASE	A204339	001	Jul 01, 2013	Jun NEWA
AB		EQ 10MG BASE	A204339	002	Jul 01, 2013	Jun NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
RIZATRIPTAN BENZOATE

AB	APOTEX INC	EQ 5MG BASE	A202477	001	Jul 01, 2013	Jun NEWA
AB		EQ 10MG BASE	A202477	002	Jul 01, 2013	Jun NEWA
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A203062	001	Jul 01, 2013	Jun NEWA
AB		EQ 10MG BASE	A203062	002	Jul 01, 2013	Jun NEWA
AB	GLENMARK GENERICS	EQ 5MG BASE	A201914	001	Jul 01, 2013	Jun NEWA
AB		EQ 10MG BASE	A201914	002	Jul 01, 2013	Jun NEWA
AB	NATCO PHARMA LTD	EQ 5MG BASE	A203478	001	Jul 01, 2013	Jun NEWA
AB		EQ 10MG BASE	A203478	002	Jul 01, 2013	Jun NEWA
AB	SANDOZ	EQ 5MG BASE	A078739	001	Jul 01, 2013	Jun NEWA
AB		EQ 10MG BASE	A078739	002	Jul 01, 2013	Jun NEWA

ROCURONIUM BROMIDEINJECTABLE; INJECTION
ZEMURON

AP	+	ORGANON USA INC	50MG/5ML (10MG/ML)	N020214	001	Mar 17, 1994	Jan CAHN
		@	10MG/ML (10MG/ML)	N020214	002	Mar 17, 1994	Jan CAHN
AP	+		100MG/10ML (10MG/ML)	N020214	003	Mar 17, 1994	Jan CAHN

ROPINIROLE HYDROCHLORIDETABLET; ORAL
REQUIP

AB	+	GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658	001	Sep 19, 1997	Mar CAHN
AB			EQ 0.5MG BASE	N020658	002	Sep 19, 1997	Mar CAHN
AB			EQ 1MG BASE	N020658	003	Sep 19, 1997	Mar CAHN
AB			EQ 2MG BASE	N020658	004	Sep 19, 1997	Mar CAHN
AB			EQ 3MG BASE	N020658	006	Jan 27, 1999	Mar CAHN
AB			EQ 4MG BASE	N020658	007	Jan 27, 1999	Mar CAHN
AB			EQ 5MG BASE	N020658	005	Sep 19, 1997	Mar CAHN

ROPINIROLE HYDROCHLORIDE

>D>	AB	COREPHARMA	EQ 0.25MG BASE	A078230	001	May 20, 2008	Jul DISC
>A>		@	EQ 0.25MG BASE	A078230	001	May 20, 2008	Jul DISC
>D>	AB		EQ 0.5MG BASE	A078230	002	May 20, 2008	Jul DISC
>A>		@	EQ 0.5MG BASE	A078230	002	May 20, 2008	Jul DISC
>D>	AB		EQ 1MG BASE	A078230	003	May 20, 2008	Jul DISC
>A>		@	EQ 1MG BASE	A078230	003	May 20, 2008	Jul DISC
>D>	AB		EQ 2MG BASE	A078230	004	May 20, 2008	Jul DISC
>A>		@	EQ 2MG BASE	A078230	004	May 20, 2008	Jul DISC
>D>	AB		EQ 3MG BASE	A078230	005	May 20, 2008	Jul DISC
>A>		@	EQ 3MG BASE	A078230	005	May 20, 2008	Jul DISC
>D>	AB		EQ 4MG BASE	A078230	006	May 20, 2008	Jul DISC
>A>		@	EQ 4MG BASE	A078230	006	May 20, 2008	Jul DISC
>D>	AB		EQ 5MG BASE	A078230	007	May 20, 2008	Jul DISC
>A>		@	EQ 5MG BASE	A078230	007	May 20, 2008	Jul DISC

TABLET, EXTENDED RELEASE; ORAL
REQUIP XL

AB	+	GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008	001	Jun 13, 2008	Mar CAHN
		@	EQ 3MG BASE	N022008	002	Jun 13, 2008	Mar CAHN
AB			EQ 4MG BASE	N022008	003	Jun 13, 2008	Mar CAHN
AB			EQ 6MG BASE	N022008	006	Apr 10, 2009	Mar CAHN
AB			EQ 8MG BASE	N022008	004	Jun 13, 2008	Mar CAHN
AB			EQ 12MG BASE	N022008	005	Oct 31, 2008	Mar CAHN

ROPINIROLE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	EQ 2MG BASE	A090869	001	May 17, 2012	Apr CAHN
AB			EQ 4MG BASE	A090869	002	May 17, 2012	Apr CAHN
AB			EQ 6MG BASE	A090869	003	May 17, 2012	Apr CAHN
AB			EQ 8MG BASE	A090869	004	May 17, 2012	Apr CAHN
AB			EQ 12MG BASE	A090869	005	May 17, 2012	Apr CAHN
AB		ALEMBIC LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013	Apr NEWA
AB			EQ 4MG BASE	A202786	002	Apr 22, 2013	Apr NEWA
AB			EQ 6MG BASE	A202786	003	Apr 22, 2013	Apr NEWA
AB			EQ 8MG BASE	A202786	004	Apr 22, 2013	Apr NEWA
AB			EQ 12MG BASE	A202786	005	Apr 22, 2013	Apr NEWA

ROSIGLITAZONE MALEATETABLET; ORAL
AVANDIA

AB		SB PHARMCO	EQ 2MG BASE	N021071	002	May 25, 1999	Jan CFTG
AB			EQ 4MG BASE	N021071	003	May 25, 1999	Jan CFTG
AB	+		EQ 8MG BASE	N021071	004	May 25, 1999	Jan CFTG
		ROSIGLITAZONE MALEATE					
AB		TEVA	EQ 2MG BASE	A076747	001	Jan 25, 2013	Jan NEWA
AB			EQ 4MG BASE	A076747	002	Jan 25, 2013	Jan NEWA
AB			EQ 8MG BASE	A076747	003	Jan 25, 2013	Jan NEWA

ROTIGOTINEFILM, EXTENDED RELEASE; TRANSDERMAL
NEUPRO

+	UCB INC	2MG/24HR	N021829	001	May 09, 2007	May CRLD
		8MG/24HR	N021829	006	Apr 02, 2012	May CRLD

SAQUINAVIR MESYLATETABLET; ORAL
INVIRASE

+ HOFFMAN LA ROCHE EQ 500MG BASE N021785 001 Dec 17, 2004 Feb CAHN

SELEGILINE HYDROCHLORIDETABLET; ORAL
SELEGILINE HYDROCHLORIDE

@ DAVA PHARMS INC 5MG A074641 001 Aug 02, 1996 Jan DISC

SERTACONAZOLE NITRATECREAM; TOPICAL
ERTACZO

+ VALEANT LUXEMBOURG 2% N021385 001 Dec 10, 2003 Jun CAHN

SERTRALINE HYDROCHLORIDETABLET; ORAL
SERTRALINE HYDROCHLORIDE

@ DR REDDYS LABS LTD	EQ 25MG BASE	A076442	001	Apr 30, 2007	Apr DISC
@	EQ 50MG BASE	A076442	002	Apr 30, 2007	Apr DISC
@	EQ 100MG BASE	A076442	003	Apr 30, 2007	Apr DISC

SILDENAFIL CITRATETABLET; ORAL
SILDENAFIL CITRATE

AB	ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr CAHN
AB	ACTAVIS PHARMA	EQ 20MG BASE	A200149	001	Feb 25, 2013	Feb NEWA
AB	AMNEAL PHARMS	EQ 20MG BASE	A202025	001	Feb 28, 2013	Feb NEWA

SODIUM CHLORIDEINJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%

MEDEFIL INC	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Mar NEWA
	22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Mar NEWA
	27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Mar NEWA
	45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Mar NEWA
	90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012	Mar NEWA

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MEDEFIL INC 9MG/ML (9MG/ML) N202832 001 Jan 06, 2012 Mar CPOT

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 450MG/100ML N017864 001 Jan DISC

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

+ MCPRF 10-91.5MCI/ML A203605 001 Jun 28, 2013 Jun NEWA

SODIUM PHENYL BUTYRATEPOWDER; ORAL
BUPHENYL

AB	+ MEDICIS	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Mar CFTG
	SODIUM PHENYL BUTYRATE					
AB	SIGMAPHARM LABS LLC	3GM/TEASPOONFUL	A202819	001	Mar 22, 2013	Mar NEWA

>D> SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE>D> TABLET; ORAL
>D> VISICOL

>D>	+ SALIX PHARMS	0.398GM;1.102GM	N021097	001	Sep 21, 2000	Jul DISC
>A>	@	0.398GM;1.102GM	N021097	001	Sep 21, 2000	Jul DISC

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

+ HOSPIRA 142MG/ML;276MG/ML N018892 001 May 10, 1983 Jun CRLD

SODIUM POLYSTYRENE SULFONATE

	POWDER; ORAL, RECTAL						
	KAYEXALATE						
AA	+ COVIS PHARMA SARL	453.6GM/BOT	N011287	001			Apr CAHN
	SUSPENSION; ORAL, RECTAL						
	SODIUM POLYSTYRENE SULFONATE						
	@ ROXANE	15GM/60ML	A089049	001	Nov 17, 1986		Mar DISC

STAVUDINE

	CAPSULE; ORAL						
	STAVUDINE						
AB	HETERO LABS LTD III	15MG	A078957	001	Dec 29, 2008		Apr CAHN
AB		20MG	A078957	002	Dec 29, 2008		Apr CAHN
AB		30MG	A078957	003	Dec 29, 2008		Apr CAHN
AB		40MG	A078957	004	Dec 29, 2008		Apr CAHN

STREPTOZOCIN

	INJECTABLE; INJECTION						
	ZANOSAR						
	+ TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982		Apr CAHN

SUCCIMER

	CAPSULE; ORAL						
	CHEMET						
	+ RECORDATI RARE	100MG	N019998	002	Jan 30, 1991		May CAHN

SULFACETAMIDE SODIUM

	LOTION; TOPICAL						
	KLARON						
AB	+ VALEANT BERMUDA	10%	N019931	001	Dec 23, 1996		Feb CAHN
	OINTMENT; OPHTHALMIC						
	SULFACETAMIDE SODIUM						
AT	PERRIGO CO TENNESSEE	10%	A080029	001			Jun CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

	INJECTABLE; INJECTION						
	SULFAMETHOXAZOLE AND TRIMETHOPRIM						
	+ TEVA PHARMS USA	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991		Mar CAHN
	TABLET; ORAL						
	SULFAMETHOPRIM						
	@ NOVEL LABS INC	400MG;80MG	A070022	001	Feb 15, 1985		Mar DISC
	SULFAMETHOPRIM-DS						
	@ NOVEL LABS INC	800MG;160MG	A070032	001	Feb 15, 1985		Mar DISC
	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH						
	@ SANDOZ	800MG;160MG	N018598	004	May 19, 1982		Jun DISC

SULINDAC

	TABLET; ORAL						
	SULINDAC						
AB	HERITAGE PHARMS INC	150MG	A073262	002	Sep 06, 1991		Apr CMFD
AB		200MG	A073262	001	Sep 06, 1991		Apr CMFD

SUMATRIPTAN SUCCINATE

	INJECTABLE; SUBCUTANEOUS						
	SUMATRIPTAN SUCCINATE						
AP	AUROBINDO PHARMA LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758	001	Apr 23, 2013		Apr NEWA
AP	SAGENT AGILA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010		Feb CAHN
AP	TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077907	001	Feb 06, 2009		Mar CAHN
	SYSTEM; IONTOPHORESIS						
	ZECUITY						
	+ NUPATHE	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013		Jan NEWA
	TABLET; ORAL						
	SUMATRIPTAN SUCCINATE						
AB	HIKMA PHARMS	EQ 25MG BASE	A078298	001	May 21, 2013		May NEWA
AB		EQ 50MG BASE	A078298	002	May 21, 2013		May NEWA
AB		EQ 100MG BASE	A078298	003	May 21, 2013		May NEWA

TACROLIMUS

>A>	CAPSULE, EXTENDED RELEASE; ORAL						
>A>	ASTAGRAF XL						
>A>	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013	Jul	NEWA
>A>		EQ 1MG BASE	N204096	002	Jul 19, 2013	Jul	NEWA
>A>	+	EQ 5MG BASE	N204096	003	Jul 19, 2013	Jul	NEWA
	OINTMENT; TOPICAL						
	PROTOPIC						
	+	ASTELLAS 0.03%	N050777	001	Dec 08, 2000	Jun	CRLD

TAMSULOSIN HYDROCHLORIDE

	CAPSULE; ORAL						
	TAMSULOSIN HYDROCHLORIDE						
AB	AUROBINDO PHARMA LTD	0.4MG	A202433	001	Apr 30, 2013	Apr	NEWA

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE; INJECTION
LYMPHOSEEK KIT

+	NAVIDEA BIOPHARMS	N/A	N202207	001	Mar 13, 2013	Mar	NEWA
---	-------------------	-----	---------	-----	--------------	-----	------

TENIPOSIDE

INJECTABLE; INJECTION
VUMON

	+	CORDEN PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Apr	CAHN
>D>	+		10MG/ML	N020119	001	Jul 14, 1992	Jul	CAHN
>A>	+	HQ SPECILT PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Jul	CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL
TERBINAFINE HYDROCHLORIDE

>A>	AB	CIPLA LTD	EQ 250MG BASE	A077137	001	Jul 02, 2007	Jul	CAHN
>D>	AB	WATSON LABS	EQ 250MG BASE	A077137	001	Jul 02, 2007	Jul	CAHN

TERBUTALINE SULFATE

INJECTABLE; INJECTION
TERBUTALINE SULFATE
@ TEVA PHARMS USA

1MG/ML

A076853	001	Jul 20, 2004	Mar	CAHN
---------	-----	--------------	-----	------

TESTOSTERONE

GEL; TRANSDERMAL
TESTOSTERONE

PERRIGO ISRAEL 25MG/2.5GM PACKET
50MG/5GM PACKET

N203098	002	Jan 31, 2013	Jan	NEWA
N203098	003	Jan 31, 2013	Jan	NEWA

GEL, METERED; TRANSDERMAL
TESTOSTERONE

PERRIGO ISRAEL 12.5MG/1.25GM ACTUATION

N203098	001	Jan 31, 2013	Jan	NEWA
---------	-----	--------------	-----	------

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
TESTOSTERONE CYPIONATE

AO	SUN PHARM INDS LTD	100MG/ML
AO		200MG/ML

A201720	001	Jun 03, 2013	May	NEWA
A201720	002	Jun 03, 2013	May	NEWA

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELATESTYL

@ ENDO PHARMS 200MG/ML
+ 200MG/ML

N009165	001		Jan	CAHN
N009165	003		Jan	CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
THEOPHYLLINE

AB	+	TEVA PHARMS	450MG
----	---	-------------	-------

A081236	001	Nov 09, 1992	Mar	CAHN
---------	-----	--------------	-----	------

THIABENDAZOLESUSPENSION; ORAL
MINTEZOL

@ MERCK SHARP DOHME 500MG/5ML

N016097 001

May CAHN

TABLET, CHEWABLE; ORAL
MINTEZOL

@ MERCK SHARP DOHME 500MG

N016096 001

May CAHN

THIOGUANINETABLET; ORAL
THIOGUANINE

+ ASPEN GLOBAL INC 40MG

N012429 001

Mar CAHN

TILUDRONATE DISODIUMTABLET; ORAL
SKELID

@ SANOFI AVENTIS US EQ 200MG BASE

N020707 001 Mar 07, 1997 Jun DISC

TIMOLOL MALEATESOLUTION, GEL FORMING/DROPS; OPHTHALMIC
TIMOPTIC-XE

AB + VALEANT PHARMS LLC EQ 0.25% BASE

N020330 001 Nov 04, 1993 Jan CAHN

AB + EQ 0.5% BASE

N020330 002 Nov 04, 1993 Jan CAHN

SOLUTION/DROPS; OPHTHALMIC
ISTALOL

BT + BAUSCH AND LOMB EQ 0.5% BASE

N021516 001 Jun 04, 2004 May CAHN

TIMOLOL MALEATE

@ AKORN EQ 0.25% BASE

A074515 001 Mar 25, 1997 Jun DISC

@ APOTEX INC EQ 0.25% BASE

A075411 001 Sep 08, 2000 Apr DISC

@ EQ 0.5% BASE

A075412 001 Sep 08, 2000 Apr DISC

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB MYLAN PHARMS INC EQ 2MG BASE

A091502 001 Nov 09, 2012 May CAHN

AB EQ 4MG BASE

A091502 002 Nov 09, 2012 May CAHN

AB EQ 6MG BASE

A091502 003 Nov 09, 2012 May CAHN

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

@ MYLAN PHARMS INC EQ 2MG BASE

A076282 001 Dec 16, 2003 Feb DISC

@ EQ 4MG BASE

A076282 002 Dec 16, 2003 Feb DISC

TOBRAMYCINPOWDER; INHALATION
TOBI PODHALER

+ NOVARTIS 28MG

N201688 001 Mar 22, 2013 Mar NEWA

SOLUTION/DROPS; OPHTHALMIC
TOBRAMYCIN

@ APOTEX INC 0.3%

A065087 001 Feb 25, 2002 Apr DISC

TOLAZAMIDETABLET; ORAL
TOLAZAMIDE

+ MYLAN PHARMS INC 250MG

A070259 001 Jan 02, 1986 Mar CTEC

+ 500MG

A070259 003 Mar 17, 1986 Mar CTEC

@ WATSON LABS 250MG

A070514 001 Jan 09, 1986 Mar DISC

@ 500MG

A070515 001 Jan 09, 1986 Mar DISC

TOPIRAMATE

TABLET; ORAL

TOPAMAX

AB	JANSSEN PHARMS	25MG	N020505	004	Dec 24, 1996	Apr	CRLD
AB	+	100MG	N020505	001	Dec 24, 1996	Apr	CRLD
	TOPIRAMATE						
AB	ACTIVIS TOTOWA LLC	25MG	A078637	001	Feb 27, 2013	Feb	NEWA
AB		50MG	A078637	002	Feb 27, 2013	Feb	NEWA
AB		100MG	A078637	003	Feb 27, 2013	Feb	NEWA
AB		200MG	A078637	004	Feb 27, 2013	Feb	NEWA
AB	UNICHEM LABS LTD	200MG	A090162	004	Feb 19, 2013	Feb	NEWA
	@ UPSHER SMITH	25MG	A078499	001	Jan 07, 2010	Jun	DISC
	@	50MG	A078499	002	Jan 07, 2010	Jun	DISC
	@	100MG	A078499	003	Jan 07, 2010	Jun	DISC
	@	200MG	A078499	004	Jan 07, 2010	Jun	DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP	ACCORD HLTHCARE	EQ 4MG BASE/VIAL	A202351	001	Jun 26, 2013	Jun	NEWA
----	-----------------	------------------	---------	-----	--------------	-----	------

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

+	PROSTRAKAN INC	EQ 60MG BASE	N020497	001	May 29, 1997	May	CAHN
---	----------------	--------------	---------	-----	--------------	-----	------

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB	HETERO LABS LTD III	5MG	A079234	001	Jan 27, 2009	Apr	CAHN
AB		10MG	A079234	002	Jan 27, 2009	Apr	CAHN
AB		20MG	A079234	003	Jan 27, 2009	Apr	CAHN
AB		100MG	A079234	004	Jan 27, 2009	Apr	CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	ACCORD HLTHCARE INC	50MG	A202390	001	May 16, 2013	Apr	NEWA
AB	CSPC OUYI PHARM CO	50MG	A091498	001	Mar 29, 2013	Mar	NEWA
	TABLET, EXTENDED RELEASE; ORAL						
	RYZOLT						
	@ PURDUE PHARMA	100MG	N021745	001	Dec 30, 2008	Jan	DISC
	@	200MG	N021745	002	Dec 30, 2008	Jan	DISC
	@	300MG	N021745	003	Dec 30, 2008	Jan	DISC
	TRAMADOL HYDROCHLORIDE						
AB2	ACTAVIS ELIZABETH	100MG	A091609	001	Jun 27, 2012	Apr	CAHN
AB2		200MG	A091609	002	Jun 27, 2012	Apr	CAHN
AB2		300MG	A091609	003	Jun 27, 2012	Apr	CAHN
AB1	PAR PHARM INC	100MG	A078783	001	Nov 13, 2009	Feb	CRLD
AB2	+	SUN PHARMA GLOBAL	A091607	001	Dec 30, 2011	Feb	CRLD

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL

MEKINIST

	GLAXOSMITHKLINE LLC	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	May	NEWA
		EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	May	NEWA
+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	May	NEWA

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

>D>	AB	CIPLA	1MG	A077307	002	Jun 12, 2007	Jul	DISC
>A>		@	1MG	A077307	002	Jun 12, 2007	Jul	DISC
>D>	AB		2MG	A077307	001	Jun 12, 2007	Jul	DISC
>A>		@	2MG	A077307	001	Jun 12, 2007	Jul	DISC
>D>	AB		4MG	A077307	003	Jun 12, 2007	Jul	DISC
>A>		@	4MG	A077307	003	Jun 12, 2007	Jul	DISC
		@ DR REDDYS LABS LTD	1MG	A078493	001	Aug 25, 2008	Apr	DISC
		@	2MG	A078493	002	Aug 25, 2008	Apr	DISC
		@	4MG	A078493	003	Aug 25, 2008	Apr	DISC

TRANEXAMIC ACID

INJECTABLE; INJECTION
TRANEXAMIC ACID

AP	CUSTOPHARM INC	100MG/ML	A201580	001	Jun 14, 2013	Jun NEWA
----	----------------	----------	---------	-----	--------------	----------

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC
TRAVOPROST

	PAR PHARM	0.004%	A091340	001	Mar 01, 2013	Feb NEWA
--	-----------	--------	---------	-----	--------------	----------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB	TEVA PHARMS USA	50MG	A071523	001	Dec 11, 1987	Mar CAHN
----	-----------------	------	---------	-----	--------------	----------

AB		100MG	A071524	001	Dec 11, 1987	Mar CAHN
----	--	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

@	ANGELINI LLC	150MG	N022411	001	Feb 02, 2010	May DISC
---	--------------	-------	---------	-----	--------------	----------

@		300MG	N022411	002	Feb 02, 2010	May DISC
---	--	-------	---------	-----	--------------	----------

+	ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010	Jun CMFD
---	-----------------	-------	---------	-----	--------------	----------

		300MG	N022411	002	Feb 02, 2010	Jun CMFD
--	--	-------	---------	-----	--------------	----------

TREPROSTINIL

INJECTABLE; IV (INFUSION)-SC

REMODULIN

	UNITED THERAP	1MG/ML	N021272	001	May 21, 2002	May CAIN
--	---------------	--------	---------	-----	--------------	----------

		2.5MG/ML	N021272	002	May 21, 2002	May CAIN
--	--	----------	---------	-----	--------------	----------

		5MG/ML	N021272	003	May 21, 2002	May CAIN
--	--	--------	---------	-----	--------------	----------

+		10MG/ML	N021272	004	May 21, 2002	Jun CAIN
---	--	---------	---------	-----	--------------	----------

SOLUTION; INHALATION

TYVASO

+	UNITED THERAP	EQ 0.6MG BASE/ML	N022387	001	Jul 30, 2009	May CAIN
---	---------------	------------------	---------	-----	--------------	----------

TRETINOIN

CREAM; TOPICAL

RETIN-A

AB	+	VALEANT BERMUDA	0.025%	N019049	001	Sep 16, 1988	Jun CAHN
----	---	-----------------	--------	---------	-----	--------------	----------

AB1	+		0.05%	N017522	001		Jun CAHN
-----	---	--	-------	---------	-----	--	----------

AB	+		0.1%	N017340	001		Jun CAHN
----	---	--	------	---------	-----	--	----------

GEL; TOPICAL

ATRALIN

+	DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Apr CAHN
---	-----------	-------	---------	-----	--------------	----------

RETIN-A MICRO

>D>	+	VALEANT INTL	0.04%	N020475	002	May 10, 2002	Jul CTEC
-----	---	--------------	-------	---------	-----	--------------	----------

>A> AB	+		0.04%	N020475	002	May 10, 2002	Jul CTEC
--------	---	--	-------	---------	-----	--------------	----------

>D>	+		0.1%	N020475	001	Feb 07, 1997	Jul CTEC
-----	---	--	------	---------	-----	--------------	----------

>A> AB	+		0.1%	N020475	001	Feb 07, 1997	Jul CTEC
--------	---	--	------	---------	-----	--------------	----------

TRETINOIN

>A> AB		SPEAR PHARMS INC	0.04%	A202567	001	Jul 17, 2013	Jul NEWA
--------	--	------------------	-------	---------	-----	--------------	----------

>A> AB			0.1%	A202026	001	Jul 17, 2013	Jul NEWA
--------	--	--	------	---------	-----	--------------	----------

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL									
KENALOG									
	@	APOTHECON	0.025%		N011601	003		Apr	DISC
	@		0.1%		N011601	006		Apr	DISC
TRIACET									
	@	TEVA	0.025%		A084908	001		Apr	DISC
	@		0.5%		A084908	003		Apr	DISC
TRIAMCINOLONE ACETONIDE									
AT	+	FOUGERA PHARMS	0.025%		A085692	001		Apr	CRLD
AT	+		0.1%		A085692	003		Apr	CRLD
	@	G AND W LABS	0.025%		A089797	001	May 31, 1991	May	DISC
	@	TARO	0.025%		A086277	001		Apr	DISC
	@		0.1%		A086276	001		Apr	DISC
	@		0.5%		A086275	001		Apr	DISC
INJECTABLE; INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL									
TRIVARIS									
	@	ALLERGAN	8MG/0.1ML (8MG/0.1ML)		N022220	001	Jun 16, 2008	May	DISC
LOTION; TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT		VERSAPHARM INC	0.025%		A202374	001	May 08, 2013	Apr	NEWA
AT			0.1%		A202374	002	May 08, 2013	Apr	NEWA
AT	+	WOCKHARDT EU OPERATN	0.025%		A088450	001	Apr 01, 1985	Apr	CAHN
OINTMENT; TOPICAL									
KENALOG									
	@	APOTHECON	0.025%		N011600	003		Apr	DISC
	@		0.1%		N011600	001		Apr	DISC
TRIAMCINOLONE ACETONIDE									
	@	TARO	0.025%		A040040	001	Sep 30, 1994	May	DISC
	@		0.025%		A040374	001	Jun 05, 2001	May	DISC
	@		0.1%		A087902	001	Dec 27, 1982	May	DISC
	@		0.5%		A040386	001	Jun 05, 2001	May	DISC

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL									
TRIHEXYPHENIDYL HYDROCHLORIDE									
>D> AA		WEST WARD	2MG		A040337	002	Feb 16, 2000	Jul	DISC
>A>		@	2MG		A040337	002	Feb 16, 2000	Jul	DISC
>D> AA			5MG		A040337	001	Feb 16, 2000	Jul	DISC
>A>		@	5MG		A040337	001	Feb 16, 2000	Jul	DISC

TRIMETHOPRIM

TABLET; ORAL									
TRIMETHOPRIM									
>D> AB		TEVA	100MG		N018679	001	Jul 30, 1982	Jul	CRLD
>A> AB	+		100MG		N018679	001	Jul 30, 1982	Jul	CRLD
	@		200MG		A071259	001	Jun 18, 1987	Jun	DISC

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL									
TROSPIMUM CHLORIDE									
AB		PADDOCK LLC	60MG		A201291	001	May 24, 2013	May	NEWA

URSODIOL

TABLET; ORAL									
URSODIOL									
AB		PAR PHARM	250MG		A202540	001	Feb 14, 2013	Feb	NEWA
AB			500MG		A202540	002	Feb 14, 2013	Feb	NEWA
	@	TEVA PHARMS USA	250MG		A079184	001	May 13, 2009	Apr	DISC
	@		500MG		A079184	002	May 13, 2009	Apr	DISC

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL									
VALACYCLOVIR HYDROCHLORIDE									
AB		ACTAVIS GRP PTC	EQ 1GM BASE		A090370	002	Mar 16, 2011	Mar	CAHN
AB			EQ 500MG BASE		A090370	001	Mar 16, 2011	Mar	CAHN

VALPROIC ACID

CAPSULE; ORAL					
VALPROIC ACID					
AB	SUN PHARM INDS LTD	250MG	A091037	001	Feb 22, 2013 Feb NEWA
CAPSULE, DELAYED RELEASE; ORAL					
STAVZOR					
	@ BANNER PHARMACAPS	125MG	N022152	001	Jul 29, 2008 Jun DISC
	@	250MG	N022152	002	Jul 29, 2008 Jun DISC
	@	500MG	N022152	003	Jul 29, 2008 Jun DISC

VECURONIUM BROMIDE

INJECTABLE; INJECTION					
VECURONIUM BROMIDE					
AP	TEVA PHARMS USA	10MG/VIAL	A074688	001	Aug 25, 1999 Apr CAHN
AP		20MG/VIAL	A074688	002	Aug 25, 1999 Apr CAHN

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL					
VENLAFAXINE HYDROCHLORIDE					
>A> AB	VALEANT BERMUDA	EQ 37.5MG BASE	A090071	001	Apr 15, 2011 Jul CAHN
>A> AB		EQ 75MG BASE	A090071	002	Apr 15, 2011 Jul CAHN
>A> AB		EQ 150MG BASE	A090071	003	Apr 15, 2011 Jul CAHN
>D> AB	VALEANT INTL	EQ 37.5MG BASE	A090071	001	Apr 15, 2011 Jul CAHN
>D> AB		EQ 75MG BASE	A090071	002	Apr 15, 2011 Jul CAHN
>D> AB		EQ 150MG BASE	A090071	003	Apr 15, 2011 Jul CAHN

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION					
VERAPAMIL HYDROCHLORIDE					
	@ INTL MEDICATION	2.5MG/ML	A070451	001	Dec 16, 1985 Mar DISC
TABLET, EXTENDED RELEASE; ORAL					
VERAPAMIL HYDROCHLORIDE					
AB	CARACO	120MG	A090529	001	Dec 30, 2011 May CAHN
AB		180MG	A090529	002	Dec 30, 2011 May CAHN
AB		240MG	A090529	003	Dec 30, 2011 May CAHN

VERTEPORFIN

INJECTABLE; INJECTION					
VISUDYNE					
+	VALEANT PHARMS INC	15MG/VIAL	N021119	001	Apr 12, 2000 Jan CAHN

VINCRIStINE SULFATE

INJECTABLE; INJECTION					
VINCRIStINE SULFATE PFS					
AP	TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999 Apr CAHN

VINORELBINE TARTRATE

INJECTABLE; INJECTION					
VINORELBINE TARTRATE					
AP	TEVA PHARMS USA	EQ 10MG BASE/ML	A076028	001	Feb 03, 2003 Apr CAHN

VORICONAZOLE

FOR SUSPENSION; ORAL					
VFEND					
AB	+ PFIZER	200MG/5ML	N021630	001	Dec 19, 2003 May CFTG
VORICONAZOLE					
AB	MYLAN PHARMS INC	200MG/5ML	A202361	001	May 28, 2013 May NEWA

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

AB	AMNEAL PHARMS	1MG	A202202	001	Mar 04, 2013	Feb	NEWA
AB		2MG	A202202	002	Mar 04, 2013	Feb	NEWA
AB		2.5MG	A202202	003	Mar 04, 2013	Feb	NEWA
AB		3MG	A202202	004	Mar 04, 2013	Feb	NEWA
AB		4MG	A202202	005	Mar 04, 2013	Feb	NEWA
AB		5MG	A202202	006	Mar 04, 2013	Feb	NEWA
AB		6MG	A202202	007	Mar 04, 2013	Feb	NEWA
AB		7.5MG	A202202	008	Mar 04, 2013	Feb	NEWA
AB		10MG	A202202	009	Mar 04, 2013	Feb	NEWA
AB	IPCA LABS LTD	1MG	A200104	001	Jun 27, 2013	Jun	NEWA
AB		2MG	A200104	002	Jun 27, 2013	Jun	NEWA
AB		2.5MG	A200104	003	Jun 27, 2013	Jun	NEWA
AB		3MG	A200104	004	Jun 27, 2013	Jun	NEWA
AB		4MG	A200104	005	Jun 27, 2013	Jun	NEWA
AB		5MG	A200104	006	Jun 27, 2013	Jun	NEWA
AB		6MG	A200104	007	Jun 27, 2013	Jun	NEWA
AB		7.5MG	A200104	008	Jun 27, 2013	Jun	NEWA
AB		10MG	A200104	009	Jun 27, 2013	Jun	NEWA

ZALEPLON

CAPSULE; ORAL

SONATA

AB	PFIZER	5MG	N020859	001	Aug 13, 1999	Apr	CAHN
AB	+	10MG	N020859	002	Aug 13, 1999	Apr	CAHN

ZIDOVUDINE

TABLET; ORAL

RETROVIR

	@ VIV HLTHCARE	300MG	N020518	002	Oct 04, 1996	Apr	DISC
	ZIDOVUDINE						
AB	HEC PHARM USA INC	300MG	A202058	001	Oct 07, 2011	Feb	CMFD
	@	300MG	A202058	001	Oct 07, 2011	Jan	DISC
AB	+	HETERO LABS LTD III	A090092	001	Apr 25, 2008	Apr	CRLD

ZOLEDRONIC ACID

INJECTABLE; INJECTION

ZOLEDRONIC ACID

AP	DR REDDYS LABS LTD	EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Mar	NEWA
>D>	AP	EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Jul	CDFR
AP	EMCURE PHARMS LTD	EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Mar	NEWA
>D>	AP	EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Jul	CDFR

INJECTABLE; IV (INFUSION)

RECLAST

AP	+	NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	Mar	CTEC
		ZOLEDRONIC ACID						
AP		ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Feb	NEWA
AP		AGILA SPECLTS	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Feb	NEWA
AP		DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Feb	NEWA
>A>	AP		EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Jul	CDFR
AP		EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Mar	NEWA
>A>	AP		EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Jul	CDFR
>A>	AP	GLAND PHARMA LTD	EQ 4MG BASE/5ML	A202930	001	Aug 05, 2013	Jul	NEWA
AP		HIKMA FARMACEUTICA	EQ 4MG BASE/5ML	A202182	001	Jun 03, 2013	May	NEWA
AP		HOSPIRA INC	EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Mar	NEWA
AP		PHARMACEUTICS	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Feb	NEWA
>A>	AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Jul	NEWA
AP		PHARMS	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Apr	NEWA
	+	SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Feb	NEWA
AP			EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Feb	NEWA
		ZOMETA						
AP	+	NOVARTIS	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Feb	CFTG

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

AB	APOTEX INC	2.5MG	A202078	001	May 14, 2013	Apr	NEWA
AB		5MG	A202078	002	May 14, 2013	Apr	NEWA
AB	GLENMARK GENERICS	2.5MG	A201779	001	May 14, 2013	Apr	NEWA
AB		5MG	A201779	002	May 14, 2013	Apr	NEWA
AB	MYLAN PHARMS INC	2.5MG	A203186	001	May 14, 2013	Apr	NEWA
AB		5MG	A203186	002	May 14, 2013	Apr	NEWA

ZOMIG

AB	IPR	2.5MG	N020768	001	Nov 25, 1997	Apr	CFTG
AB	+	5MG	N020768	002	Nov 25, 1997	Apr	CFTG

TABLET, ORALLY DISINTEGRATING; ORAL

ZOLMITRIPTAN

AB	APOTEX INC	2.5MG	A202476	001	May 14, 2013	Apr	NEWA
AB		5MG	A202476	002	May 14, 2013	Apr	NEWA
AB	GLENMARK GENERICS	2.5MG	A202560	001	May 14, 2013	Apr	NEWA
AB		5MG	A202560	002	May 14, 2013	Apr	NEWA
AB	ZYDUS PHARMS USA INC	2.5MG	A202890	001	May 15, 2013	Apr	NEWA
AB		5MG	A202890	002	May 15, 2013	Apr	NEWA

ZOMIG-ZMT

AB	ASTRAZENECA	2.5MG	N021231	001	Feb 13, 2001	Apr	CFTG
AB	+	5MG	N021231	002	Sep 17, 2001	Apr	CFTG

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

@	DR REDDYS LABS LTD	5MG	A077985	001	Apr 23, 2007	Apr	DISC
@		10MG	A077985	002	Apr 23, 2007	Apr	DISC

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

AB	ACTAVIS ELIZABETH	6.25MG	A078179	002	Oct 13, 2010	Apr	CAHN
AB		12.5MG	A078179	001	Jun 06, 2011	Apr	CAHN
AB	WATSON LABS INC FL	6.25MG	A090153	001	Mar 25, 2013	Mar	NEWA
AB		12.5MG	A090153	002	Mar 25, 2013	Mar	NEWA

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

@	COREPHARMA	25MG	A077876	001	Feb 21, 2007	Feb	DISC
@		50MG	A077876	002	Feb 21, 2007	Feb	DISC
@		100MG	A077876	003	Feb 21, 2007	Feb	DISC
@	DR REDDYS LABS LTD	25MG	A077645	002	Sep 29, 2006	Mar	DISC
@		50MG	A077645	003	Sep 29, 2006	Mar	DISC
@		100MG	A077645	001	Dec 22, 2005	Mar	DISC

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL
TYLENOL

>A>	+	MCNEIL CONS	650MG	N019872	001	Jun 08, 1994	Jul CTNA
>A>	+		650MG	N019872	002	Jan 11, 2001	Jul CTNA
		TYLENOL (CAPLET)					
>D>	+	MCNEIL CONS	650MG	N019872	001	Jun 08, 1994	Jul CTNA
		TYLENOL (GELTAB)					
>D>	+	MCNEIL CONS	650MG	N019872	002	Jan 11, 2001	Jul CTNA

ASPIRIN

CAPSULE; ORAL
ASPIRIN

+	PLX PHARMA	325MG	N203697	001	Jan 14, 2013	Jan NEWA
---	------------	-------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	APOTEX INC	5MG/5ML	A090188	002	Apr 22, 2008	Apr DISC
	BIO PHARM INC	5MG/5ML	A090474	002	Mar 30, 2009	May CAHN
	CARACO	5MG/5ML	A091327	001	Oct 17, 2011	May CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	APOTEX INC	5MG/5ML	A090188	001	Apr 22, 2008	Apr DISC
	BIO PHARM INC	5MG/5ML	A090474	001	Mar 30, 2009	May CAHN
	CARACO	5MG/5ML	A091327	002	Oct 17, 2011	May CAHN

TABLET; ORAL
CETIRIZINE HYDROCHLORIDE ALLERGY

>A>		CIPLA LTD	5MG	A077318	001	Jul 25, 2013	Jul NEWA
>A>			10MG	A077318	002	Jul 25, 2013	Jul NEWA

TABLET, CHEWABLE; ORAL
CETIRIZINE HYDROCHLORIDE ALLERGY

+	SANDOZ	10MG	A078692	002	Feb 14, 2008	Apr CRLD
	CHILDREN'S ZYRTEC ALLERGY					
@	MCNEIL CONS	5MG	N021621	003	Nov 16, 2007	Apr DISC
+		5MG	N021621	003	Nov 16, 2007	Feb CRLD
@		10MG	N021621	004	Nov 16, 2007	Feb DISC
	CHILDREN'S ZYRTEC HIVES RELIEF					
@	MCNEIL CONS	5MG	N021621	005	Nov 16, 2007	Apr DISC
+		5MG	N021621	005	Nov 16, 2007	Feb CRLD
@		10MG	N021621	006	Nov 16, 2007	Feb DISC

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
DYNA-HEX

	BAJAJ MEDICAL LLC	0.75%	N020111	001	Sep 11, 1997	Apr CAHN
--	-------------------	-------	---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL
PREVANTICS MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar CTNA
	PREVANTICS SWAB					
+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar CTNA
	PREVANTICS SWABSTICK					
+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar CTNA

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

	AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013	Feb NEWA
--	-------------	-----------	---------	-----	--------------	----------

FAMOTIDINE

TABLET; ORAL
PEPCID AC

>A>		MCNEIL CONS	10MG	N020902	001	Aug 05, 1999	Jul CTNA
		PEPCID AC (GELTAB)					
>D>		MCNEIL CONS	10MG	N020902	001	Aug 05, 1999	Jul CTNA

FEXOFENADINE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY
 DR REDDYS LABS LTD 30MG
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES
 DR REDDYS LABS LTD 30MG

A202978 001 Jan 18, 2013 Jan NEWA
 A202978 002 Jan 18, 2013 Jan NEWA

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC
 KETOTIFEN FUMARATE
 @ APOTEX INC EQ 0.025% BASE

A077354 001 May 09, 2006 Apr DISC

LEVONORGESTREL

TABLET; ORAL
 LEVONORGESTREL
 AB LUPIN LTD 0.75MG
 AB NOVEL LABS INC 1.5MG

A091328 001 Jan 23, 2013 Jan NEWA
 A202508 001 Feb 22, 2013 Feb NEWA

LORATADINE

SYRUP; ORAL
 LORATADINE
 @ APOTEX INC 1MG/ML

A075565 001 Oct 05, 2004 Apr DISC

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
 LORATADINE AND PSEUDOEPHEDRINE SULFATE
 @ WATSON LABS INC FL 5MG;120MG

A076208 001 Jan 28, 2004 Feb DISC

MICONAZOLE NITRATE

CREAM; VAGINAL
 MICONAZOLE NITRATE
 APHENA PHARMA MD 2%

A074366 001 Feb 22, 1996 Jan CAHN

MINOXIDIL

SOLUTION; TOPICAL
 MINOXIDIL (FOR MEN)
 @ APOTEX INC 2%
 MINOXIDIL (FOR WOMEN)
 @ APOTEX INC 2%
 MINOXIDIL EXTRA STRENGTH (FOR MEN)
 @ APOTEX INC 5%

A074924 001 Apr 29, 1998 Apr DISC
 A074924 002 Apr 29, 1998 Apr DISC
 A075839 001 Oct 01, 2001 Apr DISC

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE
 AKORN INC 0.025%;0.3%

A202795 001 Jan 24, 2013 Jan NEWA

OMEPRazole; SODIUM BICARBONATE

FOR SUSPENSION; ORAL
 ZEGERID OTC
 + MSD CONSUMER 20MG/PACKET;1.68GM/PACKET

N022283 001 Jun 17, 2013 Jun NEWA

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL
 OXYTROL FOR WOMEN
 + MSD CONSUMER 3.9MG/24HR

N202211 001 Jan 25, 2013 Jan NEWA

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL
 POLYETHYLENE GLYCOL 3350
 PAR PHARM 17GM/SCOOPFUL

A079214 001 Jan 31, 2013 Jan NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
 RANITIDINE HYDROCHLORIDE
 @ WATSON LABS EQ 75MG BASE

A075212 001 Jan 14, 2000 Mar DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 07 JULY 2013

NO JULY 2013 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2013 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8399445	Aug 24, 2025	U-1373			
<u>ACYCLOVIR - SITAVIG</u>						
N 203791 001					NP	Apr 12, 2016
<u>ADAPALENE - DIFFERIN</u>						
N 022502 001	8435502	Sep 15, 2026	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8445543	Jul 12, 2027	U-1078		NPP	Feb 01, 2016
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	>A> 6251912	Jul 29, 2018	DS DP U-1067		>A> NCE	Jul 12, 2018
	>A> 8426586	Oct 10, 2029	DS DP		>A> ODE	Jul 12, 2020
	>A> RE43431	Jan 22, 2022	DS DP			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	>A> 6251912	Jul 29, 2018	DS DP U-1067		>A> NCE	Jul 12, 2018
	>A> 8426586	Oct 10, 2029	DS DP		>A> ODE	Jul 12, 2020
	>A> RE43431	Jan 22, 2022	DS DP			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	>A> 6251912	Jul 29, 2018	DS DP U-1067		>A> NCE	Jul 12, 2018
	>A> 8426586	Oct 10, 2029	DS DP		>A> ODE	Jul 12, 2020
	>A> RE43431	Jan 22, 2022	DS DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 001	8349843	Oct 07, 2015	DS DP			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 002	8349843	Oct 07, 2015	DS DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 001	>A> 8475839	May 16, 2023	DP			
	>A> 8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 002	>A> 8475839	May 16, 2023	DP			
	>A> 8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 003	>A> 8475839	May 16, 2023	DP			
	>A> 8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 004	>A> 8475839	May 16, 2023	DP			
	>A> 8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 005	>A> 8475839	May 16, 2023	DP			
	>A> 8475839*PED	Nov 16, 2023				
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	8357394	Dec 08, 2026	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N 021912 001 >A>	6589508	Apr 03, 2014	U-793			
	7348362	Jun 22, 2021	DP U-793			
	7462645	Jun 22, 2021	U-793			
	7465756	Jun 22, 2021	DP			
	7473710	Jun 22, 2021	U-793			
	7541385	Jun 22, 2021	U-793			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 001	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 002	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 003	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 004	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002					NC	Dec 20, 2014
					NCE	Feb 25, 2016
<u>AZTREONAM - CAYSTON</u>						
N 050814 001	8399496	Dec 20, 2021	DP U-1377			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Oct 02, 2024	DS DP U-1321		ODE	Dec 28, 2019
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	6780877	Sep 19, 2019	DS DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8415342	Nov 07, 2030	U-80			
	>A> 8481526	Jan 09, 2031	DS			
<u>BOCEPREVIR - VICTRELIS</u>						
N 022258 001					M-126 NPP	Feb 27, 2016 Feb 13, 2016
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001					NC	Apr 19, 2016
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	8354409	Apr 19, 2022	DP U-1371			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8129431	Sep 11, 2025	DS DP		NP	Apr 05, 2016
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	7888310	Jul 25, 2023	U-976			
	7888310	Jul 25, 2023	U-1379			
	8137992	Jul 25, 2023	U-1380			
	8137993	Jul 25, 2023	U-1379			
	8137994	Jul 25, 2023	U-1379			
	8431155	Apr 30, 2032	DP U-1379			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	7410651	Jun 09, 2020	DP U-1325		NDF	Jan 14, 2016
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	RE43799	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8387615	Nov 10, 2024	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8387615	Nov 10, 2024	DP			
	>A> 8461211	Sep 09, 2018	U-1118			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8475832	Mar 02, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8475832	Mar 02, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8475832	Mar 02, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8475832	Mar 02, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	>A> 8454996	Sep 24, 2019	U-1421			
	>A> 8470361	Oct 14, 2029	DP U-1421			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	>A> 8454996	Sep 24, 2019	U-1421			
	>A> 8470361	Oct 14, 2029	DP U-1421			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001					ODE	Nov 29, 2019
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002					ODE	Nov 29, 2019
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N 021406 001	RE43580	Feb 02, 2021	DP U-227			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 001					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 002					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 003					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 004					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE</u>						
A 090704 003					PC	Jun 02, 2013
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	8062667	Mar 29, 2029	DP			
<u>CELECOXIB - CELEBREX</u>						
N 020998 001	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 002	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 003	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 004	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 002	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 005	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 007	7422388	Apr 25, 2027	DP U-1397			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Aug 25, 2027	U-1356			
	8383611	Oct 20, 2020	DP			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	8371292	Aug 25, 2027	U-1357			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 001	8187632	Jun 23, 2021	DP			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 002	8187632	Jun 23, 2021	DP			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535 001	8450338	Oct 10, 2028	DP			
	8481083	Oct 10, 2028	DP			
<u>CLOBAZAM - ONFI</u>						
N 203993 001					ODE	Oct 21, 2018
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 201402 001					PC	Jul 31, 2013
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	8460641	Nov 05, 2028	DP U-1410			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	7635704	Oct 26, 2026	DS DP U-257			
<u>COLCHICINE - COLCRYS</u>						
N 022352 001	8415395	Oct 06, 2028	U-1007			
	8415396	Oct 06, 2028	U-1007			
	8440721	Feb 17, 2029	U-1007			
	8440722	Feb 17, 2029	U-1020			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	8415345	Jan 20, 2030	DS DP U-1406		ODE	May 29, 2020
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002 >A>	7994185	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
>A>	8415345	Jan 20, 2030	DS DP U-1406		ODE	May 29, 2020
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	5540938	Jul 30, 2018	U-1030			
	8354437	Dec 22, 2026	U-1030			
	8440703	Apr 08, 2025	U-1030			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005					D-135 PED	Feb 01, 2016 Aug 01, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					I-665	Jan 23, 2016
<u>DESONIDE - VERDESO</u>						
N 021978 001	8460641	Nov 05, 2028	DP U-1412			
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	5990100	Mar 24, 2018	DP U-1408		NDF	Apr 11, 2016
	8277780	Apr 23, 2028	DP U-1408			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	6673838	Feb 11, 2022	DS DP U-860		>A> I-675	Feb 14, 2016
	6673838	Feb 11, 2022	DS DP U-1364			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	6673838	Feb 11, 2022	DS DP U-860		>A> I-675	Feb 14, 2016
	6673838	Feb 11, 2022	DS DP U-1364			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIFLUPREDNATE - DUREZOL</u>						
N 022212 001	6114319	May 18, 2019	DP		I-653	Jun 13, 2015
	6114319*PED	Nov 18, 2019			M-127	Mar 22, 2016
					ODE	Jun 13, 2019
					PED	Dec 13, 2015
					PED	Dec 13, 2019
					PED	Sep 22, 2016
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N 022568 001	8481565	Oct 04, 2026	DP			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	8394405	Apr 07, 2024	DP U-925			
	8394406	Apr 07, 2024	DP U-925			
	8470364	Apr 07, 2024	DP U-925			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	6958161	Dec 15, 2022	DP U-918		D-136	Apr 11, 2016
					NS	Apr 11, 2016
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N 021876 001	6340695	Jun 21, 2021	DP U-1382		NP	Apr 08, 2016
	7560122	Jan 25, 2019	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001	5223510	Jul 26, 2016	DS DP U-992			
	5223510	Jul 26, 2016	DS DP U-1261			
	8410167	Apr 16, 2029	U-1387			
	8410167	Apr 16, 2029	U-1388			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N 021676 001	RE43916	Jun 30, 2014	U-1326			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	RE43916	Jun 30, 2014	U-1326			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001					M-61	Oct 18, 2015
					PED	Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002					M-61	Oct 18, 2015
					PED	Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004					M-61	Oct 18, 2015
					PED	Apr 18, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 001	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 002	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 003	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 001	5519021	May 21, 2013				
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014				
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 002	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-248			
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
>A>	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 002	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
>A>	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 001	8318802	Mar 15, 2027	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 002	8318802	Mar 15, 2027	DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 001	>A> 8466175	May 25, 2018	U-1417			
	>A> 8466175*PED	Nov 25, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 002	>A> 8466175	May 25, 2018	U-1417			
	>A> 8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 001	>A> 8466175	May 25, 2018	U-1417			
	>A> 8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 002	>A> 8466175	May 25, 2018	U-1417			
	>A> 8466175*PED	Nov 25, 2018				
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	>A> 8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	>A> 8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	>A> 8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	>A> 8231906	Jul 04, 2030	DS DP			
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 001					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 002					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 003					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N 204061 001	8415332	Mar 11, 2029	DP		NP	Mar 28, 2016
	8450299	Oct 07, 2025	U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 203667 001	5552394	Jul 22, 2014	U-1		NDF	May 08, 2016
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 204426 001	5552394	Jul 22, 2014	U-1			
	6652880	Mar 29, 2020	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE</u>						
N 204654 001	>A> 5552394	Jul 22, 2014	U-1			
	>A> 6667050	Apr 06, 2019	DP U-1			
	>A> 7704984	Feb 02, 2029	U-1			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 001	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 002	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 003	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8431685	Apr 13, 2025	DP U-412			
	8461105	Apr 13, 2025	DP U-412			
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N 022519 001	8449910	Jul 18, 2026	DP			
	>A> 8501228	Jul 18, 2026	U-1196			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001	5614520	Mar 25, 2019	DS DP U-954			
	8372872	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	5614520	Mar 25, 2019	DS DP U-954			
	8372872	Sep 08, 2031	U-1346			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 001 >A>	8481078	Oct 01, 2024	DP U-1416			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 002 >A>	8481078	Oct 01, 2024	DP U-1416			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 001	>A> 8486972	Apr 26, 2029	DP			
	>A> 8486973	Apr 26, 2029	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	>A> 8486972	Apr 26, 2029	DP			
	>A> 8486973	Apr 26, 2029	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	>A> 8486972	Apr 26, 2029	DP			
	>A> 8486973	Apr 26, 2029	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	>A> 8486972	Apr 26, 2029	DP			
	>A> 8486973	Apr 26, 2029	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	>A> 8486972	Apr 26, 2029	DP			
	>A> 8486973	Apr 26, 2029	DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001					>A> NP	Jul 25, 2016
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	>A> 8501158	Mar 08, 2020	U-1422			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 001	8338478	May 11, 2019	DS DP U-913			
	>A> 8501723	Jun 07, 2027	DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 002	8338478	May 11, 2019	DS DP U-913			
	>A> 8501723	Jun 07, 2027	DP			
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 001					>A> NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 003					>A> NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 004					>A> NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 006					>A> NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 001					>A> NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 002					>A> NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 003					>A> NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 004					>A> NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 005					>A> NPP	Jul 26, 2016
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	8347879	Apr 01, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	5873360	Feb 23, 2016	DP			
	6537983	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1401			
	6878698	Aug 03, 2021	U-1401			
	7101866	Aug 03, 2021	DS DP U-1401			
	7361787	Mar 23, 2023	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1401			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 001	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 002	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 003	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 004	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 001	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 002	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	>A> 8466139	Jan 09, 2021	U-596			
	>A> 8466139*PED	Jul 09, 2021				
<u>GABAPENTIN - GRALISE</u>						
N 022544 001	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N 022544 002	8333992	Oct 25, 2022	DP U-1114			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 001	8394356	Feb 01, 2015	U-1112			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 002	8394356	Feb 01, 2015	U-1112			
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 001					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 002					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 003					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 004					NCE	Mar 20, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					NCE	Jul 03, 2013
<u>GANIRELIX ACETATE - GANIRELIX ACETATE INJECTION</u>						
N 021057 001	6653286	Jun 16, 2018	U-1354			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 002	8367605	May 24, 2014	DS			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Feb 07, 2015	DS DP U-1378		NE	Feb 01, 2016
	8404215	Mar 09, 2032	U-1383		ODE	Feb 01, 2020
<u>GLYCOPYRROLATE - ROBINUL</u>						
N 012827 001	7091236	Apr 24, 2024	U-877	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCOPYRROLATE - ROBINUL FORTE</u>						
N 012827 002	7091236	Apr 24, 2024	U-877	Y		
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N 021903 001	8415337	Mar 02, 2032	DS DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
>A>	8501225	Apr 29, 2030	U-1287			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	7544799*PED	Jul 16, 2019			ODE	Jan 25, 2020
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	7544799*PED	Jul 16, 2019			ODE	Jan 25, 2020
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	8067437	Jun 02, 2020	U-1168			
>A>	8479730	Oct 11, 2028	DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	6844013	Dec 13, 2018	DS DP U-1221			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	6844013	Dec 13, 2018	DS DP U-1221			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN</u>						
N 021017 002 >A>	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN</u>						
N 021018 002 >A>	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 020563 003 >A>	7291132	Aug 09, 2024	DP			
<u>IOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N 022290 001					I-669	Mar 20, 2016
<u>IRON SUCROSE - VENOFER</u>						
N 021135 005					NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8367102	Sep 21, 2021	U-1347			
<u>ITRACONAZOLE - ONMEL</u>						
N 022484 001 >A>	8486456	Oct 03, 2028	DP U-1054			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8410274	Dec 28, 2026	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8377982	May 28, 2024	U-1363			
	8377982*PED	Nov 28, 2024				
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	>A> 6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	>A> 6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	>A> 6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	>A> 6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	>A> 6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	>A> 6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	>A> 6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	>A> 6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	>A> 6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	>A> 6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	>A> 5635517	Oct 04, 2019	DS DP U-1211		I-672	Jun 05, 2016
	>A> 6045501	Aug 28, 2018	U-1210		NS	Jun 05, 2016
	>A> 6281230	Jul 24, 2016	U-1212		ODE	Jun 05, 2020
	>A> 6281230	Jul 24, 2016	U-1414			
	>A> 6315720	Oct 23, 2020	U-1210			
	>A> 6555554	Jul 24, 2016	DP U-1211			
	>A> 6561976	Aug 28, 2018	U-1210			
	>A> 6561977	Oct 23, 2020	U-1210			
	>A> 6755784	Oct 23, 2020	U-1210			
	>A> 6908432	Aug 28, 2018	U-1210			
	>A> 7119106	Jul 24, 2016	DP			
	>A> 7189740	Apr 11, 2023	U-1215			
	>A> 7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	>A> 7855217	Nov 24, 2024	DS DP			
	>A> 7968569	Oct 07, 2023	U-1216			
	>A> 8204763	Aug 28, 2018	U-1249			
	>A> 8288415	Jul 24, 2016	DS DP			
	>A> 8315886	Oct 23, 2020	U-1249			
	>A> 8404717	Apr 11, 2023	U-1215			
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 001					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 002					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 003					PC	Feb 16, 2013
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 001	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 002	6500829	Mar 07, 2022	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 003	6500829	Mar 07, 2022	DS DP			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001	>A> 8481598	Mar 02, 2031	U-839		>A> NCE*	Jul 25, 2018
	>A> RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002	>A> 8481598	Mar 02, 2031	U-839		>A> NCE*	Jul 25, 2018
	>A> RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003	>A> 8481598	Mar 02, 2031	U-839		>A> NCE*	Jul 25, 2018
	>A> RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004	>A> 8481598	Mar 02, 2031	U-839		>A> NCE*	Jul 25, 2018
	>A> RE43879	Jun 03, 2023	U-839			
<u>LEVONORGESTREL - PLAN B ONE-STEP</u>						
N 021998 001					>A> RTO*	Apr 30, 2016
					>A> RTO**	Apr 30, 2016
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	5785053	Dec 05, 2015	DP		NP	Jan 09, 2016
	7252839	Nov 13, 2023	DP			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 001	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 002	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 003	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 004	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 005	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 006	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 007	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 008	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 009	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 010	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 011	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 012	7101569	Oct 02, 2023	U-759			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2015	DS	U-1317	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2015	DS	U-1317	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2015	DS	U-1317	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 001	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	>A> 8470347	Sep 17, 2026	DP			
	>A> 8470347*PED	Mar 17, 2027				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 002	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	>A> 8470347	Sep 17, 2026	DP			
	>A> 8470347*PED	Mar 17, 2027				
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 202872 001	5800807	Jan 29, 2017	DP			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	6716416	May 20, 2022	DP			
	7052679	Mar 20, 2022	DP			
	7078020	Oct 26, 2021	DP U-1375			
	7090830	Oct 26, 2021	DP			
	7458374	Aug 18, 2024	DP			
	7537009	Oct 26, 2021	DP			
	7585493	Oct 26, 2021	DP			
	7601337	Oct 26, 2021	DP			
	8074644	Oct 26, 2021	DP			
	8173107	Oct 26, 2021	DP			
	8235037	Oct 26, 2021	DP			
	8387612	Oct 23, 2026	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	6414016	Sep 05, 2020	U-717		I-670	Apr 19, 2016
	6414016	Sep 05, 2020	U-1392			
	6982283	Dec 04, 2022	U-1391			
	7064148	Aug 30, 2022	U-739			
	7064148	Aug 30, 2022	U-1404			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020	U-1203			
	8071613	Sep 05, 2020	U-1393			
	8097653	Nov 14, 2022	U-1214			
	8097653	Nov 14, 2022	U-1394			
	8389542	Nov 14, 2022	DP U-1345			
	8389542	Nov 14, 2022	DP U-1395			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	5532372	Jul 02, 2018	DS		>A> I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	5532372	Jul 02, 2018	DS		>A> I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	5532372	Jul 02, 2018	DS		>A> I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	5532372	Jul 02, 2018	DS		>A> I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005					>A> D-134	Apr 26, 2015
					>A> I-674	Jun 28, 2016
					>A> NCE	Oct 28, 2015
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE - SUCLEAR</u>						
N 203595 001					NC	Jan 18, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 001	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025		U-539		
	8283379	Nov 22, 2025		U-539		
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025		U-539		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 002	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025		U-539		
	8283379	Nov 22, 2025		U-539		
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025		U-539		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 003	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025		U-539		
	8283379	Nov 22, 2025		U-539		
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025		U-539		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 004	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025		U-539		
	8283379	Nov 22, 2025		U-539		
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025		U-539		
<u>MESALAMINE - CANASA</u>						
N 021252 002	8217083	Jun 06, 2028	DP			
	8436051	Jun 06, 2028	DP			
<u>MESALAMINE - APRISO</u>						
N 022301 001 >A>	8496965	Apr 20, 2018	DP			
<u>MESALAMINE - DELZICOL</u>						
N 204412 001	5541170	Jul 30, 2013	DP	U-141		
	5541171	Jul 30, 2013	DP	U-141		
	6649180	Apr 13, 2020	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574 001	8475841	Mar 20, 2018		U-604		
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574 002	8475841	Mar 20, 2018		U-604		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018		U-973		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018		U-973		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	RE44186	Jul 31, 2023	DS DP	U-1097		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP	U-1097		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP	U-1097		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7459428	Feb 02, 2019		U-1036		
	8414921	Jul 21, 2028	DP	U-1036		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7459428	Feb 02, 2019		U-1036		
	8414921	Jul 21, 2028	DP	U-1036		
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	8420663	Sep 30, 2029		U-1185		
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	8420663	Sep 30, 2029		U-1185		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	8420663	Sep 30, 2029	U-1185			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP U-1415			
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
A 090903 001					>A> PC	Dec 28, 2013
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 001	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 003	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 005	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568 001	5914396	Jun 22, 2016	DS		NCE	Jan 29, 2018
	6166197	Dec 26, 2017	DS		ODE	Jan 29, 2020
	6222025	Mar 06, 2015	DS			
	6451991	Feb 11, 2017	DS			
	7015315	Mar 21, 2023	DS			
	7101993	Sep 05, 2023	DS			
	7407943	Aug 01, 2021	U-1353			
	7511131	Dec 13, 2025	DS			
<u>MOMETASONE FUROATE - ELOCON</u>						
N 019625 002					NP	Apr 19, 2016
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	8450311	May 29, 2029	DP			
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N 050703 001	5569672	Oct 29, 2013	U-1358			
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N 050746 001	5569672	Oct 29, 2013	U-1358			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 001	6306900	Feb 27, 2018	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 002	6306900	Feb 27, 2018	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001					NP	Jun 27, 2016
<u>NEPAFENAC - NEPAFENAC</u>						
N 203491 001	5475034	Jun 06, 2014	U-100			
	6403609	Jul 17, 2018	DP			
	7947295	Jun 08, 2024	DP			
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152 001	8460704	Mar 12, 2029	U-1409			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	>A> 8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	>A> 8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	>A> 8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	>A> 8455524	Apr 18, 2027	U-1029			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001	8389537	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	>A> 8501760	Jul 18, 2026	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002	8389537	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	>A> 8501760	Jul 18, 2026	DS DP			
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 001					ODE	May 10, 2020
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 001					>A> NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 002					>A> NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 003					>A> NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 004					>A> NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 005					>A> NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 006					>A> NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 001					>A> NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 002					>A> NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 003					>A> NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 004					>A> NPP	Jul 26, 2016
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N 021861 001	8399508	Sep 17, 2022	U-726			
	8399508*PED	Mar 17, 2023				
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	6489346	Jul 16, 2016	DS DP U-588	Y		
	6645988	Jul 16, 2016	DS DP	Y		
	6699885	Jul 16, 2016	U-588	Y		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	6489346	Jul 16, 2016	DS DP U-623	Y		
	6489346	Jul 16, 2016	DS DP U-624	Y		
	6645988	Jul 16, 2016	DS DP	Y		
	6699885	Jul 16, 2016	U-623	Y		
	6699885	Jul 16, 2016	U-624	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022281 001	6489346	Jul 15, 2016	DP U-1025	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	DP	Y		
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022283 001	>A> 5840737	Jul 16, 2016	U-1025			
	>A> 6780882	Jul 16, 2016	DP			
	>A> 7399772	Jul 16, 2016	U-1025			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002					NPP	Dec 21, 2015
<u>OSPemIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2020	U-1369		NCE	Feb 26, 2018
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	>A> 8470890	Feb 13, 2024	U-1369			
	>A> 8470890	Feb 13, 2024	U-1370			
<u>OXYBUTYNIN - OXYTROL FOR WOMEN</u>						
N 202211 001	5601839	Apr 26, 2015	DP U-1329		NP	Jan 25, 2016
	5834010	Apr 26, 2015	DP U-1329			
	6743441	Apr 26, 2020	DP U-1329			
	7081249	Apr 26, 2020	DP U-1329			
	7081250	Apr 26, 2020	DP U-1329			
	7081251	Apr 26, 2020	DP U-1329			
	7081252	Apr 26, 2020	DP U-1329			
	7179483	Apr 26, 2020	U-1329			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 001	8409616	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 002	8409616	Nov 26, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A 079087 006					PC	Jul 07, 2013
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 005					M-93 NCE	Jul 29, 2019 Apr 30, 2014
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	5874447	Jun 10, 2017	DS		>A> NP	Jun 28, 2016
	7598271	Feb 12, 2023	DS			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 001	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 002	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 003	8440170	Mar 14, 2029	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5856336	Jan 01, 2021	DS U-998			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5856336	Jan 01, 2021	DS U-998			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5856336	Jan 01, 2021	DS U-998			
<u>PLERIXAFOR - MOZOBIL</u>						
N 022311 001	RE42152	Dec 10, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					ODE	Dec 14, 2019
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					ODE	Dec 14, 2019
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 001	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 002	6028071	Jul 16, 2022	DS DP U-1004			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	8404703	Mar 02, 2022	U-1381			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	8404703	Mar 02, 2022	U-1381			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N 202020 002	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N 202020 003	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREGABALIN - LYRICA</u>						
N 022488 001					I-651	Jun 20, 2015
<u>PROPOFOL - DIPRIVAN</u>						
N 019627 002	8476010	Dec 01, 2024	DS DP			
	8476010*PED	Jun 01, 2025				
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 001	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 002	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971 001	6635234	Jan 03, 2020	U-1405		NCE	May 15, 2018
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001 >A>	8470801	Jun 22, 2019	U-116			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001					I-667 ODE	Feb 25, 2016 Feb 25, 2020
<u>REPAGLINIDE - REPAGLINIDE</u>						
A 077571 002					>A> PC	Jan 20, 2014
<u>REPAGLINIDE - REPAGLINIDE</u>						
A 077571 003					>A> PC	Jan 20, 2014
<u>RITONAVIR - NORVIR</u>						
N 022417 001	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
>A>	8470347	Sep 17, 2026	DP			
>A>	8470347*PED	Mar 17, 2027				
<u>RIVASTIGMINE - EXELON</u>						
N 022083 005					>A> NPP	Jun 27, 2016
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A 078173 001					PC	Jun 29, 2013
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A 078173 002					PC	Jun 29, 2013
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	8431154	Feb 19, 2023	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 001	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 003	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 004	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 005	5670524	Sep 23, 2014	DS DP U-833			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	8415362	Dec 24, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	8415362	Dec 24, 2027	DS DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	8318745	Nov 17, 2024	DP			
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 020628 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 021785 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP U-995			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995			
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N 020990 001	7067555	Oct 11, 2019	DP			
	7067555*PED	Apr 11, 2020				
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	>A> 8496973	Mar 29, 2031	DS DP U-1419			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8457988	Dec 17, 2022	U-1110			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	>A> 8496973	Mar 29, 2031	DS DP U-1419			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	8343130	Oct 18, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	6745071	Feb 21, 2023	DP		NDF	Jan 17, 2016
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001	>A> 6440458	Mar 25, 2019	DP		>A> NDF	Jul 19, 2016
	>A> 6576259	Mar 25, 2019	DP			
	>A> 6884433	Mar 25, 2019	DP U-1420			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002	>A> 6440458	Mar 25, 2019	DP		>A> NDF	Jul 19, 2016
	>A> 6576259	Mar 25, 2019	DP			
	>A> 6884433	Mar 25, 2019	DP U-1420			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003	>A> 6440458	Mar 25, 2019	DP		>A> NDF	Jul 19, 2016
	>A> 6576259	Mar 25, 2019	DP			
	>A> 6884433	Mar 25, 2019	DP U-1420			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 001	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 002	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 003	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 004	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					NCE	Mar 13, 2018
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2015	DS DP U-1320		ODE	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320			
	7847061	Nov 01, 2025	U-1320			
<u>TELAPREVIR - INCIVEK</u>						
N 201917 001	8431615	May 30, 2028	U-1398			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 001	6635618	Sep 11, 2023	DS DP U-728		>A> I-673	Jun 21, 2016
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 002	6635618	Sep 11, 2023	DS DP U-728		>A> I-673	Jun 21, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N 022011 001					M-124	Jan 28, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N 022154 001					M-124	Jan 28, 2016
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088 001	>A> 8455539	Jul 25, 2023	DP			
	>A> 8455539*PED	Jan 25, 2024				
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 001					>A> M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 002					>A> M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 003					>A> M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 004					>A> M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 022577 001					>A> M-128	Jul 24, 2016
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	>A> 8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	>A> 8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	>A> 8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8419307	Feb 26, 2027	U-1386			
	8435944	Jul 05, 2027	U-1390			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 001					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 002					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 003					NP	Jan 31, 2016
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	8425934	Dec 18, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8372995	Oct 08, 2030	DP			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001 >A>	7097827	Apr 16, 2016	DP		NP	Mar 22, 2016
	7368102	Dec 19, 2022	DP U-909			
	7442388	May 10, 2020	DP			
	7516741	Jan 11, 2024	DP			
	7559325	Oct 27, 2025	DP			
	8069851	Sep 24, 2024	DP			
	8349294	May 10, 2020	DP			
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820 001	6987094	Sep 22, 2022	DP			
	7696178	Mar 17, 2023	DP			
	7939502	Jun 14, 2022	U-1324			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 001	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 002	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001 >A>	5258510	Nov 02, 2013	DS DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002 >A>	5258510	Nov 02, 2013	DS DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003 >A>	5258510	Nov 02, 2013	DS DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	7378423	Sep 13, 2025	DS DP		NCE ODE	May 29, 2018 May 29, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	7378423	Sep 13, 2025	DS DP		NCE ODE	May 29, 2018 May 29, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	7378423	Sep 13, 2025	DS DP		NCE ODE	May 29, 2018 May 29, 2020
<u>TRANEXAMIC ACID - TRANEXAMIC ACID</u>						
A 202093 001					PC	Jul 02, 2013
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001 >A>	8487005	Mar 04, 2025	DP U-1182			
<u>TRAVOPROST - TRAVATAN Z</u>						
N 021994 001	8388941	Sep 20, 2027	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	7999007	Mar 29, 2029	DP U-1413			
>A>	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	7999007	Mar 29, 2029	DP U-1413			
>A>	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	7999007	Mar 29, 2029	DP U-1413			
>A>	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	7999007	Mar 29, 2029	DP U-1413			
>A>	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001 >A>	8497393	Dec 15, 2028	DS			
<u>TROSPIMUM CHLORIDE - TROSPIMUM CHLORIDE</u>						
A 091289 001					PC	Apr 10, 2013
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8426392	Jun 12, 2030	U-1389			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N 021214 001	6770675	Nov 24, 2018	DP U-1322			
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001 >A>	8470818	Aug 02, 2026	U-1418			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N 021817 001	8052987	Oct 27, 2023	U-1199			

Footnote: 1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5). 2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 33rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>